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ABSTRACT
Human leucocyte antigen incompatible (HLAi) transplantation represents a key 
strategy for improving access for sensitised patients to the preferable treatment, 
of transplantation, for end-stage renal failure (ESRF). This laboratory based 
observational research study aimed to investigate key populations of recipient 
lymphocytes present at various stages of the HLAi transplant procedure, and to 
assess the data obtained in combination with other pertinent laboratory and 
clinical information, in order to build up an immunological profile.
Data was collected from blood samples provided by seven prospective and 
thirteen retrospective HLAi kidney transplant recipients, and nine normal control 
individuals. Flow cytometry was utilised to examine lymphocyte subsets, and to 
perform T and B cell immunophenotyping. HLA-specific antibody definition was 
carried out using a single antigen bead-based assay, employing Luminex 
technology. Longitudinal data for the prospective participants, and collective data 
on the retrospective cohort, was scrutinised for any trends or significant 
associations.
The effects of preconditioning and immunosuppression received were evident in 
the lymphocyte subset results of both groups of patients. Pre-treatment results in 
the prospective cohort also confirmed a chronic renal failure effect of reduced cell 
counts. Both groups of participants showed increased populations of memory T 
cells following transplantation, suggesting reconstitution from within this 
compartment. A peak in HLA-DR expression on T cells, at six months post­
transplantation, was noted in the prospective group. Conversely, memory B cells 
remained depressed in both cohorts, with the repopulating B cells demonstrating 
a transitional or mature B cell phenotype in the prospective participants. A 
possible link between increased populations of plasmablasts post­
transplantation, and detected levels of HLA-specific antibodies was indicated.
The results demonstrated some intriguing trends and patterns that are worthy of 
further investigation, and it is recommended that elements of this pilot study are 
extended into larger prospective studies. As this study highlights, there is still 
much knowledge to be gained and potential laboratory support that could be 
given, that may improve the delivery of HLAi transplant programmes and thereby 
access to the superior treatment of transplantation for sensitised patients.
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CHAPTER 1 INTRODUCTION
1.1 Background to the study
Antibody incompatible transplantation (AiT) describes the crossing of the 
previously ‘taboo’ antibody barrier, to either human leucocyte antigen (HLA) or 
ABO blood group antigens. Since the turn of the century, developments in AiT, 
as a treatment for end stage renal failure (ESRF), have led to the successful 
introduction of programmes in most UK renal transplant centres, and worldwide, 
facilitating access to transplantation for recipient-donor pairs previously deemed 
unsuitable. This current laboratory based observational research study aimed to 
investigate aspects of the immune response of renal transplant recipients 
undergoing the specialised therapy of HLA incompatible (HLAi) transplantation. 
Advances in all areas of renal transplantation including surgical, laboratory, 
immunosuppression and post-transplant care, means that this approach to 
transplanting a patient, who may be unlikely to receive a donor kidney in the 
standard way, is successful in carefully selected, and thoroughly investigated, 
cases.
However, there is much that is not understood about the biological process of 
HLAi transplantation, both in terms of what is happening to the patient’s immune 
system and their responses during the pre-transplant protocol, and post­
transplant, when the donor kidney is in-situ. The main focus of this study was to 
examine key populations of lymphocytes present at various stages of the 
procedure, and to view this new data in combination with other pertinent 
laboratory and clinical data, in order to build up an immunological profile of HLAi 
transplant recipients. The development of additional ways of monitoring HLAi 
transplantation patients has the potential to further enhance the delivery of this 
treatment in a tailored, individualised manner, as information provided to 
clinicians may allow them to target immunosuppression and immune modulating 
therapies at the patients who require them, and decrease, or avoid their use, in 
those patients who do not. Importantly, this approach may contribute to opening 
up this treatment option to an increasing number of patients who are difficult to 
manage clinically and do not currently have access to standard transplantation. 
Finally, studying patients who have been through the HLAi transplantation
1
programme could allow insights into the long-term effects of this procedure, and 
potential enduring changes to these individuals’ immune systems.
1.2 Justification of transplantation as a treatment choice for end-stage renal 
failure (ESRF)
Transplantation is the treatment of choice for patients with ESRF in terms of 
mortality (Newstead 2008, BSHI/BTS 2014) compared to the alternative renal 
replacement therapy of dialysis. Developments in the field mean that graft 
survival, following deceased donor transplantation, continues to improve (see 
table 1.1).
Table 1.1 Long-term graft survival after first adult kidney only transplant from a 
DBD in the UK
Year of 
transplant
No. at 
risk on 
day 0
% Graft survival (95% confidence interval)
One year Two year Five year Ten year
2001-2003 2771 91 (90-92) 89 (88-90) 83 (81-84) 73 (71-75)
2004-2006 2468 93 (92-94) 91 (90-92) 85 (84-87)
2007-2009 2114 93 (92-94) 91 (90-93) 85 (84-87)
2010-2013 3071 94 (93-95)
DBD -  Donation following brain death; UK -  United Kingdom 
Adapted from NHS Blood and Transplant (NHSBT) (2015, p98)
Transplantation is also the favoured option for patients in relation to quality of life 
(Orr et a/. 2007). When compared with dialysis, kidney transplantation provides 
a financially viable service for the National Health Service (NHS). It has been 
calculated that the UK transplantation programme as a whole saves the NHS 
£316 million per annum (Department of Health (DoH) 2013). One would think that 
such an all-round successful treatment should be offered to all patients in need 
of a transplant; however, there are important reasons why this is not currently the 
case.
1.3 The donor organ shortage
Historically, within the UK, the majority of kidneys for transplantation are obtained 
from deceased donors. In 2008, a report (DoH 2008) was published by the Organ
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Donation Taskforce to address the issue of a plateau being reached in the 
number of organ donors. By 2013, the recommended actions implemented 
following the report had led to an increase in deceased organ donation of 50%, 
and an increase in transplantation of 30.5% (DoH 2013). Despite this, as 
indicated in figure 1.1, there remains a substantial shortfall between the total 
number of individuals on the organ transplant waiting list and the number of both 
registered donors and transplants performed. More recent recommendations 
(DoH 2013) aim to build further on the progress made in the UK in terms of organ 
donation rates from deceased donors, by firmly integrating the donation process 
into end of life care, and attempting to transform the attitude of the general public 
towards donation. A recent move to a new ‘soft opt-out’ system by the Welsh 
government represents a step towards these important changes. Effective from 
1st December 2015, the Human Transplantation (Wales) Act (Wales 2013), 
applies ‘deemed’ consent to individuals who have not registered a preference as 
to whether or not they wish to be considered as an organ donor upon their death.
It remains clear that donor kidneys are an incredibly valuable and limited resource 
that are not available to all patients in ESRF. For this reason, it is essential that 
this resource is utilised in the most beneficial way, and in the UK this is achieved 
by a complex deceased donor national kidney allocation scheme, managed by 
NHS Blood and Transplant - Organ Donation and Transplantation (NHSBT-ODT). 
In previous years, the allocation scheme existed for donors following brain death 
(DBDs) only; however, since 2014, a national sharing scheme is also managed 
for donors following circulatory death (DCDs).
The shortage of deceased organ donors has resulted in initiatives to increase 
donation from alternative donor sources. Transplantation is regulated under the 
Human Tissue Act 2004 (Great Britain 2004), which allows the donation of 
kidneys from live donors who typically (but not necessarily) are genetically or 
emotionally related to the recipient. In the year 2014-15,1,052 living donor kidney 
transplants were carried out, in comparison with a total of 1,880 deceased donor 
(DBD and DCD) transplants (NHSBT 2015). This is a key factor in relation to this 
research project, as not only do live donors provide an important strategy for 
increasing the donor pool, but in addition, in the majority of cases, the specialist 
treatment of HLAi transplantation is carried out with a live donor.
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Figure 1.1 Number of deceased donors and transplants in the UK. April 1st 2005
-  March 31st 2015. and the number of patients on the active transplant waiting 
list at March 31st
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1.4 Standard assessment of kidney transplant compatibility
In order for a kidney transplant to be successful, the compatibility of the potential
donor and recipient must first be assessed. In standard transplantation, the pair
must first be blood group compatible, but following on from this the immunological
compatibility is examined. This work is carried out in Histocompatibility and
Immunogenetics (H&l) laboratories, and two key areas relating to a potential
recipient’s immunological status are analysed in order to achieve the best
possible outcome for the kidney transplant and ensure that the donor kidney is
not immediately rejected by the recipient’s immune system. Immune recognition
of ‘self and ‘non-self is directed by the products of the HLA genes, which are
encoded within the major histocompatibility complex (MHC), an area of the
genome comprising over two hundred genes (Robinson et al. 2015), many of
which encode proteins with immune function. Figure 1.2 (a) depicts an overview
of the HLA region, which is located at position 6p21.3 on the short arm of
chromosome 6. The classical HLA genes, whose products are shown in figure
1.2 (b), are organised as Class I and Class II. Class I A, B and C genes encode
molecules which are expressed on all nucleated cells; Class II DR, DQ and DP
molecules have more limited expression, found on antigen presenting cells
(APCs) and activated T cells (Parham 2009).
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HLA Class I A, B and C genes each encode a heavy chain (a-chain), which combines 
with (3-2 microglobulin (f3-2m) for expression on the cell surface. (3-2 microglobulin is 
encoded outside of the MHC, on chromosome 15. The genes encoding the Class II 
molecules are located centromeric to the Class I region. The classical genes consist of 
an A gene, e.g. DQA, which encodes the a-chain, and a B gene, e.g. DQB, which 
encodes the (3-chain of the Class II molecule.
Both sets of proteins play a key role in immune recognition by presenting antigen 
to T cells, with Class I molecules presenting endogenous antigen to CD8+ T cells 
and Class II presenting exogenous antigen to CD4+ T cells (Parham 2009). A key 
feature of the HLA genes is the extensive polymorphism exhibited, with a total of 
over 14,000 HLA alleles currently documented (Robinson et al. 2015).
It has long been established that ‘tissue matching’, or attempting to achieve as 
close a match as possible between the potential recipient and donor HLA types 
results in a better transplant outcome (Opelz and Dohler 2007). As well as 
analysing recipient and donor ‘tissue types’, the other key focus for scientists is 
the analysis of a potential recipient’s sensitisation status. When individuals are 
exposed to ‘foreign’ HLA they are able to form antibodies directed towards them,
which are capable of causing immediate irreversible rejection of a transplanted
5
organ. This process of forming HLA-specific antibodies is known as sensitisation, 
and can occur by three main routes, which all involve exposure to another 
individuals’ (‘foreign’) HLA; namely blood transfusion, previous transplantation or 
pregnancy (Magee 2006, BSHI/BTS 2014).
1.5 The problem of HLA sensitisation
The sensitisation status of a potential kidney transplant recipient has a direct 
impact on potential deceased donor offers, and it is acknowledged that 
possession of HLA specific antibodies is one of the main obstacles affecting 
patients’ access to transplantation (BTS 2015). In standard transplantation, if a 
patient is known to possess antibodies against the HLA of a donor (donor specific 
antibody (DSA)) then the transplant is incompatible due to the potential for 
immediate rejection of the donor organ.
H&l scientists closely monitor a renal patient’s HLA-specific antibodies in terms 
of detecting their presence and levels using extremely sensitive techniques, and 
also by determining the antibody isotype and precisely which HLA they are 
directed towards. These ‘unacceptable antigens’ are listed on the patient’s record 
with NHSBT-ODT, and donors possessing these HLA are excluded for these 
individuals. In the UK in 2009, 41% of adult patients and 58% of paediatric 
patients on the transplant waiting list possessed HLA specific antibodies 
(BSHI/BTS 2014), and it has been demonstrated that these individuals’ 
sensitisation status has a direct impact on their likelihood of being offered a 
deceased donor kidney (Susal and Opelz 2007, BSHI/BTS 2014). Exposure to 
many different HLA types due to previous transplantation with mismatched grafts 
or multiple blood transfusions can lead to patients awaiting transplantation with 
high levels of a broad range of HLA-specific antibodies, directed against common 
HLA types. These patients may also be incompatible with a potential live donor. 
The increased use of live donors and the question of how to transplant patients 
who are sensitised, formed the impetus for the development of strategies aimed 
towards improving access to transplantation. One such important strategy was 
the development of protocols for transplanting across the DSA barrier.
6
HLAi transplantation represents a key development towards ‘opening the door’ to 
transplantation to as many renal patients as possible, including those for whom it 
may be difficult to identify a compatible donor. This is achieved by the process of 
‘desensitisation’, which aims to remove, or reduce, donor specific HLA antibodies 
from the recipient’s circulation (Doxiadis, Duquesnoy and Claas 2005). The 
reduction of antibodies pre-transplant allows the creation of a ‘window of 
opportunity’ for the transplant, which can now be deemed compatible, to proceed.
HLAi transplantation is now established within the UK and internationally (Glotz 
et al. 2004, Montgomery et a l 2000, Gloor et al. 2003). Although the precise 
procedure for antibody reduction varies from centre to centre, it generally involves 
the same techniques, usually a combination of directly filtering or absorbing 
antibody from the patient’s circulation, and the administration of an intensive drug 
regime to modulate or suppress the immune response. The success of 
desensitisation is affected by a number of factors including the levels of antibody 
present, and which particular HLA it is directed towards. The aim of the procedure 
is to reduce the antibody to a predefined level that is deemed will not be damaging 
to the kidney graft, and can be managed post-transplant. In the majority of cases, 
HLA antibody reduction is only temporary, and an antibody ‘rebound’ occurs, 
which may be rapid and at high levels (BTS 2006). Although there are a relatively 
small number of cases, and follow-up is still limited, figures from the Registry of 
AiT (held by NHSBT), show three year graft survival and three year patient 
survival, for HLAi live donor transplants, to be identical to those for deceased 
donor transplantation in highly sensitised patients (86% and 92% respectively) 
(BTS 2015).
1.6 Antibody mediated graft rejection
The role that recipient antibodies directed against donor HLA play in rejection of 
kidney allografts has been recognised since 1966, when Kissmeyer-Nielsen etal. 
(1966) described the phenomenon of hyperacute rejection (HAR). HAR is 
orchestrated by recipient pre-formed HLA-specific antibodies of the 
immunoglobulin (Ig)-G class, directed against the donor kidney, and can cause 
immediate irreversible destruction of the graft. Antibodies bind to their target 
antigen on the vascular endothelial cells of the kidney, activating the complement
7
cascade (Pescovitz 2005). This in turn initiates platelet aggregation and clotting, 
leading to occlusion of the blood vessels, and thrombosis of the graft. Graft 
necrosis is rapid, in some instances whilst the recipient is still in the operating 
theatre (Higgins et al. 2008). There is no treatment for HAR, which inevitably 
leads to graft loss, and can endanger the life of the recipient. The occurrence of 
HAR is dependent on various recipient factors including whether the DSA are 
circulating at the time of the transplant, antibody titre, whether the antibodies are 
directed towards HLA Class I or Class II antigens, and which class of antibody is 
present.
Whilst it is accepted that circulating IgG DSA directed towards HLA Class IA  and 
B antigens can cause HAR, the risk of IgG DSA against Class II antigens 
(Pollinger et al. 2007), HLA-specific antibodies of the IgM class (Fuggle and 
Martin 2004), HLA-specific antibodies in an historic serum sample (BSHI/BTS 
2014) and antibodies directed against donor antigens other than HLA (Susal and 
Opelz 2007), in causing early rejection are still controversial. Accelerated acute 
rejection within the first week post-transplant can result from memory B cells 
being stimulated to produce DSA, as a part of an amnestic response. Antibodies 
are also implicated in chronic damage to the transplanted kidney (Higgins et al. 
2008). There has been a resurgence of interest in the role of the humoral immune 
response in rejection over the last few years as observations by Terasaki (2003) 
and others implicated the importance of antibodies, as well as cellular processes, 
in allorecognition and the initiation of rejection responses against the donor graft. 
Deposition of the complement component C4d, detectable on biopsy, and 
demonstration of circulating DSA are the key diagnostic indicators of antibody 
mediated rejection (AMR) (Pescovitz 2005). Clinical parameters that can give 
early warning of AMR include a rise in creatinine levels and reduction in urine 
production. Creatinine is a chemical product generated during the course of 
muscle metabolism, and processed by the kidneys to be finally excreted in the 
urine (The Association for Clinical Biochemistry and Laboratory Medicine 2016). 
A high or rising creatinine level in blood is an indicator of poor renal function.
The observations of HAR led to the development of the pre-transplant 
crossmatch, originally performed using a complement dependent cytotoxicity 
(CDC) assay (Patel and Terasaki 1969), which analyses recipient serum taken
8
pre-transplant for antibodies directed towards donor cells. Flow cytometric (FC) 
based assays are now also commonly used, and provide increased sensitivity. 
Historically, this final test of compatibility has been used to veto a transplant in 
the face of a positive result, as pre-formed IgG antibodies directed towards HLA 
have been seen as an absolute contraindication to transplantation (Gebel and 
Bray 2008). HLAi transplantation provides a way of crossing this antibody barrier, 
by seeking to transform a crossmatch result from positive to negative, thus 
allowing transplantation to proceed. As pointed out by Gebel and Bray (2008), 
HLAi also describes transplantation which is performed in the presence of a weak 
antibody, which may only be detectable using sensitive antibody screening 
assays such as Luminex® technology, and which does not result in a positive 
crossmatch. It is crucial that the antibody titre (generally reflected by the mean 
fluorescence intensity (MFI) value obtained from bead-based assays), class and 
specificity is clearly defined in all potential HLAi cases so that a judgement can 
be made about whether to instigate procedures to reduce antibody levels, or 
whether to simply adjust the post-transplant management of the patient.
1.7 Desensitisation protocols as a method of facilitating HLAi 
transplantation
‘Desensitisation’ describes the application of a regimen of drugs and/or 
treatments in an attempt to remove or reduce DSA from a potential recipient’s 
circulation pre-transplant. Each case is assessed individually in terms of precisely 
what course of treatment to implement and the HLA antibody reduction target to 
achieve in order for the transplant to be deemed compatible and allowed to 
proceed; for example a CDC crossmatch conversion from positive to negative. 
The clinical protocol for desensitisation varies from centre to centre, and the full 
procedure often incorporates newly developed and potent immunosuppressive 
drugs, that aim to suppress lymphocyte activation and proliferation. Treatment 
generally involves a regimen of immunosuppression (see table 1.2) combined 
with one or more of the modalities summarised in table 1.3.
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Table 1.2 Immunosuppressive drugs utilised in renal transplantation in Leeds
Drug Mode of action
Alemtuzumab Mab targeting CD52 cell surface antigen, present 
on mature lymphocytes (Wiseman 2016)
Basiliximab
(Simulect)
Mab targeting the a-chain of the IL-2 receptor 
(CD25) (Wiseman 2016). Blocks IL-2 binding and 
subsequent T cell proliferation
Cyclophosphamide, 
active metabolite 
phosphoramide 
mustard
DNA alkylating agent (Wiseman 2016). Inhibits 
DNA replication and cell division
Cyclosporin Calcineurin inhibitor, prevents production of IL-2, 
and subsequent T cell activation (Janeway et al. 
2005)
Mycophenolate, 
active metabolite 
mycophenolic acid 
(mycophenolate 
mofetil (MMF))
Blocks purine biosynthesis, affecting T and B 
lymphocyte proliferation (Parham 2009). Inhibition 
of antibody production by B cells
Prednisone/
methylprednisolone
Anti-inflammatory, down regulation of gene 
expression of ‘inflammatory mediators’ (Janeway 
etal. 2005)
Tacrolimus (FK506) Calcineurin inhibitor, prevents production of IL-2 
(Janeway et al. 2005)
Mab -  monoclonal antibody; IL -  interleukin; DNA - deoxyribonucleic acid
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1.8 Laboratory based HLAi transplantation research reported in the
literature
Despite the experience gained, questions remain around the immunological 
process of desensitisation and subsequent HLAi transplantation. It is recognised 
that it is not always realistic to aim to completely remove HLA-specific IgG, and 
that this is not always necessary for a successful outcome. Moreover, a reduction 
in antibody titre to a level that will not cause HAR and is manageable post­
transplant with immunosuppressive drugs and additional sessions of 
plasmapheresis, will still allow for transplantation. The question of whether it is 
important to prevent resynthesis of antibody post-transplant has been 
investigated by Higgins et al. (2007). The study concluded that DSA levels 
increased within the first month post-transplant in most patients, but a correlation 
with clinical features of rejection was not always observed. Where rejection and 
rises in DSA occurred together, in some cases it was possible to achieve 
resolution of the rejection in the continued presence of DSA. The link between 
circulating DSA post-transplant and rejection, in standard transplantation, has 
formed the basis of other studies (Terasaki 2003) but is not clear cut, as levels of 
DSA in serum samples may not be truly indicative of damage to the graft. No 
detectable antibody, or low levels, may simply mean that antibody is being bound 
and retained in the kidney (BTS 2006, Higgins et al. 2008). The observations by 
Higgins et al. (2007) provide evidence for the theory of kidney transplant 
accommodation, which describes the maintenance of the graft in the presence of 
circulating potentially harmful antibodies. Mechanisms for graft accommodation 
have been suggested, but investigations around this phenomenon are ongoing.
Modulation of the antibody response, with antibody reduction treatments resulting 
in a long-term depletion of DSA, is another feature often observed with successful 
AiT (BTS 2006). Zachary, Montgomery and Leffell (2005) suggest that elimination 
of DSA is by an active down-regulation process, which is mediated by T 
lymphocytes. This is important as often T cell depleting agents are administered 
as part of the immunosuppression regime, and raises the question that this may 
be removing key regulatory T cells (Tregs) as well as those involved in initiating 
allorecognition.
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How individual patients respond to a desensitisation protocol in terms of antibody 
levels is often unpredictable, and, as observed by Higgins et al. (2007), HLA- 
specific antibodies can often remain at low titre. Zachary, Montgomery and Leffell 
(2005) investigated antibody depletion by specific desensitisation methods in an 
attempt to identify factors associated with antibody persistence. Further 
elucidation of this issue would be valuable in predicting which patients will 
respond well in desensitisation programmes, resulting in a way of targeting 
treatment for the patients in whom resistance to desensitisation is expected. The 
study analysed the frequency of antibody elimination and the factors that could 
influence this. DSA persistence was shown to have a significant association with 
DSA titre at the initiation of treatment, i.e. if the antibody level was high before 
desensitisation treatment commenced, then it was more likely to persist following 
treatment and post-transplant. Zachary, Montgomery and Leffell (2005) comment 
that this could be a reflection of the number of B lymphocyte clones, specific for 
a particular donor antigen.
Both the Higgins et al. (2007) and Zachary, Montgomery and Leffell (2005) 
studies raise important questions around the topics of graft accommodation and 
antibody modulation, in terms of what is happening to the patient’s immune 
system whilst they are undergoing desensitisation, and what are the key cellular 
mediators involved in the modulation of DSA. Zachary, Montgomery and Leffell 
(2005) state that transplantation, and concomitant exposure to donor antigens is 
essential for targeted DSA elimination to occur, and that third party HLA-specific 
antibodies (not directed against donor antigens) can persist.
Other studies investigating the underlying processes occurring during 
desensitisation include a study examining ‘third party’ HLA and non-HLA antibody 
levels, and their relationship to DSA levels (Krishnan et al. 2008). Another 
potential area of interest is complement activation in AiT patients (Hamer et al.
2008). A more recent report (Field et al. 2014) described the potential use of 
serum biomarkers in predicting early acute rejection in a cohort of HLAi kidney 
transplant recipients. Out of a series of biomarkers analysed, interferon-gamma- 
inducible protein 10 (IP-10) and neutrophil gelatinase-associated lipocalin 
(NGAL) exhibited significantly increased levels in patients who went on to develop 
acute rejection.
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Previous work from our centre (Cherukuri et al. 2012) has involved 
immunophenotyping of renal patients undergoing ‘standard’ transplantation. 
Populations of lymphocytes studied included naive and memory T and B cells, 
transitional B cells and regulatory B cells. Kamburova et al. (2014) also applied 
the laboratory tool of immunophenotyping to renal transplant recipients, to 
compare the results of rituximab and non-rituximab treated patients. 
Reconstitution, post-rituximab treatment, has been the topic of several other 
previous studies. Kopchaliiska et al. (2009) used immunophenotyping to 
investigate the reconstitution of B cell subsets in a group of eleven highly 
sensitised renal transplant recipients who had been treated with rituximab. Due 
to its therapeutic use in autoimmune disorders, there is a considerable amount of 
data concerning B cell reconstitution post-rituximab treatment in rheumatoid 
arthritis patients (Roll, Dornerand Tony 2008, Leandro et al. 2006). Splenic B cell 
populations have also been studied, and compared to peripheral blood cell 
populations, following certain desensitisation treatments (Ramos et al. 2007). 
Importantly, this study demonstrated that memory (CD27+) and plasma cell 
(CD138+) subsets survived in the spleen following treatment with both 
plasmapheresis/lvlg and rituximab. The main focus of these latter studies was in 
relation to reconstitution post-rituximab treatment. Although this remains relevant 
in terms of lymphocyte repopulation post ablative therapy, rituximab is no longer 
the primary desensitisation tool utilised in the Leeds centre.
The studies described above highlight the fact that questions remain around the 
immunological processes occurring both during desensitisation and post­
transplantation, and increased understanding of this area would be a step 
towards predicting how patients will respond to this treatment. 
Immunosuppressive drugs and the desensitisation process deplete cells involved 
in the immune response directed towards the donor organ, but uncertainties 
remain about the associated immunological long-term effects, including cellular 
reconstitution. Also, of key importance is the effect of desensitisation on cells 
identified as being important in regulation of the immune response.
1.9 Data collection for this study
This research study sought to investigate HLAi transplant recipients, in order to 
gain an insight into the underlying immune processes underpinning individuals’
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responses to desensitisation, chiefly using the laboratory based method of flow 
cytometry. The rationale for the choice of lymphocyte populations to study was 
two-fold; firstly based around some of the literature described above, and 
secondly around the T cell and B cell populations that are known to be important 
in the allo-immune response to the transplanted kidney. The defining feature of 
HLAi transplantation patients is that they possess DSA. However, the detection 
of donor relevant HLA-specific antibodies in the circulation may be viewed as a 
symptom, with the source of the problem being that these potential recipients all 
have immunological memory of certain HLA. Therefore, immune memory was a 
key element that was considered when designing the study.
Three sets of data were collected on each participant peripheral blood sample; a 
commercial kit was utilised to study lymphocyte subsets present, commercial 
fluorophore labelled antibodies were grouped into ‘panels’ for 
immunophenotyping of key T and B lymphocyte populations and the specificity of 
HLA antibodies present was analysed. The rationale behind the lymphocyte 
populations investigated, by immunophenotyping, follows.
1.9.1 Recent thymic emigrants (RTE) immunophenotyping 
This T cell panel was included to analyse the populations of naive and memory 
T cells present, and to identify recent thymic emigrants (RTEs). The cell surface 
markers utilised were CD4, CD45RO and CD31. CD4 ‘helper’ T cells were defined 
as naTve or ‘resting’ T cells, negative for CD45RO (therefore presumed to be 
positive for 0 0 4 5 ^ ) or activated effector or memory T cells (CD45RO positive). 
Different isoforms of the transmembrane tyrosine phosphatase CD45 marker are 
created by the alternative splicing of mRNA from the CD45 gene (Parham 2009). 
The larger of the CD45 isoforms is 0 0 4 5 ^ , present on naive T cells, facilitating 
relatively weak signals in response to specific antigen. In contrast, the smaller 
extracellular domain of CD45RO allows stronger signals in response to antigen by 
its more effective association with the T cell receptor (TCR) and other co­
receptors (Parham 2009). In the peripheral blood circulation of a healthy adult, 
approximately half of the ap T cells are naive and half are memory (Parham
2009).
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Furthermore, naive T cells that have recently undergone their development and 
exited the thymus into the peripheral circulation, termed RTEs, were identified by 
this panel as being CD4+CD45RO'CD31+. During T cell development in the 
thymus, the TCR gene undergoes rearrangements in order to generate the huge 
diversity seen in the receptor molecule. During this process, gene fragments are 
deleted as circular excision products, orT cell receptor excision circles (TRECs). 
Although TRECs can be used as a marker of recent thymic development, they 
are not replicated, so dilute out with each cellular division (Miltenyi Biotec 2016, 
Kohler and Thiel 2009). Expression of the CD31 marker has been identified as 
correlating with the presence of TRECs, and hence has become a marker for 
RTEs (Kohler and Thiel, 2009). The number of RTEs leaving the thymus 
decreases with age due to thymic involution, the replacement of the T cell 
producing tissue of the thymus with fatty tissue, which begins one year following 
birth in humans (Parham 2009, Ribeiro and Perelson 2007).
1.9.2 Activated T cell immunophenotyping
This immunophenotyping panel was included in order to investigate HLA-DR 
expression levels on CD4 and CD8 T cells. Monoclonal antibodies (Mabs) 
directed against CD3, CD4 and HLA-DR were included, and data was gathered 
on the CD3+CD4+HLA-DR+ and CD3+CD8+HLA-DR+ populations. Whilst HLA 
Class I molecules are expressed by all nucleated human cells, Class II 
expression is limited to specialised cells of the immune system, particularly 
antigen presenting cells. Resting T cells do not express Class II molecules, but 
expression is induced on activated T cells (Parham 2009). An increase in the 
percentage of T cells expressing HLA-DR may imply an increase in the activation 
status of T cells present, ultimately leading to an increase in effector cells. 
However, it could also correspond with already activated T cells undergoing 
proliferation, and thereby increasing in percentage terms. Both of these scenarios 
are of interest to assess in a transplantation setting.
1.9.3 Regulatory T cell (Treq) immunophenotyping
The cell markers used for this panel consisted of CD4, CD25 and the intracellular 
protein Forkhead Box P3 (FoxP3). Effector T cells (CD4+CD25+) were identified 
by this panel, alongside regulatory T cells (Tregs). The latter represent a distinct 
population of CD4 T cells, which are characterised as expressing high levels of
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CD25 in conjunction with the transcription factor FoxP3 (CD4+CD25hiFoxP3+), 
sometimes referred to as ‘scurfin’. The gene for FoxP3 is located on the X- 
chromosome and is uniquely expressed in Treg cells (Dijke, Weimar and Baan 
2008, Kang, Tang and Bluestone 2007). Tregs are so called due to their 
‘suppressor’ qualities in regulating other effector T cells, of particular importance 
in preventing ‘self-reactivity’ to auto antigens. Initial investigations leading to the 
discovery of FoxP3 and greater understanding of the role of Tregs were instigated 
by research into certain autoimmune conditions (U.S. National Library of 
Medicine 2016). Immunodysregulation, polyendocrinopathy, enteropathy X- 
linked (IPEX) syndrome is caused by mutations in the FoxP3 gene, resulting in a 
reduction or absence of Tregs, and dysregulation of the immune response (van 
der Vliet and Nieuwenhuis 2007).The severe and systemic nature of IPEX clearly 
demonstrates the essential role that Tregs play in controlling the immune 
response.
In normal function, the suppressive effect of Tregs, initiated when an autoreactive 
CD4 T cell and Treg cell interact with the same APC, is achieved by the 
production and release of cytokines, such as interleukin-4 (IL-4), interleukin-10 
(IL-10) and transforming growth factor-beta (TGF-p). These immune modulating 
cells are of interest to monitor in an HLAi transplantation setting, due to their 
potential role in the dampening of the allo-response and ultimately the 
achievement of transplant tolerance.
In this study, Tregs were analysed according to the method of Arumugakani, 
Wood and Carter (2008) (detailed in section 2.8 of this report), which is carried 
out using peripheral blood mononuclear cells (PBMCs) isolated from whole blood.
1.9.4 Memory B cell immunophenotyping
For B lymphocytes, it was deemed to be important to include cell markers 
characteristic for both naive and mature B cells, in order to attempt to ascertain 
the status of the reconstituting immune system, post-transplantation. Memory B 
cells can reside in the secondary lymphoid organs, in a quiescent state, for the 
life-time of an individual. These long-lived memory clones are different to the 
effector B cells that participate in a primary immune response, in that they are 
isotype switched and have undergone somatic hypermutation (Parham 2009).
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Thus, the secondary response initiated by memory B cells is both stronger and 
faster than when the antigen was originally encountered. This is clearly of key 
relevance in the setting of HLAi transplantation where an antibody barrier is being 
crossed, and information gained around the presence of memory B cells (albeit 
in the periphery) may be useful to tie in with an emergent alloresponse.
The cell surface marker CD27 was employed to distinguish between naive 
(negative for CD27), and memory B cells (positive for CD27). The memory B cells 
were then further defined as either isotype class switched (IgD negative) or IgM 
memory B cells (IgD dull/positive). The stage of development of the circulating 
memory B cells could be important, as switched (IgD negative) memory B cells 
secrete high affinity IgG antibody.
1.9.5 Transitional B cell immunophenotyping
The cell surface markers CD19, CD24, CD38 and CD27 were utilised to 
investigate different populations of B cells present. Three sets of data were 
recorded. Firstly, cells positive for CD19, CD38 and CD24 were noted as being 
mature B cells. B lymphocytes possessing the immature phenotype 
CD19+CD38hiCD24hi were designated as transitional B cells (Cherukuri et al 
2012), and CD19+CD38hiCD27+ as plasmablasts, on the developmental pathway 
to becoming plasma cells.
1.9.6 Plasma B cell immunophenotyping
The characteristic marker, CD138, was used to identify any circulating 
plasmablasts, using two phenotyping strategies. Plasmablasts were defined as 
being CD20' (CD19+CD138+CD20"). In addition, information was gathered on the 
population of CD19+ B cells that expressed CD38 and CD138 
(CD19+CD38+CD138+). CD20 is expressed throughout the B cell lineage, but 
importantly not on plasma cells, which is relevant in the context of the use of 
rituximab. Consequently, CD20' plasma cells are able to persist long-term in 
‘survival niches’ located in the secondary lymphoid organs (Ramos et al. 2007). 
It was planned to investigate the relationship between HLA-specific antibody 
levels and cell populations present.
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1.10 Risk assessment for HLAi transplantation
HLAi transplantation is generally defined as transplantation proceeding where the 
recipient possesses HLA-specific antibodies, which are relevant in the context of 
the donor HLA type, in a current sample. Often, the definition infers crossmatch 
positivity due to current DSA. However, for the purposes of this study, potential 
recipients were considered as participants if they had any level of DSA present, 
directed against a live donor, which necessitated some degree of transplant pre­
conditioning.
The assessment of recipient-donor compatibility is carried out as an analysis of 
risk versus benefit. This is in terms of the risk of the likelihood of unmanageable 
immediate or early rejection of the graft balanced against the benefit to the patient 
of receiving a kidney transplant. This analysis must be viewed in the context of 
the chance of the patient receiving a kidney graft from another source (either a 
deceased donor offer, or a living donor), and the clinical urgency of the individual 
case. An evaluation of recipient versus donor alloreactivity, informed by a detailed 
antibody profile of the recipient and usually a pre-transplant recipient versus 
donor crossmatch, is a crucial part of this decision making process.
1.10.1 The Leeds approach
The British Transplantation Society guidelines for AiT (2015) state that potential 
HLAi transplant recipients should be risk assessed according to parameters 
known to affect transplant outcome, including positive CDC crossmatch, high FC 
crossmatch, cumulative levels of DSA in excess of 10,000 MFI, presence of 
multiple DSAs, presence of HLA Class I directed DSA, potential use of a 
deceased donor and presence of repeat HLA mismatches.
This guidance is followed in Leeds, where each potential HLAi transplantation 
has always been managed in a ‘case by case’ approach, and the precise pre­
transplant work-up is individualised, according to the clinical and laboratory 
profile of the recipient-donor pair. Currently, in order to gather laboratory data 
from the same time point, a ‘baseline’ crossmatch is recommended by the 
laboratory, to service users, which comprises a CDC crossmatch, FC crossmatch 
and HLA-specific antibody definition using a single antigen bead (SAB) based
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method. If multiple DSAs are present, the MFIs generated by the antibody 
screening assay are added together as a total for HLA Class I and Class II 
directed antibodies. The total cumulative MFI and Class I directed cumulative MFI 
are then used in combination with the CDC and FC crossmatch results to 
generate a ‘challenge score’ which is intended to provide some guidance on how 
much clinical intervention would be required to remove the DSA and allow the 
transplant to proceed. For example, negative results for both crossmatches, and 
cumulative Class I directed DSA of less than 3,000 MFI corresponds with a 
challenge score of 0. At the other end of the risk spectrum, if both crossmatches 
are positive, and the associated cumulative Class I directed antibodies are 
greater than 5,000 MFI, with overall DSA greater than 18,000 MFI, the challenge 
score generated by this algorithm is 4.
Alongside the challenge score, a current case is often likened to a previous 
historic case, in order to build experience into the process of putting together the 
desensitisation protocol. The risk assessment is also incorporated into the 
decision of the laboratory results profile which will be interpreted as ‘compatible’ 
for each HLAi recipient-donor pair. However, as a general rule, the pre-transplant 
CDC crossmatch should be T and B cell negative, and a corresponding reduction 
in the MFI of the DSA present should be evident.
1.11 Objectives of the study
The objectives of the study were:
To monitor and gain knowledge of any fluctuations occurring in key 
populations of lymphocytes during the process of HLAi transplantation, 
and to correlate this with other laboratory and clinical factors, with 
particular reference to DSA MFI levels.
To examine the long-term effects of HLAi transplantation on recipients’ 
immune systems, and investigate the immune reconstitution process, 
post-transplantation.
It was anticipated that completion of both of these objectives would lead to an 
increased scientific understanding of what is happening to an individual’s immune
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system during the process of HLAi transplantation. This would then feed into the 
overall objectives below:
To support the development of an additional laboratory ‘tool’, some 
components of which may feed into the local risk assessment strategy 
described above, to allow clinicians to target immunosuppressive drugs 
and adjust the treatment for HLAi transplantation as a part of a 
personalised management plan. This would allow more informed 
decisions for patient care, with the aim of improving transplant outcome.
To aid in creating an expanded evidence base in order to support the 
effective management of resources involved in the field of AiT.
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CHAPTER 2 MATERIALS AND METHODS
2.1 Project overview
The project consisted of two approaches to investigating changes in the 
phenotypes and phenotype profiles of peripheral blood lymphocytes pre and 
post-HLAi kidney transplantation. The study involved analysis of blood samples 
obtained from -
(1) a prospective participant cohort of patients undergoing HLAi transplantation, 
recruited between November 2011 and November 2012, and
(2) a retrospective participant group, of HLAi kidney transplant recipients, 
transplanted at St James’s University Hospital, Leeds, between 2001 and 2011. 
This group was recruited between June 2012 and June 2013.
Each of the study samples collected was analysed for the following:
• Lymphocyte subsets (absolute counts and population percentages)
• T and B cell immunophenotypes
• Specificity of HLA antibodies present
2.2 Research Ethics Review
An application was submitted to the NHS National Research Ethics Service (NHS 
Research Ethics Committee (REC)) and the NHS Research and Development 
office (NHS R&D) through the Integrated Research Application System (IRAS) 
(Health Research Authority 2016). Supplementary information submitted 
included: the study protocol, evidence of scientific review and statistician 
comments (the latter two both from Sheffield Hallam University), copies of the 
letter for participants’ GPs, participant information sheets and consent forms. The 
latter documents are included in this report as appendices 1-3.
The NHS REC application was reviewed at the Leeds Central REC meeting on 
May 20th 2011, with full approval finally granted in July 2011 (REC reference 
number 11/YH/0102). As part of the NHS R&D approval sought, and as 
participant samples were to be collected at multiple sites, Site Specific 
Information (SSI) forms were completed and submitted to:
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Leeds Teaching Hospitals NHS Trust (R&D reference number IM11/9743) - 
approval granted August 2011.
Bradford Teaching Hospitals NHS Foundation Trust (R&D reference number 
1341) - approval granted October 2011.
Hull & East Yorkshire Hospitals NHS Trust (R&D reference number R1217) - 
approval granted January 2012.
York Hospitals NHS Foundation Trust (R&D reference number YOR-A02069) - 
approval granted April 2012.
A project site file was collated and stored in the Transplant Immunology 
Laboratory, St. James’s Hospital, Leeds (Chief Investigator’s office). This site file 
was subject to an audit by Sheffield Hallam University Research Ethics 
Committee in July 2012.
2.2.1 Obtaining informed written consent
The initial approach to all patient participants was via a nursing or medical 
member of the renal transplantation care team at each NHS site. A project 
information leaflet, and a consent form were provided to all potential participants, 
and time to consider participation in the project was given. There was time to ask 
questions or clarify points if this was required by potential participants. It was 
made clear to each participant that their involvement (or non-involvement) in the 
study was voluntary, and would not affect their clinical care in any way. A member 
of the renal clinical care team recorded the informed consent of participants who 
were willing to proceed with the study; this was in the format of a written consent 
form, which was signed and dated. A copy of the consent form was then given to 
the participant and the original was stored in the project site file by the Chief 
Investigator. Participants were able to withdraw their consent at any time during 
the study. Contact details were provided on the information leaflet, for gaining 
any further information about the study, at any point during its progression, or for 
learning about the study outcome.
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2.3 Anonymisation of study participants and samples
In order to comply with information governance regulations and also to allow 
certain analyses to be performed ‘blind’, all patient participants were allocated an 
identification number, by the Chief Investigator, upon recruitment. The 
participants were numbered sequentially in the order of their recruitment to the 
study, irrespective of which cohort they were recruited to, meaning that within the 
prospective and retrospective groups, the identification numbers were not 
sequential. The normal controls recruited were also numbered in a similar way; 
however sequential numbers were used for this cohort. In order that the results 
of the study could be interpreted in a meaningful way, the Chief Investigator kept 
a record of the identity of all participants.
For the prospective cohort, from whom multiple blood samples were collected, in 
addition to the participant number, each sample was allocated a letter, in order to 
allow identification of longitudinal samples. For example, sample 1A is the first 
study sample collected from participant 1, sample 1B is the second study sample 
collected from the same participant, and so on.
2.4 Description of the study cohort
2.4.1 Prospective study cohort
Within the year’s timeframe allotted for sample collection and analysis of the 
prospective cohort, eight patients were progressed down this route for HLAi 
kidney transplantation. Seven consented to be included in the study, and 
longitudinal blood samples were collected by specialist and research nurse 
colleagues (according to the schedule detailed in figure 2.1). One patient lacked 
the capacity to consent to the study, so was not approached for participation. Of 
the seven consenting participants, three were based in Leeds, two were from 
Bradford and two from Hull.
The Chief Investigator was alerted to potential participants by regular 
communication with specialist nurse colleagues, and also by remaining vigilant 
to patient-donor pairs being booked into the laboratory work diary, who were 
under consideration for transplantation by this specialised route.
25
Figure 2.1 Planned schedule for sample collection from the cohort of prospective
HLAi transplantation participants recruited to the study
Prospective HLAi Cohort 
(7 participants)
I
Leeds Transplant Centre
I
Blood samples* pre-transplant, minimum 1 time point
I
Transplantation
I
Blood samples post-transplant, at around 1 week
■i' >i '!•
Leeds Bradford Hull
I
Blood samples 
Around 6 months post-transplantation
I
Blood samples 
Around 1 year post-transplantation
I
Development of immunological profile’ of patients and correlation with
prediction of transplant outcome
HLAi -  HLA incompatible
* Blood samples: EDTA blood sample to examine different populations of 
lymphocytes present, by flow cytometry immunophenotyping. Plain clotted 
(serum) sample to examine HLA-specific antibodies (may have been taken as 
part of routine blood samples at some time points).
Although R&D approval was granted by four recruitment sites, no prospective 
participants were subsequently recruited from York.
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For reasons that will be expanded upon and explored in the discussion of this 
report, the sample collection for the prospective cohort did not always proceed 
straightforwardly according to the schedule in figure 2.1. Table 2.1 details actual 
samples received on the seven consenting participants.
Table 2.1 Summary of sample collection time points of the prospective HLAi 
transplantation participants recruited to the study
Participant
ID
Gender Pre-transplant 
sample collection 
time points
Post-transplant 
sample collection time 
points
Location
1 M A B C Transplant cancelled Bradford
2 F A B Transplant cancelled Leeds
3 M A B C
Patient 
re-located 
from Leeds
Leeds
7 M A B C D Leeds
9 F A B C D Bradford
11 F A B C Hull
14 F A B C D Hull
ID -  identification; M -  male; F -  female
Allocation of participant ID and sample collection time points are described in 
section 2.3.
Shaded rows indicate participants for whom it was not possible to obtain 
scheduled post-transplantation samples.
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Further explanation of the timing of the study samples collected from each 
prospective participant follows below. The days prior (-) or post (+) the scheduled 
transplant date are indicated, where the day of transplant is regarded as Day 0.
Participant 1:
1A - Day -16 (pre-antibody removal treatment)
1B - Day -9 
1C -  Day-1
For this participant, data is also included from two routine clinical samples 
denoted 1 and 1D:
Sample 1 - -4.5 months (HLAi ‘baseline’ crossmatch)
Sample 1D -  Day +11 (cancelled)
Participant 2:
2A -  Day -11 (pre-antibody removal treatment)
2B -  Day -1
Participant 3:
3A -  Day -8 (HLAi ‘baseline’ crossmatch, participant commenced on MMF)
3B -  Day -1 
3C -  Day +8
Participant 7:
7A -  Day -8 (pre-transplant crossmatch, participant commenced on MMF)
7B -  Day +5 
7C - +8 months 
7D - +13 months
Participant 9:
9A -  Day -12 (pre-transplant crossmatch, participant commenced on MMF)
9B -  Day -5
9C - +6 months (participant on haemodialysis following transplant nephrectomy) 
9D - +1 year
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Participant 11:
11 A -D a y  -9 
11B - +6 months 
11C - +1 year
Participant 14:
14A -  Day -14 (pre-antibody removal treatment)
14B -  Day 0 
1 4 C - +6 months 
14D - +1 year
2.4.2 Retrospective study cohort
Due to the specialised nature of the HLAi transplantation programme, the 
laboratory files for patients previously transplanted by this route are stored in a 
separate filing system to the standard transplanted patients. In Leeds, a 
laboratory file is created for each potential transplant recipient, and contains a 
hard copy of all their laboratory reports, some laboratory data and all pertinent 
correspondence. In order to identify the retrospective cohort, these files were 
located and cross referenced against a list of HLAi patients, provided by the Local 
Collaborator (Leeds).
Of the resultant group of thirty-two potential participants, five were immediately 
excluded; four patients had died since their transplant of causes unrelated to their 
treatment and one patient had relocated and transferred to a distant centre. This 
left a final figure of twenty-seven potential retrospective participants to consider, 
which were split across the four sites as follows:
Leeds - 1 5 ,  Bradford -  2, York -  3, Hull -  7
Specialist nurse colleagues in Leeds were consulted to advise whether any of the 
potential participants should be excluded for any reason, for example if they did 
not regularly attend clinic appointments. It was decided that the Leeds cohort 
would be prioritised for participation, due to the practicalities of sample collection
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and transport. Renal research nurse colleagues provided the chief investigator 
with the appropriate ‘post-transplant’ or ‘dialysis’ clinic lists each week, which 
were then scrutinised for the identified patients. Clinic appointments of potential 
participants would then be communicated back to the renal research nurses, who 
would approach, and collect samples from consenting patients. Of the fifteen 
patients in Leeds, one had subsequently transferred to Harrogate, and another 
to Hull. Of the remaining thirteen patients, eleven were recruited and included in 
the study.
Specialist nurse colleagues in Bradford also helped with providing clinic 
appointment dates for the two potential participants attending at this site. One of 
these patients was recruited into the study, the second patient did not consent 
within a time period to allow inclusion.
Of the three potential participants usually attending clinics in York, one was 
recruited at a clinic in Leeds. The remaining two York patients and the seven 
patients from Hull were not approached for recruitment, as the time period set for 
sample collection was exceeded before this was possible.
In this manner, a total of thirteen retrospective patient participants were recruited 
to take part in the study. The pathway of scheduled sample collection is detailed 
in figure 2.2. Further detail on the samples received from the retrospective 
participants, including time period post-transplantation, is shown in table 2.2.
2.4.3 Normal controls
During the course of the study, a total of nine normal controls were recruited from 
NHS colleagues, all from within the renal transplantation care team. They were 
all age (within 5 years) and gender matched with a retrospective and/or a 
prospective participant. All normal controls signed a consent form for participation 
in the study, and samples were collected by a nurse or medical colleague, as 
detailed in figure 2.3. Further details on the normal control group are shown in 
table 2.3.
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Figure 2.2 Planned schedule for sample collection from the cohort of
retrospective HLAi transplantation participants recruited to the study
Retrospective HLAi Cohort 
(13 participants)
I
i  I
Leeds Bradford
I
Blood samples*
Single post-transplant time point
I
Development of ‘immunological profile’ of patients and correlation with
transplant outcome
HLAi -  HLA incompatible
* Blood samples: EDTA blood sample to examine different populations of 
lymphocytes present, by flow cytometry immunophenotyping. Plain clotted 
(serum) sample to examine HLA-specific antibodies.
Although R&D approval was granted by four recruitment sites, no retrospective 
participants were subsequently recruited from York or Hull.
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Table 2.2 Sample collection time points of the retrospective HLAi transplantation
participants recruited to the study
Participant ID Gender Time post­
transplantation
Location
4 F 8 months York
5 F 9 months Leeds
6 M 11 months Leeds
8 F 11 years Leeds
10 F 2 years Leeds
12 F 7.5 years Leeds
13 F 5 years Leeds
15 F 4 years Bradford
16 M 8 years Leeds
17 F 8 years Leeds
18 M 4 years Leeds
19 F 4 years Leeds
20 M 6 years Leeds
ID -  identification; F -  female; M - male
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Figure 2.3 Planned schedule for sample collection from the cohort of normal
control participants recruited to the study
Normal controls 
(9 participants)
_ _
Healthy volunteers (NHS staff colleagues)
No history of renal failure/transplantation 
Age & gender matched with study participants
I
Single blood sample* for comparison with study participants
* Blood sample: EDTA blood sample to examine different populations of 
lymphocytes present, by flow cytometry immunophenotyping.
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Table 2.3 Details of the normal control participants recruited to the study
Normal 
control 
participant ID
Gender Age (years) Matched patient participant ID 
(matched with normal control 
for gender & age +/- 5 years)
Prospective
cohort
Retrospective
cohort
1 M 38 7
2 M 50 6
3 F 40 14 12
4 F 51 17
5 F 27 13
6 F 40 11 5
7 F 54 15
8 F 30 10
9 M 28 1 16
ID -  identification; M -  male; F -  female
Each normal control was matched with a study participant, from either, or both of, 
the prospective cohort and/or the retrospective cohort, for gender and age (± 5 
years).
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2.5 Key technology utilised in this research: flow cytometry
The main laboratory technology used for this research study was flow cytometry. 
Flow cytometry literally describes the measurement of cells as they pass in single 
file past a specific point of ‘interrogation’. The strength of flow cytometry lies in 
that it allows very rapid analysis of many thousands of single human cells, or 
‘events’. Essentially, as each cell passes through a laser beam, information is 
collected about its morphology and, when used in conjunction with fluorophore 
tagged antibodies, its surface antigen profile.
A typical bench-top flow cytometer consists of the following (a simplified 
diagrammatic representation of which is shown in figure 2.4):
• A laser light source
• A flow cell, where the cells are forced into single file to a point where the 
light source is focused. The flow cytometer utilised in this study contained 
a cuvette flow cell, which facilitates the injection of the cell sample through 
the centre of a stream of liquid (sheath fluid)
• A lens system which focuses the light into the flow cell
• Optical components which collect and focus light of different colours (i.e. 
wavelengths) onto the detectors
• Electronics to amplify and process the resulting signals
• A computer in order to analyse the complex data generated by the flow 
cytometer, and display it in a useful and informative manner.
(Chapel etal. 1999, Ormerod 1999)
The flow cytometer can measure both light scattered by individual cells, and 
fluorescence. In the first instance, the data from the analysis can be displayed as 
a ‘dot-plot’ with each dot representing a single event, or cell (Chapel et al. 1999).
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Figure 2.4 The basic principle of a flow cytometer
Sampir
Reproduced with permission from BD Biosciences (2008, p2)
Copyright Becton, Dickinson and Company
A simplified diagramatic overview showing the key features of a flow cytometer, including 
the laser light source focussed on the flow cell where the cells contained within the 
sample are forced into single file for analysis. Emitted light of different wavelengths is 
collected by the detectors and analysed by the electronics and computer software.
When a sample of cells from human whole blood is run through a flow cytometer, 
a characteristic dot-plot can be viewed as a two-dimensional graph of side scatter 
versus forward scatter, where side scatter represents light scattered by cellular 
granularity, and forward scatter represents light scattered by cell size (figure 2.5). 
This initial analysis then allows the selection, by ‘gating’, of a particular cell type, 
e.g. lymphocytes, for further analysis.
If the cells to be analysed are first stained with a fluorescence-labelled 
monoclonal antibody, then more detailed information can be collected, from the 
flow cytometer, concerning cellular surface antigen expression. Fluorescence 
describes the phenomenon of a molecule being excited by light of a specific 
wavelength, and then losing this excitation energy by emitting light of a longer 
wavelength (Omerod 1999). Emitted light can then be measured by the flow 
cytometer, and if multiple fluorochromes are used, which emit light at different 
wavelengths, then multiple analyses of the same cell can be collected. The 
difference between the absorption and emission spectra is known as the ‘Stokes 
shift’ (Wulff 2006).
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Figure 2.5 An example of a whole blood dot-plot obtained during the study
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SSC -  side scatter (cellular granularity); FSC -  forward scatter (cell size)
The characteristic dot-plot for human whole blood cells, where side scatter represents 
light scattered by cellular granularity, and forward scatter represents light scattered by 
cell size. Different cell populations may be selected by ‘gating’ for further analysis. The 
main populations identifiable from a sample of whole blood are indicated, and an 
example of the lymphocyte selection is presented.
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Due to the fact that the emission spectra of two, or more, fluorochromes can 
overlap, compensation must often be applied to allow for any emitted light from 
one fluorochrome spilling into the detection area of another fluorochrome to be 
corrected. The excitation and emission wavelengths of the fluorochromes 
employed for use in this study are shown in table 2.4.
The flow cytometer used for this study, a FACSCalibur (Becton Dickinson) is a 
two-laser instrument, with one 488nm argon-ion laser and a second 630nm 
helium-neon laser. The 630nm laser can excite allophycocyanin (APC), with all 
the other fluorochromes in table 2.4 being excited by the 488nm laser. This 
instrument is routinely able to detect four-colour fluorescence. The instrument is 
in regular use for a routine NHS diagnostic service, and, as such, is calibrated 
and maintained according to relevant Clinical Pathology Accreditation (CPA) and 
European Federation for Immunogenetics (EFI) accreditation standards.
Immunofluorescence in flow cytometry describes how monoclonal antibodies, 
labelled with a fluorochrome, can be used to identify cells of the immune system. 
During haematopoiesis, different populations of blood cells arise from stem cells 
via a process of development along various lineages. At each stage of this 
process, cells at a particular stage of development along a certain lineage, will 
express characteristic cell surface protein markers, which can be categorised 
according to the cluster of differentiation (CD) nomenclature (Ormerod 1999,). 
These CD markers can be visualised using flow cytometry in combination with 
immunofluorescence, a technique known as immunophenotyping. The cells of 
interest are first selected from the dot-plot of forward scatter versus side scatter, 
and then analysed further using the fluorescent signal from the monoclonal 
antibody-fluorochrome conjugate, which will directly bind its target surface 
antigen wherever present, in a process of direct staining.
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Table 2.4 The excitation and emission properties of the fluorochromes used in
this study
Fluorochrome Excitation wavelength 
(nm)
Emission wavelength 
(nm)
Allophycocyanin (APC) 650 660
Fluorescein 
isothiocyanate (FITC)
494 520
Phycoerythrin (PE) 496 578
Peridinin chlorophyll-A 
protein (PerCP)
482 678
Alexa Fluor 495 519
nm -  nanometre
A selection of conjugated monoclonal antibodies used together in a panel can be 
used to identify and define a population of a distinct set of immune cells. This 
approach was taken in this study in the methods described below. Isotype 
controls were used as a negative control in all immunophenotyping tests. This 
constituted a control immunoglobulin, of the same mouse immunoglobulin isotype 
as the test antibody, with the appropriate bound fluorochrome, which was not 
directed against human cells. Any background staining can then be observed and 
accounted for. In addition, original antibody titration experiments included 
unstained cells which were uniformly negative.
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2.6 Staining whole blood for lymphocyte subset analysis, using Multitest™ 
antibody panels and Trucount™ tubes (Becton Dickinson (BD))
2.6.1 Summary of the assay
The BD Multitest™ kit (product code 340504) was used to allow identification and 
enumeration of the three main populations of lymphocytes: T cells, B cells and 
NK cells. The kit further differentiates T cells into ‘helper’ CD4+ and ‘cytotoxic’ 
CD8+ subsets. A full list of reagent and kit manufacturers and suppliers used in 
this study is included as appendix 4.
The kit consists of two different ‘cocktails’ of monoclonal antibody reagents 
(described more fully in table 2.5), in 1ml of buffered saline with 0.1% sodium 
azide (BD Biosciences 2011). Each monoclonal antibody is labelled with a 
fluorochrome. When whole blood is added directly to the monoclonal antibody 
‘cocktails’, the antibodies bind specifically to their surface antigen targets on the 
cells in the blood. This then allows fluorescence detection and identification using 
a flow cytometer.
Within the Trucount™ tubes a mesh grid contains a lyophilised pellet, which 
dissolves upon addition of the kit reagents and blood sample, releasing a known 
quantity of fluorescent beads. This allows the analysis software to perform a 
calculation comparing the test cellular events with the known bead events 
resulting in absolute counts (cells/pl) for the numbers of each lymphocyte subset. 
The correct lot number of Trucount™ tubes was entered into the software for 
each use, in order that the correct absolute count of beads was used for the 
analysis.
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Table 2.5 The composition of the two cocktails of monoclonal antibody reagents
in the Trucount™ tubes
Conjugated 
monoclonal antibody
Targeted cell 
population
CD markers used to 
define population
‘Cocktail' 1 (tube 1):
CD3-FITC T lymphocytes CD3+
CD8-PE ‘Cytotoxic’ T 
lymphocytes
CD3+CD8+
CD45-PerCP Total lymphocytes CD45+
CD4-APC ‘Helper’ T lymphocytes CD3+CD4+
‘Cocktail’ 2 (tube 2):
CD3-FITC T lymphocytes CD3+
CD16-PE & CD56-PE NK cells CD16+CD56+
CD45-PerCP Total lymphocytes CD45+
CD19-APC B lymphocytes CD19+
CD -  cluster of differentiation
The MultiSET software generates absolute counts (cells/|jl) and % ratios for each 
of the targeted cell populations shown
2.6.2 Method
Study participant whole blood was collected into an ethylenediaminetetraacetic 
acid (EDTA) anticoagulant. Two 7ml tubes of blood were taken from each 
participant. In the majority of cases the blood samples were analysed on the 
same day that they were taken, and all were analysed within 24 hours. Blood 
samples from Bradford and Hull were transported at ambient temperature.
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Two Trucount™ tubes were used for each test. These were labelled with the 
participant identification, and tube number (1 and 2). 15pl of each of two 
Multitest™ monoclonal antibody ‘cocktails’ was added, just above the mesh grid, 
to the appropriate tube. A tube of EDTA anti-coagulated blood was mixed by 
careful inversion, and 50pl was added to each of the Trucount™ tubes, taking 
care that the blood was pipetted into the bottom of the tube, adjacent to the 
monoclonal antibodies. The contents of the tubes were mixed gently by manual 
agitation, and incubated for 15 minutes, at room temperature. 450pl of BD 
FACS™ lysing solution (diluted 1:10 with distilled water) was then added to each 
tube, and the contents were incubated for 15 minutes at room temperature. The 
samples were then analysed on a FACSCalibur™ flow cytometer (Becton 
Dickinson), using the MultiSET software (BD). All study participant tests were 
analysed within one hour of being set up. An example of the data generated by 
the MultiSET software is shown in figure 2.6.
Following the protocol for routine laboratory analysis (Cellular Immunology 
Standard Operating Procedure (SOP)) the following acceptance criteria were 
applied. The information required was obtained from the quality control (QC) 
section present on the test report and all tests fulfilled these criteria:
• The lymphocyte total count was 100% +/-10%. This figure is provided as 
a ‘lymphosum’ and consists of the sum of the percentage of T cells, B cells 
and NK cells. A figure which was markedly different to 100% would have 
indicated that the lymphocyte gate was not accurately placed.
• The difference in the percentage of CD3 cells between tube 1 and tube 2 
was <5%. This comparison of the CD3 percentage obtained from the two 
tubes provides a technical check, for instance for pipetting errors.
• The CD3 absolute count range was similar (+/-5%) between tube 1 and 
tube 2. Similarly to above, this also provides a technical check.
In addition, a further check consisted of examining the sum of the results of the T 
helper and T suppressor cells (% ratio and absolute counts) and assessing if this 
was approximately equal to the total T lymphocyte count result.
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Figure 2.6 A representative example of the raw data, generated at the point of 
acguisition, by the Multitest™ kit for the enumeration of T lymphocytes, B 
lymphocytes and NK cells
CD3/CD8/CD45/CD4
Lymph Events 4209
Bead Events 1828
CD3+ %Lymph 76
CD3+ Abs Cnt 1836
CD3+CD8+ %Lymph 32
CD3+CD8+ Abs Cnt 770
CD3+CD4+ %Lymph 43
CD3+CD4+ Abs Cnt 1035
CD3+CD4+CD8+ %Lymph 0
CD3+CD4+CD8+ Abs Cnt 10
CD45+ Abs Cnt 2408
T H/S Ratio 1.34
I :
CXMVPerCP CDJ-H GvTfTc
. ma pc
CD3/CD16+56/C D45/CD19
Lymph Events 3257
Bead Events 1351
CD3+ %Lymph 77
CD3+ Abs Cnt 1930
CD16+CD56+ %Lymph 7
CD16+CD56+ Abs Cnt 168
CD19+ %Lymph 16
CD19+ Abs Cnt 397
CD45+ Abs Cnt 2522
The gating strategy for the Multitest™ kit is shown, with tube 1 analysis in the top panel, 
and tube 2 analysis in the lower panel. Tube 1 analysis first identifies the lymphocyte 
population (CD45+), then from this identifies the CD3+CD8+ cells and the CD3+CD4+ cells. 
The analysis of tube 2 also first gates the CD45+ population, then from this, the CD19+ 
cells and the CD3"CD16+CD56+ cells. The MultiSET software (BD) generates a report 
from this data detailing absolute counts (cells/pl) and % ratios for each of the targeted 
cell populations.
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2.7 Staining whole blood for immunophenotyping analysis
Participant blood samples were collected into EDTA anticoagulant blood tubes 
for this assay. All commercial monoclonal antibodies had been previously titrated 
from the manufacturer’s recommendations to ensure optimal staining. The same 
procedure was followed for each immunophenotyping panel.
Sufficient 5ml polystyrene round bottom tubes (Falcon) were labelled for the 
immunophenotyping panels to be set up, including one tube for an isotype control. 
A volume of 7.5pl of each commercial monoclonal antibody was added to the 
appropriate tube, except all APC labelled antibodies, of which 2pl was added. 
The participant EDTA blood sample was gently mixed by inversion, and 75pl 
added to each immunophenotyping panel tube. The contents of the tubes were 
carefully mixed by manual agitation, and incubated in the dark, at room 
temperature, for 30 minutes.
3 ml of BD FACS™ lysing solution (diluted 1:10 with distilled water) was then 
added to each tube, with a further incubation in the dark, at room temperature, 
for 15 minutes. Following this incubation, the tubes and contents were centrifuged 
at 250g for 5 minutes. The supernatant was decanted, and the cells resuspended 
in 3ml of 1% (volume for volume (v/v)) foetal bovine serum (FBS) (Invitrogen) in 
phosphate buffered saline (PBS). The tubes were again centrifuged at 250g for 
5 minutes. The supernatant was decanted, and the washing procedure repeated 
once more. The supernatant was decanted, and the cells were resuspended in 
approximately 500pl 0.5% (v/v) formaldehyde (BDH) in PBS. All study samples 
were then stored at 4°C and analysed on the flow cytometer within 24 hours. The 
flow cytometer was set to collect a total count of 20,000 events for the analysis.
Specifically, the immunophenotyping panels, which were all set up following the 
general method described above, are described in more detail below. A checklist, 
using a tick box format, was designed, and used during assay set up for every 
sample, to ensure all commercial antibodies were added correctly. In all cases, 
the lymphocytes were first selected by gating as shown in figure 2.5.
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2.7.1 T cell immunophenotyping panels
Three immunophenotyping panels that identified specific populations of T cells 
were used for this study. The rationale for their inclusion is discussed in the 
introduction of this report. Two of the panels examined cell surface markers, 
whilst the third (regulatory T cell (Treg) panel) involved the analysis of an 
intracellular marker, and is described separately in section 2.8.
One T cell panel analysed naTve (CD4+CD45R0‘) and memory (CD4+CD45RO+) T 
cells present, and identified the population of recent thymic emigrants (RTEs) as 
possessing the phenotype CD4+CD45RO'CD31+. Table 2.6 details the 
composition of this immunophenotyping panel, and the gating strategy employed 
is described in figure 2.7.
A second T cell panel, the ‘activated’ T cell panel, assessed HLA-DR positivity on 
CD4 and CD8 T cells. Table 2.7 details this panel, and the gating strategy 
employed is described in figure 2.8.
Table 2.6 ‘Recent thymic emigrants’ (RTE) immunophenotyping panel
Antibody specificity Fluorescent conjugate Supplier & product 
code
CD4 APC BD Biosciences 345771
CD31 PE BD Biosciences 340297
CD45RO FITC BD Pharmingen 555492
Table 2.7 ‘Activated’ T cell immunophenotyping panel
Antibody specificity Fluorescent conjugate Supplier & product 
code
CD3 PerCP BD Biosciences 345766
CD4 APC BD Biosciences 345771
HLA-DR PE BD Biosciences 347401
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Figure 2.7 The gating strategy for the RTE immunophenotyping panel
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Following the initial selection of the lymphocyte population, the CD4+ cells were 
selected by gating (R5)
(b) FL4 -  CD4, FL1 -  CD45RO
The naive T cells CD45RO' (CD45RA+) (upper left quadrant) and memory T cells 
CD45RO+ (upper right quadrant) cell populations were identified
(c) FL1 -  CD45RO, FL2 -  CD31
The RTEs can be identified as a percentage of CD4+ cells (from gate R5), shown 
in the lower right quadrant, with the phenotype CD4+CD45RO'CD31+
(Gate R6 was not used in this analysis)
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Figure 2.8 The gating strategy for the activated T cell immunophenotyping panel
CD4+ 
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CD3 CD3
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CD4+HLA-DR+cells CD8+HLA-DR+ cells
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(a) FL3 -  CD3, SSC -  side scatter
Following the initial selection of the lymphocyte population, the CD3+ T cells were 
gated (R4)
(b) FL3 -  CD3, FL4 -  CD4
From gate R4, the CD4+ (upper right quadrant) or CD4' (CD8+) (upper left) cells 
could then be selected
(c) FL4 -  CD4, FL2 -  HLA-DR
Gating on the CD4+ cells in (b), the CD4+HLA-DR+ population were identified in 
the upper right quadrant
(d) FL4 -  CD4, FL2 -  HLA-DR
Gating on the CD4- cells in (b), the CD8+HLA-DR+ population were identified in 
the lower right quadrant
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2.7.2 B cell immunophenotyping panels
The study also employed three immunophenotyping panels to analyse specific 
populations of B cells. As with the T cell panels described above, the rationale for 
studying these cell markers was described in the introduction. The B cell panels 
all examined cell surface antigens.
The first B cell panel was used to assess ‘memory’ B cells by employing the CD27 
cell marker. In this manner, the B cell populations could be analysed for naive 
(CD27-) and memory (CD27+) B cells, and the memory B cells could be further 
divided into ‘switched’ and ‘non-switched’, according to IgD expression. The 
target markers used for this panel are shown in table 2.8, and the gating strategy 
is shown in figure 2.9.
A second B cell panel, for ‘transitional’ B cells aimed to identify CD38+CD24+ 
cells, to gain information about the maturity of B cells present within peripheral 
blood. This panel is described more fully in table 2.9, and figure 2.10.
Finally, an immunophenotyping panel to identify any plasmablasts or plasma cells 
present was used. Two different strategies were followed, employing the cell 
markers CD19, CD38, CD138 and CD20 on the study samples. This ‘plasma cell’ 
panel is described in table 2.10 and figure 2.11.
The following isotype control commercial antibodies were included in each assay:
Mouse lgG1-APC -  BD Biosciences (345818)
Mouse lgG1-FITC -  BD Biosciences (345815)
Mouse lgG2-PE - BD Pharmingen (555574)
Mouse lgG1-PerCP - BD Biosciences (345817)
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Table 2.8 ‘Memory* B cell immunophenotyping panel
Antibody specificity Fluorescent conjugate Supplier & product 
code
CD19 PerCP BD Biosciences 345790
CD27 PE BD Pharmingen 555441
IgD FITC BD Pharmingen 555778
Table 2.9 Transitional1 B cell immunophenotyping panel
Antibody specificity Fluorescent conjugate Supplier & product 
code
CD19 PerCP BD Biosciences 345790
CD24 PE BD Pharmingen 555428
CD38 APC BD Biosciences 345807
CD27 FITC BD Biosciences 555440
Table 2.10 ‘Plasma’ B cell immunophenotyping panel
Antibody specificity Fluorescent conjugate Supplier & product 
code
CD19 PerCP BD Biosciences 345790
CD38 APC BD Biosciences 345807
CD138 FITC BD Pharmingen 552723
CD20 PE BD Biosciences 345793
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Figure 2.9 The gating strategy for the memory B cell immunophenotyping panel
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(a) FL3 -  CD19, SSC -  side scatter. Following the initial selection of the 
lymphocyte population, the CD19+ B cells were gated (R4)
(b) FL3-C D 19, FL2-C D 27. TheCD19 B cells were separated intoCD27' naive 
(upper left quadrant) and CD27+ memory (upper right quadrant) populations
(c) FL2 -  CD27, FL1 -  IgD. The memory B cells were then further analysed 
according to IgD expression, which is not identified on ‘switched’ memory B cells. 
IgG ‘switched’ memory cells (IgD ) fall within the upper left quadrant; IgM 
memory cells (lgD+) in the upper right quadrant, and naive B cells are lower right
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Figure 2.10 The gating strategy for the transitional B cell immunophenotyping 
panel
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(a) FL4 -  CD38, FL2 -  CD24. Following the selection of the CD19+ population, 
as shown for the memory B cell strategy shown in figure 2.9, the CD38 and CD24 
expression was analysed, identifying the mature B cells (CD19+CD38+CD24+) 
in the upper right quadrant
(b) FL4 -  CD38, FL2 -  CD24. The quadrants were re-drawn on this plot in order 
to obtain data on the CD19+CD38hiCD24hi transitional B cells (upper right)
(c) FL4 -  CD38, FL1 -  CD27. In addition, this panel included CD27 which is a 
marker for memory B cells (upper and lower right quadrants). The upper right 
quadrant was noted as containing the CD19+CD38hiCD27+ plasmablast 
population
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Figure 2.11 The gating strategy for the plasma B cell immunophenotyping panel
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(a) FL4 -  CD38, FL1 -  CD138. The CD19+ population was first selected, as 
shown for the memory B cell strategy shown in figure 2.9. The CD19+ population 
was then analysed further according to CD38 and CD138 expression, to identify 
the plasmablast population (upper right quadrant) as being 
CD19+CD38+CD138+
(b) FL1 -  CD138, FL2 -  CD20. A plot of CD138 versus CD20 was then used to 
analyse the CD19+ cells further. Using this strategy, plasm ablasts were defined 
as the population of cells that were CD19+CD138+CD20‘ (upper left quadrant)
2.8 Intracellular staining of human FoxP3 in peripheral blood mononuclear 
cells (PBMCs)
The immunophenotyping panel employed to study regulatory T cells (Tregs) 
contained a monoclonal antibody directed against human FoxP3, alongside cell 
surface markers (table 2.11). Unlike the immunophenotyping panels already 
described, whose target CD markers were all expressed on the cell surface, 
FoxP3 is contained within the cell nucleus, and required a method for intracellular 
staining. The method was performed using PBMCs, so these first required 
separation from whole blood. Participant blood samples were collected into EDTA 
anticoagulant blood tubes for this assay.
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Table 2.11 Treqs immunophenotyping panel
Antibody specificity Fluorescent conjugate Supplier & product 
code
CD4 APC BD Biosciences 345771
CD25 PE BD Biosciences 341011
FoxP3 Alexa Fluor BD Pharmingen 560047
2.8.1 Preparation of PBMCs from whole blood
Lympholyte®-H cell separation media (Cedarlane CL5015) was taken from 
storage at 4°C and allowed to reach room temperature. Lympholyte® 
(‘lymphoprep’) density gradient medium (density of 1.077g/ml) facilitates the 
isolation of PBMCs. During centrifugation, granulocytes and erythrocytes are 
sedimented through the separation medium due to their increased density 
compared to PBMCs. A ‘buffy coat’ layer containing PBMCs is suspended on top 
of the lympholyte, whilst the plasma, and platelet layer is above (figure 2.12).
Two 15ml ‘V-bottomed’ tubes were labelled for each participant. 3ml of 
lympholyte was added to each of the two 15ml tubes, using a plastic pastette. 
The blood sample was gently mixed, and 3ml of whole blood was carefully 
‘layered’ onto the lympholyte. The tubes were then centrifuged, at room 
temperature, at 500g for 20 minutes, to separate the blood into layers of 
plasma/platelets, PBMCs and polymorphonuclear cells/erythrocytes.
The PBMC buffy coat layer was then carefully removed from each tube using a 
plastic pastette, and transferred to a fresh, labelled 15ml tube, containing 
approximately 2 ml of PBS/FBS (1%). The tubes were topped up with PBS/FBS, 
and centrifuged at 150g, for 10 minutes, to wash the cells and remove the 
lympholyte.
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Figure 2.12 Isolation of PBMCs using Lvmpholvte®-H cell separation media
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Adapted from Cedarlane (2014)
Reproduced with permission from Cedarlane
Lympholyte® density gradient medium facilitates the isolation of PBMCs. Whole blood is 
first ‘layered’ onto the lympholyte. During centrifugation, granulocytes and erythrocytes 
are deposited through the medium due to their increased density compared to PBMCs. 
A buffy coat layer containing PBMCs becomes suspended on top of the lympholyte, 
whilst the plasma, and platelet layer is above.
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Following centrifugation, the supernatant was decanted, and the cells 
resuspended in PBS/FBS. The tubes were again topped up with PBS/FBS for a 
second wash, centrifuging as above. The supernatant was again removed, and 
the cells resuspended in 1ml PBS/FBS.
2.8.2 Counting of PBMCs
A mix of 450 pi of 0.4% (v/v) trypan blue (Sigma T8154) and 50 pi of cells was 
made up in a 5 ml Falcon tube. Trypan blue assists in the visualisation of viable 
cells by dye exclusion methodology with live cells not taking up the stain and dead 
cells staining blue (Strober 2001). A haemocytometer and microscope were used 
to calculate the number of cells present in this mix, and therefore in the isolated 
PBMC sample, and the cells resuspended in PBS/FBS to a concentration of 1 x 
106 per ml in the 15 ml tube.
1 ml (1 x 106 cells) of PBMCs was then aliquoted into each of two labelled 5 ml 
Falcon tubes. Each tube was topped up with PBS/FBS, and the cells washed by 
centrifugation at 250g for 5 minutes.
2.8.3 Cell surface staining of PBMCs
The supernatant was decanted from each tube, and the resultant cell pellet 
containing 1 x 106 cells, was resuspended by tapping the tube. The following 
antibodies were then added to the tubes:
Tube 1: Jest 2 pi CD4-APC
5 pi CD25-PE
Tube 2: Control 2 pi APC isotype control
5 pi PE isotype control
The contents of the tubes were gently mixed by agitation, and then incubated in 
the dark, at room temperature, for 20 minutes. Following incubation, each tube 
was topped up with PBS/FBS, and the cells washed as before. The cells were 
then re-suspended, and a second wash carried out.
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2.8.4 PBMCs fixation and permeabilisation
The human FoxP3 buffer set (BD Pharmingen 560098) was prepared, as follows:
FoxP3 Buffer A, containing diethylene glycol and formaldehyde, (10x 
concentration supplied) was diluted 1:10 in distilled water.
FoxP3 Buffer B, containing ^0.09% sodium azide, (50x concentration supplied) 
was diluted 1:50 in buffer A. The resulting solution is then known as buffer C.
Following the second wash, the supernatant was decanted, and the cell pellet 
was gently vortexed in order to prevent the cells ‘clumping’ together. 2 mis of 
diluted buffer A was then added to each of the two tubes of cells, in order to ‘fix’ 
the cells. The cells were incubated with buffer A for 10 minutes, in the dark at 
room temperature. Following incubation, the tubes and contents were centrifuged 
at 250g for 5 minutes, and the resultant supernatant removed. The tubes were 
then briefly vortexed, before the cells were resuspended in 500 pi of buffer C, in 
order to permeabilise the cells, for 30 minutes, in the dark, at room temperature.
2.8.5 Intracellular staining of PBMCs
Following incubation, the cells were washed twice in PBS/FBS as previously 
described. After the second wash, the following antibodies were added to the cell 
pellets in the tubes:
Tube 1: Test 15 pi FoxP3-Alexa fluor
Tube 2: Control 15 pi FITC isotype control (BD Biosciences 345815).
(FITC and Alexa fluor share the same properties in terms of 
fluorescence wavelength, hence the use of the FITC isotype 
control).
The contents of the tubes were gently mixed, and then incubated in the dark, at 
room temperature, for 30 minutes. Following incubation, the cells were washed 
twice, as before and then, finally, the cells were resuspended in approximately 
500pl PBS/0.5% formaldehyde. All study samples were stored at 4°C and 
analysed on the flow cytometer within 24 hours.
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An example of the data obtained from this panel is shown in figures 2.13 and 
2.14.
Figure 2.13 A dot plot of side scatter versus forward scatter for separated PBMCs
COM 8 FOXTPEC. 16 M  13 008
Side scatter
■Monocytes
Lymphocytes
Forward scatter
The initial dot-plot of side scatter versus forward scatter for the Tregs panel 
demonstrated a different appearance to those obtained in the analyses using 
whole blood, as the polymorphonuclear cells were removed during the lympholyte 
PBMC isolation. Thus, only populations of monocytes and lymphocytes remained 
visible (lymphocytes gated; monocytes can be discerned as a separate 
population of slightly larger cells shifted along the FSC axis). A gate was drawn 
around the lymphocytes which were then used for subsequent analyses.
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Figure 2.14 The gating strategy for the Treq immunophenotvpinq panel
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(a) FL4 -  CD4, SSC -  side scatter. Following the selection of the lymphocyte 
population, as described in figure 2.13, the CD4+ cells were identified (R5) and 
gated.
(b) FL4 -  CD4, FL2 -  CD25. The CD4+ cells were further analysed according to 
CD25 expression, with both CD4+CD25+ cells (upper right quadrant) and 
CD4+CD25' cells (upper left quadrant) present
(c) FL2 -  CD25, FL1 -  FoxP3. Data on the Tregs was then collected, by plotting 
CD25 expression versus FoxP3. The population of Tregs was identified in the 
upper right quadrant as CD4+CD25hi FoxP3+
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All the data from the immunophenotyping panels were stored on the computer 
linked to the flow cytometer, so that the final analysis and recording of positive 
events in gated areas could be carried out simultaneously for all samples, for 
each panel. In this manner, the results from each panel were scrutinised for all 
participants and normal controls together, in an attempt to maintain consistency 
in gating and selecting cell populations, thereby minimising bias. This reanalysed 
‘panel-by-panel’ data was additionally briefly reviewed by an expert adviser for 
flow cytometry (Dr Clive Carter), who was ‘blinded’ to the sample identity, again 
to ensure scientific rigour and minimise bias.
2.9 Key technology utilised in this research: Luminex xMap®
Luminex xMAP is similar to a flow cytometry based system, in that it is a bench 
top instrument which utilises fluorescence detection for the analysis of biological 
samples. In the case of Luminex, assays are designed around colour-coded 
polystyrene beads, or microspheres (Luminex Corporation 2014). The instrument 
consists of a LABScan™ 100 flow analyser, combined with a Luminex® XY 
platform (allowing automated sample analysis) and a sheath delivery system 
(One Lambda 2013). The majority of H&l service laboratories employ Luminex 
technology for routine HLA-specific antibody screening and/or HLA typing.
2.10 HLA-specific antibody detection using Luminex technology
The LABScreen® Single Antigen assay (One Lambda), designed for use on the 
Luminex instrument, is capable of detecting and specifically identifying HLA Class 
I and Class II antibodies, of the IgG class. Earlier cell-based methods were often 
not able to uniquely define the HLA target of the antibody, due to cellular 
expression of multiple HLAs, further complicated by the phenomenon of linkage 
disequilibrium. Single antigen solid-phase assays utilising purified HLA have 
since revolutionised HLA-specific antibody detection (Pei et al. 2003, Stastny et 
al. 2009). The purified HLAs are coated onto Luminex microspheres, which are 
uniquely identified by internal fluorescent tags. The assay is analysed using 
Luminex xMAP technology, which works by using two lasers; a classification laser 
which excites and analyses the internal fluorescent dye mixture, which contains 
a red-infrared ratio specific for each bead, and a reporter laser which excites and 
analyses any fluorescence on the outside of the bead.
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During the assay, a diagrammatic representation of which is shown in figure 2.15, 
serum from the individual being investigated is incubated with the HLA-coated 
Luminex microspheres. Any HLA-specific antibodies present in the serum bind to 
their target HLA coated on the beads. Bound IgG is then labelled with a 
secondary anti-human IgG antibody, which is conjugated with phycoerythrin (PE). 
The Luminex classification laser identifies each bead, and the reporter laser 
detects and analyses the PE signal resulting from bound, ‘PE-tagged’ IgG. 
Negative and positive control beads are included in the assay. The negative 
control bead is a ‘blank’ bead which is not coated with any HLA, whilst the positive 
control bead is coated with purified human IgG (One Lambda 2013).
The LABScreen® Single Antigen assay Class I combi beads (LS1A04 - One 
Lambda) and the LABScreen® Single Antigen assay Class II combi beads 
(LS2A01) were used in this study, which, respectively, detect and define 
antibodies directed against HLA-A, B and Cw and antibodies directed against 
HLA-DR, DQ and DP. Local worksheets were used to document and analyse the 
results, alongside the supplied kit worksheets, for each lot number, which detailed 
the specificity of each bead.
This assay was performed on participant separated serum samples, which were 
prepared from a whole blood sample collected in a plain clotted tube (containing 
no anticoagulant). Serum samples were then frozen and stored (-20°C) until 
towards the end of the study, when all samples had been received, and then run 
together as a batch. The serum was retrieved from the freezer, and allowed to 
defrost at room temperature, before being used in this assay.
2.10.1 Separation of serum from whole blood samples, for HLA-specific antibody 
analysis
All retrospective cohort and prospective cohort study participants had their blood 
analysed for the presence of HLA-specific antibodies. HLA-specific antibodies 
are present in the serum component of whole blood, which was separated from 
a plain clotted blood collection tube for each participant, and stored frozen (-20°C) 
until analysis. The serum was separated in a manner that ensured that it was free 
from contaminating lipids and red blood cells.
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Figure 2.15 The basic principle of the LABScreen® assay (One Lambda)
Alloantibody
Antigen
— Luminex Bead
Wortley (VHBio)
Reproduced with permission from A. Wortley
A single purified HLA is coated onto each set of uniquely identifiable microspheres. Any 
alloantibody present in the patient sample being analysed will bind to its specific HLA 
target. Bound IgG is then detected using a phycoerythrin (PE)-labelled anti-human IgG 
antibody.
A plain clotted (without gel separator) blood tube was collected for each 
participant. Upon receipt, each sample was checked to ascertain that the blood 
had clotted, and placed in a refrigerator (4°C) for at least 1 hour, to allow the clot 
to retract. The tube was then centrifuged at 800g, for 5 minutes. The liquid serum 
component of the blood was then taken off with a plastic pastette, and aliquoted 
into a labelled V-bottomed centrifuge tube (12mls). This tube was centrifuged at 
800g for 5 minutes.
Upon completion of centrifugation, each serum sample was removed from the V- 
bottomed tube, using a plastic pastette, and aliquoted into at least two 1.5 ml 
microfuge tubes. Care was taken to leave behind any red cell pellet, so that the 
serum was free from red cell contamination. The serum was then stored in the 
1.5ml microcentrifuge tubes at -20°C.
2.10.2 Preparation for the LABScreen® single antigen assay 
The samples to be tested were recorded on a ‘batch plate layout’, which included 
positive (‘in-house’ for Class I or Class II) and negative (LS-NC -  One Lambda) 
control sera, in order to be certain of each serum sample’s location on the test
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plate. The Class I and Class II beads, and the assay buffer were removed from 
the refrigerator and allowed to reach room temperature. Both Class I and Class 
II sets of beads were vortexed thoroughly.
The wash buffer (x10 concentration supplied with kit, <1% sodium azide) was 
diluted 1:10 in distilled water. The assay was performed in a filter plate which was 
‘pre-wetted’ before adding any test sera or reagents, by adding 300pl of wash 
buffer to each of the wells. The filter plate was then incubated on a plate shaker 
for 10 minutes. After 10 minutes, the buffer was removed from the filter plate 
wells, by the use of a vacuum manifold, attached to a laboratory sink tap.
2.10.3 Incubation of beads and sera
The method for routine laboratory analysis was followed (Transplant Immunology 
SOP). This is a locally validated method, which deviates from the manufacturer’s 
method, mainly in terms of the volumes of test sera and reagents used.
10pl of each serum sample was carefully aliquoted to a well on the filter plate, 
according to the ‘batch plate layout’. 2.5 pi of Class I beads were added to the 
Class I test samples, and 2.5 pi of Class II beads to the Class II tests. Beads and 
serum were mixed with the pipette tip during the addition of the beads. The 
contents of the filter plate were carefully mixed on the vortexer, and then 
incubated in the dark, at room temperature, for 30 minutes. Following incubation, 
non-specifically bound antibody was removed by washing the contents of each 
well with 150 pi of wash buffer. The wash buffer was mixed with the contents of 
each well upon addition, and then removed from the wells by using the vacuum 
manifold. A further 3 wash steps were then carried out, each using 200 pi of wash 
buffer.
2.10.4 Addition of secondary conjugated detection antibody
The supplied PE conjugated anti-human IgG was diluted with wash buffer 1:100, 
and then 50pl was added to each test well. The contents of each well were mixed 
with the pipette tip, upon each addition. The plate was then covered, and gently 
vortexed, before incubation in the dark, at room temperature, for 30 minutes.
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Following incubation, the contents of each well was washed using 150pl wash 
buffer as above. A further 4 washes were then carried out using 200|jl of wash 
buffer. The beads contained in each well were finally resuspended in 80pl of PBS 
and mixed using the pipette tip. The plate was carefully vortexed, and then 
analysed immediately on the Luminex platform.
2.10.5 Set-up of the Luminex instrument
Luminex set-up and analysis of the single antigen beads (SAB) assay was 
facilitated by the expert Antibody Section Lead (Mrs Kat Cullen). The standard 
routine daily start-up and shut-down procedures were followed, including laser 
warm-up, washing and calibration. A ‘new multi-batch’ was started, the 
appropriate bead lot numbers entered, and the batch information was entered 
into the Luminex software before starting the analysis. In all aspects, the samples 
were run in a manner similar to routine serum samples analysed in the H&l 
laboratory, so that the results could be compared to those previously obtained for 
participants. Assay set-up and analysis is validated locally to a standard 
acceptable to both CPA and the EFI. The results from the single antigen assays 
were analysed using HLA Fusion™ analysis software (One Lambda, Inc.).
In order for the results to be valid:
The mean channel fluorescence (MCF) of the positive control bead was > 500. 
The mean channel fluorescence (MCF) of the negative control bead was < 1500. 
The ratio of the positive control/negative control must be >2.
A minimum bead count of 50 for each bead was used for analysis, based upon 
local validation data.
The antibody screening data was analysed in a ‘batch’ to minimise any bias and 
ensure that data from all the tests was interpreted in a consistent manner. In line 
with local validation data, and in order to allow comparison with previous routine 
antibody screening results, beads with a mean fluorescence intensity (MFI) of 
1000 or higher were considered to be positive. A ‘first read’ was initially performed 
noting all positive beads with an MFI of 1000 or greater. Beads with reactivity of 
500-1000 MFI were also recorded on the worksheet as being ‘weak’. The data 
was then scrutinised further, paying particular attention to whether or not the
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positive beads for an antigen were ‘clustered’ together on the results read-out, 
and to check that all beads for a given antigen were positive in order for the 
antibody to be confidently assigned. Strong, genuine antibodies tend to appear 
consecutively in the raw data, with similar MFI results, and with all beads bearing 
the particular antigen being positive. There are often several beads detecting 
antibodies directed against a single antigen present within the kit, and if not all 
appear to be clearly positive, then the antibody may be weak, non-genuine, or 
against a single allelic variant of the antigen. A percentage panel reactive 
antibody (% PRA) was calculated for each test by dividing the number of positive 
beads by the total number of beads for each panel, and multiplying by 100. Where 
necessary, individual antibody profiles were converted to a percentage calculated 
reaction frequency (% cRF) in order to reflect the frequency of the detected 
specificities in the UK organ donor pool. An online tool provided by NHSBT 
(2016a), used for this conversion, compares the unacceptable antigens of an 
individual against the HLA types of 10,000 blood group identical organ donors, in 
order to generate a percentage which is representative of the incompatible 
potential donors.
The analysis until this point was performed ‘blind’, in that the donor HLA 
mismatches and the patients’ previous antibody profiles were not examined until 
later in the process. It was hoped that this, too, may reduce bias and ensure 
scientific rigour of the study. Subsequently, the antibody screening data was also 
studied within the context of the participant’s own HLA type. Since it is not 
possible for individuals to form antibody against self-antigen (excepting allelic 
antibodies), knowledge of the participant’s HLA type is important when analysing 
antibody data, in order to avoid assigning ‘self-directed antibodies. Verification 
of analysis and advice on interpretation was sought from the expert antibody 
screening section lead, in the case of complex antibody profiles.
2.11 HLA typing to assist in the interpretation of antibody screening results
In order to allow a full exploration of the antibody screening results, following the 
initial data analysis, they were subsequently required to be reviewed in the 
context of the participant’s HLA type (for the reasons explained above). In 
addition, it was necessary to have access to the full HLA type of the transplant
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donor, in order to assess if DSA was present in a participant’s antibody screening 
profile. In several cases this meant that additional HLA typing was required.
Due to the nature of the HLA molecule bound to the beads, the LABScreen® 
single antigen assay is capable of detecting antibody directed against the DQa- 
chain (encoded by the DQA1 gene), the DPa-chain (encoded by the DPA1 gene) 
and the DPp-chain (encoded by the DPB1 gene). These genes are not routinely 
typed, for the purposes of live donor transplantation, so this prior information was 
lacking in places. Therefore, in the instance of a participant appearing to possess 
an antibody directed against DQa, DPa or DPp, some additional HLA typing was 
undertaken, in order to allow the results to be interpreted fully.
Five recipient-donor pairs had additional HLA typing work carried out in order to 
allow full interpretation of the participant’s HLA antibody screening data. Routine 
DNA samples from the five recipients and their respective donors were located in 
the laboratory DNA archive. DNA samples are routinely stored at -35°C for a 
minimum of 10 years, according to laboratory protocol. The 10 DNA samples 
located were originally extracted from whole blood collected into EDTA, by one 
of two routinely employed DNA extraction methods; rapid salting-out (an ‘in- 
house’ method), or using the Maxwell® 16 DNA extraction instrument (Promega) 
with the Maxwell® 16 Blood DNA Purification kit (AS1010).
Two different HLA typing methods were employed to obtain the information 
required; a commercial polymerase chain reaction (PCR)-sequence specific 
primers (SSP) assay, which is routinely used in the H&l laboratory in Leeds for 
HLA-DPB1 typing, and a Luminex based PCR-reverse sequence specific 
oligonucleotide probes (RSSO) assay. The latter is routinely used within the H&l 
laboratory for HLA-A, B, C, DRB1, DRB3/4/5 and DQB1 typing.
2.11.1 HLA-DPB1 typing using AllSet™ Gold PCR-SSP kit (Life Technologies) 
Two participant-donor pairs were lacking the HLA-DPB1 typing data, which was 
required to fully interpret the participant’s antibody screening profile. The four 
DNA samples were HLA-DPB1 typed using AIISet+™ Gold PCR-SSP (54070D -  
Life Technologies) trays according to standard routine laboratory protocol. The
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DNA was quantitated prior to testing using a Nanodrop 1000 spectrophotometer 
(Thermo Scientific), and the concentration was adjusted to 50ng/pl. The PCR 
results were analysed both manually and by using the UniMatch® Plus software, 
which is supplied with the kits.
2.11.2 HLA typing using LABType® PCR-RSSO typing kits (One Lambda)
The ten DNA samples were HLA typed for HLA-DPA1/DPB1 and/or DQA1/DQB1 
using LABType® PCR-RSSO typing kits, according to standard routine laboratory 
protocol. This local protocol follows a fully validated method which deviates from 
the manufacturer’s method, mainly in terms of the volumes of test DNA/PCR 
product and reagents used.
The details of the kits were as follows:
LABType SSO Class II DPA1/DPB1 (03RSSO2PZ -  One Lambda)
LABType SSO Class II DQA1/DQB1 (03RSSO2QZ -  One Lambda)
The DNA was quantitated prior to testing using a Nanodrop 1000 
spectrophotometer (Thermo Scientific), and the concentration was adjusted to 
20ng/pl.
As the use of the above kits is fully validated for clinical use for HLA-DQB1 typing 
only, wherever it was possible the HLA-DQB1 type or HLA-DPB1 type obtained 
was cross-referenced to that already held on the laboratory database for the 
individual, in order to verify the HLA-DQA1/DPA1 result respectively. Where no 
HLA-DPB1 result was already available for the individual, the LABType® result 
was verified against the Allset+™ Gold DPB1 result.
2.12 Data analysis
2.12.1 General strategy for analysis of lymphocyte subsets and 
immunophenotyping laboratory data
In order to examine the data generated during this study with no bias, the 
lymphocyte subset results and the data from the immunophenotyping panels 
were initially analysed independently without segregating participants according
66
to clinical outcome. Any trends or patterns were noted, and outliers investigated. 
Following this initial approach, the data was also interpreted in the light of clinical 
criteria, e.g. whether the patient experienced graft rejection or not. By using this 
strategy, the scientific rigour of the study was maintained, whilst still yielding the 
fullest interpretation of the data.
Each participant’s lymphocyte subset results were initially viewed as both 
absolute counts and percentage of total lymphocytes, side by side, as it was 
noted that the two graphs could look very different, and it was deemed possible 
that a false perception of what was happening to each lymphocyte subset could 
be gained if the results were presented in one format only. The absolute counts 
of cells were more informative as these gave a true indication of any change to 
an individual’s immune cell profile during the HLAi transplant protocol. For 
example, it was by examining the absolute cell counts that the effect of the 
conditioning for the HLAi transplantation, in terms of eliminating an individual’s 
key immune cells, could be seen. The length of time that an individual remained 
immunocompromised post HLAi transplantation was also evident. During this 
time the percentages of cells present could remain fairly high for some 
populations; however they may be a percentage of a very small number. 
Although, at first glance, they could be misleading, percentages were also 
interesting as they indicated how the cell populations changed relative to each 
other and also how the different cell populations recovered post conditioning and 
transplantation.
2.12.2 Clinical and additional laboratory data collection
Clinical data, such as that related to the conditioning protocol followed by each 
patient, immunosuppressive drugs received and transplant outcome, was 
obtained by a combination of means. Where possible, information was gathered 
from the Leeds Teaching Hospitals (LTH) Pathology electronic results system 
(Telepath) or the LTH renal medicine electronic results system 
(Bradford/Hull/Leeds/York - BHLY). However, the majority of clinical data was 
obtained with the help of clinical and research colleagues via access to the main 
LTH results server, and directly from the patients’ medical case notes.
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Additional laboratory data, such as crossmatch and HLA-specific antibody 
screening results, was obtained from the Transplant Immunology results 
database or from the patients’ laboratory files. In certain instances, in particular 
to collect data related to antibody MFI levels, it was necessary to locate and 
review the raw laboratory data.
The serum creatinine levels and, where required, the CD45+ cell counts, for each 
participant were accessed from the LTH Pathology electronic results system 
(Telepath) or the LTH renal medicine electronic results system (BHLY).
2.12.3 Presentation and analysis of the study results
The study raw data was first collated into Microsoft Excel spreadsheets, and 
subsequently transferred to GraphPad Prism version 6.07 for Windows software. 
All following graphing and analysis of the data was performed using GraphPad. 
The data for the collective cohorts was analysed by one-way analysis of variance 
(ANOVA), using the Kruskal-Wallis test, followed by Dunn’s multiple comparisons 
test (with 95% confidence interval). The Kruskal-Wallis probability (p)-value is 
provided for each analysis, and significant p-values indicated for the multiple 
comparisons. Dunn’s multiple comparisons test reported the p-value in the 
following manner: >0.05 (not significant), £0.05 (*), £0.01 (**), £0.001 (***), 
£0.0001 (****). For the analyses performed on the stratified retrospective cohort, 
assessing the differences between two sets of data, the Mann-Whitney t-test was 
performed. Advice on scrutinising the data was taken from an expert advisor, 
statistician Dr Karen Kilner (Sheffield Hallam University).
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CHAPTER 3 LYMPHOCYTE SUBSET ANALYSIS OF PROSPECTIVE 
AND RETROSPECTIVE HLAi TRANSPLANT RECIPIENTS
3.1 Summary of the study participants
3.1.1 The prospective participant cohort
Seven prospective HLAi transplant participants were recruited to the study and 
longitudinal samples were collected as detailed in section 2.4.1. An overview of 
this cohort is presented in tables 3.1 and 3.2, showing key laboratory and clinical 
data for the group. In order to provide an indication of renal function post­
transplantation, the serum creatinine levels were accessed for each participant; 
these are displayed in table 3.3. Most recent creatinine levels, and levels obtained 
at times closest to both six months and one year post-transplantation, were 
recorded.
Table 3.1(a) indicates that, of the seven prospective participants, two were ABO 
blood group incompatible, in addition to being HLAi cases. Four of the participants 
had been previously transplanted, and it is of interest that, in two of these cases, 
preparation for transplantation took place against a background of repeat donor 
HLA mismatches. For participant 2, the repeat mismatches of HLA-A2, DR4, and 
DQ8 were present, which had also been represented in the previous related 
donor (mother). These HLA specificities were present as DSA against the current 
potential donor (half-sister). Participant 7 also demonstrated a repeat HLA 
mismatch with a previous deceased donor, for HLA-DR4. HLA-DR4 was not, 
however, present as a DSA in this participant, pre-transplantation.
As indicated in table 3.2, participants 1 and 2 did not progress to transplantation. 
In both cases this was due to the crossmatch and HLA-specific antibody results 
(shown in table 3.1(b)) indicating that the recipient versus donor incompatibility 
remained evident on the day prior to the scheduled transplantation, resulting in 
the procedure being cancelled. These two cases showed similarities, in that they 
both involved patients with multiple HLA Class I and Class II directed antibodies, 
which did not respond sufficiently to the antibody removal treatment.
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Table 3.3 Serum creatinine levels for the prospective participant cohort
Participant ID Creatinine (pmol/L)
Approximately 
6 months post­
transplantation
Approximately 
1 year post­
transplantation
Latest 
(time post­
transplant date)
1 N/A N/A 1193 
(2 years and 6 
months)
2 N/A N/A 1060 
(2 years and 4 
months)
3 Out of region 
(199 at 3 months 
post-transplant)
Out of region 
(745 at 16 
months post­
transplant)
686 
(2 years and 4 
months)
7 137 120 135 
(1 year and 9 
months)
9 415 287 595 
(1 year and 9 
months)
11 96 73 80
(1 year and 8 
months)
14 198 185 185 
(1 year and 6 
months)
ID - identification
pmol/L -  micromoles per litre
N/A - not applicable
Adult reference range for serum creatinine (Leeds & Bradford Pathology 
Service 2011):
female 49-90 pmol/L, male 64-104 pmol/L
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As shown in table 3.1(b), for participant 1, the MFI values obtained for DSAs 
directed against HLA-B44, DR11 and DP4 reduced over the course of the pre­
conditioning treatment, but the HLA-A2 antibody MFI level increased from 6,472 
to 14,862. This situation was reproduced with participant 2, who experienced an 
increase in the MFI value of HLA-A2 antibody over the treatment period, from a 
pre-assessment figure of 800 to 5,139 pre-transplantation. This was 
accompanied by an increase in HLA-DQ8 directed DSA from an MFI of 5,882 to 
11,438. A possible explanation for this antibody ‘escape’ from desensitisation, put 
forward at the time, was that a DSA blocking factor was being removed during 
the plasma exchange cycles. It had previously been reported (Kosmoliaptsis et 
al. 2009) that IgM HLA-specific antibodies could block IgG HLA-specific 
antibodies from binding to the HLA molecules immobilised on the single antigen 
beads in the Luminex assay, leading to reduced readings for IgG DSAs. An 
alternative explanation is that complement fixation by HLA specific antibodies can 
interfere with the binding of the secondary IgG detection antibody, thereby 
affecting the fluorescence levels detected and leading to an inaccurate 
measurement of allo-antibody present, or false negative results (Schnaidt et al. 
2011). These phenomena illustrate the technical shortcomings of the single 
antigen bead assay, and are now known as the prozone effect (Schnaidt et al. 
2011). Several strategies of pretreating test sera are now employed by H&l 
laboratories to counteract these difficulties, including heat inactivation, and the 
use of dithiothreitol (DTT) and EDTA.
The remaining five prospective participants progressed to transplantation as 
planned, with the final report reiterating the proviso that there was a risk of 
accelerated acute rejection due to historic or current low level DSAs. Table 3.1(b) 
indicates that for participant 9, the pre-transplant assessment flow cytometric 
crossmatch had converted to B cell positive. However, it was noted that the 
positivity observed was weak, and the HLA-DQ and DP antibodies responsible 
had reduced in terms of their MFI value following pre-treatment. Similarly, a B cell 
positive flow cytometric crossmatch was observed for participant 14, at pre­
transplant assessment. However, in the setting of a reduced DSA, and no further 
incompatibilities, this was not deemed to be a contraindication.
As indicated in table 3.2, participant 3 relocated to a different transplant centre, 
and was lost to follow-up until their return 16 months later with a failing graft. A 
creatinine level of 745 (table 3.3) reflects this graft failure. Of the four transplanted 
participants from whom follow-up samples were obtained, 3 had stable graft 
function (7,11 and 14), and a fourth (9) suffered graft failure due to renal stenosis. 
The results in table 3.3 are consistent with these outcomes, showing improving 
or relatively stable creatinine results for participants 7,11 and 14, whilst those for 
participant 9 remained high.
3.1.2 The retrospective participant cohort
Thirteen retrospective HLAi transplant participants were recruited, as described 
in section 2.4.2. An overview of this cohort is provided in tables 3.4 and 3.5, 
showing key laboratory and clinical data for the group. As with the prospective 
cohort, selected serum creatinine results were recorded (appendix 5).
As indicated in table 3.4(a), of the 13 retrospective participants, two were ABO 
blood group incompatible, in addition to being HLAi cases. In this context, 
participant 5 is of interest, as a transplant using the same donor had been 
previously attempted, using rituximab and plasma exchange for the pre­
conditioning protocol. However, the anti-A blood group titre was not sufficiently 
reduced using this conditioning protocol in order for the transplant to proceed. It 
was therefore decided, by the clinical team, that a specific anti-A absorption 
column (protein-A column) would be used, in a second attempt at transplantation, 
alongside plasma exchange.
The DSAs present pre-transplantation are listed in table 3.4(a). Three cases 
(participants 6, 8, and 17) had historic DSA, which were no longer detectable in 
most recent serum samples. Two cases (13 and 17) involved HLA-specific 
antibodies, which were cross-reactive with the donors’ HLA, causing a positive 
crossmatch. Where it is known, the sensitising event is shown. This can often be 
difficult to ascertain, especially in the case of blood transfusion or pregnancy. 
Sometimes this is due to incomplete medical records, or poor communication 
between the clinical team and the laboratory. Often, the patient may be unsure, 
or unwilling to disclose, if they have ever received a blood transfusion, or, in the 
case of female patients, if they have ever conceived.
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Table 3.4(b) displays initial assessment and pre-transplantation assessment 
crossmatch results for the cohort. Participant 4 was noted for persistent positivity 
in the flow cytometric crossmatch. Results from an autologous crossmatch and 
antibody screening allowed the allo-crossmatch results to be explained by the 
presence of non-HLA antibodies, and the transplantation proceeded as 
scheduled.
The crossmatch results for participant 5 appear to denote a worsening situation; 
however, the initial assessment samples were assessed 3 months prior to the 
pre-transplant samples, so reflect a historic result. The crossmatch results for 
participant 15 (table 3.4(b)) also appear somewhat incongruous, as the pre­
transplant samples indicated a B cell positive result for the CDC assay, whilst the 
flow cytometric assay was negative. However, the positivity observed was noted 
as being weak, and attributed to an IgM antibody, and therefore not considered 
a contraindication for the transplantation to proceed.
As indicated in table 3.5, the conditioning treatment for participant 19 included 
the administration of rituximab, a monoclonal antibody directed towards the B cell 
surface marker CD20 (Beimler, Susal and Zeier 2006). The presence of this drug 
in the recipient peripheral blood samples can result in a false B cell positive 
crossmatch, or can mean that there are insufficient circulating B cells remaining 
to perform the assay. For this reason, a different pre-transplantation assay, 
Lifecodes DSA, was performed to assist in result interpretation for this participant.
3.2 Prospective participant results
The results from the prospective cohort were analysed separately from the 
retrospective cohort results, as the former all have multiple sample time points, 
and were viewed against the background of the individualised transplant 
schedule for each participant. Full data sets were obtained for all the prospective 
participants. For each participant, a ‘procedural timeline’ is first presented, 
followed by graphs of the longitudinal lymphocyte subset results, both as absolute 
counts (cells/pl) and as a percentage of total lymphocytes (CD45+).
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3.2.1 Participant 1
A procedural timeline is shown for participant 1 in figure 3.1. Results from two 
clinical samples from this patient are included. Sample 1 (-4.5 months) was taken 
at the point of the HLAi ‘baseline assessment of challenge’ crossmatch, in order 
to help interpret crossmatch results for the complex case of this individual. A 
further sample (1D -  Day +11) was taken for clinical reasons, to elucidate why 
the required antibody reduction had not been achieved for this patient.
Figure 3.2 shows the results of lymphocyte subset analysis for participant 1. The 
absolute cell counts showed a steady decrease in cell numbers up until the day 
prior to transplant. The fact that this decrease in cell numbers was proportional 
across cell types is indicated in that the percentages of the cell markers 
represented does not alter between the point of baseline crossmatch (-4.5 
months) and Day -9 (figure 3.2 (b)). However, 1 day prior to transplant (Day -1) 
the percentage of CD3+ and CD4+ cell populations appeared to increase, most 
likely due to the sudden dip in the absolute count of CD45+ cells observed 
between the week prior and the day prior to transplantation.
A clinical sample, taken 11 days post the scheduled transplantation (Day +11), 
indicated that the cell populations were starting to recover in terms of both 
numbers and percentages, as expected once the conditioning regimen was 
halted. In this manner, participant 1 represents a good example of why it is 
important to view the absolute counts of cell populations alongside the 
percentages, as, at first glance, figures 3.2 (a) and 3.2 (b) appear to contradict 
each other, and it is only when the absolute count of CD45+ cells is considered 
that the plots have meaning.
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Figure 3.1 Timeline showing key study, laboratory and clinical interventions for
participant 1
Study/laboratory timeline
Clinical event timeline
Day -16  
Study sample 
1A
(pre-treatment)
D a y -14 
Plasma 
exchange 
Low dose Ivlg
Day -3 
Plasma 
exchange 
Lew dose Ivlg
Day 0
Transplantation  
- cancelled
Day -11 
P asms 
•exchange 
Low ccse vig
Day -2 
Plasma 
exchange 
Lew dose Ivlg
Day -7 
Plasma 
exchange 
Low dose Ivlg
Day -9
Study sample 
1B
-4.5 months 
Study sample 1 
HLAi baseline’ 
crcssmstch
Day +11 (cancelled) 
Study sample 1D
D ay-76
Cyclophosphamide 
(ISOmg.'cayj 
Plasms excharga 
Low dose Ivlg
Day-1
Study sample 1C 
= re-t*ansplart crcssmstch 
HLA sntibocy screening 
srd  speoific ty a r  a lysis
HLA - human leucocyte antigen HLAi - HLA incompatible
mg/day - milligrams per day Ivlg - intravenous immunoglobulin
The timeline is not drawn to scale. Study samples are indicated in red 
text/textbox. Study/laboratory interventions are shown on the top of the timeline. 
Clinical interventions are indicated on the bottom of the timeline.
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Figure 3.2 Longitudinal results of lymphocyte subset analysis for participant 1
(a)
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(a) Absolute cell counts (cells/|jl) plotted at the sample collection time points 
indicated on the x-axis; (b) Lymphocyte subset percentages plotted as a 
percentage of total lymphocytes (CD45+). A dotted line indicates Day 0 
(scheduled day of transplant -  cancelled). Sample time points are described fully 
in figure 3.1.
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3.2.2 Participant 2
A procedural timeline is shown for participant 2 in figure 3.3. Figure 3.4 shows 
the results of lymphocyte subset analysis for participant 2, who was monitored 
over two time points, and differs quite markedly from participant 1, in that between 
the samples taken pre-treatment and 1 day prior to the scheduled transplant, 
there was an increase in the total numbers of CD45+ cells, CD3+ cells and CD4+ 
cells (figure 3.4 (a)). This was also demonstrated for the CD3+ and CD4+ 
populations in terms of their overall percentages (figure 3.4 (b)).
Figure 3.3 Timeline showing key study, laboratory and clinical interventions for 
participant 2
Study/laboratory timeline
Day -11
Study sample 2A  
pre-treatment) 
C'cssmatch  
HLA antibody 
screerirg  end 
specificity analysis
Day -7
HLA artibody  
screening and 
specif city analysis
Dsy -1
Study sample 2B 
= ra-t'snsplart c-cssmatch 
HLA antibody screening and 
soecificity ar a lysis
Day -S 
P asms 
exchange 
L s tt.ccsa  via.
D a y -4 
P=asma 
sxcnange 
-■Laa.acia.yig.
D a y -11
Plasma exchange 
Low dose ivlg 
M M F f ig  twice/day}
Day 0
Transp lan ta tion  
- cancelled______
Day -7 Day -2
Flssma Flssm a
exchange exchange
Low dose Ivlo Low dose Ivlo
Clinical event timeline
HLA - human leucocyte antigen Ivlg -  intravenous immunoglobulin
MMF - mycophenolate mofetil g twice/day - gram twice per day
The timeline is not drawn to scale. Study samples are indicated in red 
text/textbox. Study/laboratory interventions are shown on the top of the timeline. 
Clinical interventions are indicated on the bottom of the timeline.
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Figure 3.4 Longitudinal results of lymphocyte subset analysis for participant 2
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(a) Absolute cell counts (cells/|jl) plotted at the sample collection time points 
indicated on the x-axis; (b) Lymphocyte subset percentages plotted as a 
percentage of total lymphocytes (CD45+). Sample time points are described fully 
in figure 3.3.
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In addition, it was noted that participant 2 possessed an absolute cell count in 
excess of double that of participant 1 across all cell types. Appendix 6 
demonstrates that within the ‘normal’ population there is variation in cell counts 
of the lymphocyte populations. Therefore, as the differences in cell counts were 
apparent pre-treatment, it is likely that this simply represents the natural variation 
observed between individuals.
3.2.3 Participant 3
A procedural timeline is shown for participant 3 in figure 3.5. Figure 3.6 shows 
the results of lymphocyte subset analysis for participant 3, who was successfully 
transplanted following his antibody removal conditioning. However, this 
participant subsequently relocated to a different centre and, therefore, the 
collection of further study samples was not possible. Interestingly, participant 3 
showed an increase in cell counts between their baseline crossmatch sample 
(Day -8) and the day prior to transplant (Day -1), most markedly in the CD45+, 
CD3+, CD4+ and CD8+ populations (figure 3.6 (a)). All lymphocyte subsets were 
subsequently depleted by eight days post transplantation (Day +8). Participant 3 
returned to Leeds sixteen months post-transplantation, with a failing graft, with 
both rejection and BK virus infection identified as the cause.
3.2.4 Participant 7
A procedural timeline is shown for participant 7 in figure 3.7. Figure 3.8 shows 
the results of lymphocyte subset analysis for participant 7, indicating the reduction 
in lymphocyte numbers immediately post-transplantation, and recovery at 8 
months and 13 months post-transplantation. Although the profile for the 
percentage of NK cells present (figure 3.8 (b)) shows a striking increase at five 
days post-transplantation (Day +5), all lymphocyte subsets were depleted at this 
point (figure 3.8 (a)). Therefore, this increase in percentage is not as significant 
as it may first appear.
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Figure 3.5 Timeline showing key study, laboratory and clinical interventions for
participant 3
Study/laboratory timeline
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MMF - mycophenolate mofetil g twice/day - gram twice per day
Ivlg - intravenous immunoglobulin
The timeline is not drawn to scale. Study samples are indicated in red 
text/textbox. Study/laboratory interventions are shown on the top of the timeline. 
Clinical interventions are indicated on the bottom of the timeline.
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Figure 3,6 Longitudinal results of lymphocyte subset analysis for participant 3
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(a) Absolute cell counts (cells/pl) plotted at the sample collection time points 
indicated on the x-axis; (b) Lymphocyte subset percentages plotted as a 
percentage of total lymphocytes (CD45+). A dotted line indicates Day 0 (day of 
transplant). Sample time points are described fully in figure 3.5.
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Figure 3.7 Timeline showing key study, laboratory and clinical interventions for
participant 7
Study/laboratory timeline
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The timeline is not drawn to scale. Study samples are indicated in red 
text/textbox. Study/laboratory interventions are shown on the top of the timeline. 
Clinical interventions are indicated on the bottom of the timeline.
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Figure 3.8 Longitudinal results of lymphocyte subset analysis for participant 7
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(a) Absolute cell counts (cells/pl) plotted at the sample collection time points 
indicated on the x-axis; (b) Lymphocyte subset percentages plotted as a 
percentage of total lymphocytes (CD45+). A dotted line indicates Day 0 (day of 
transplant). Sample time points are described fully in figure 3.7.
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3.2.5 Participant 9
A procedural timeline is shown for participant 9 in figure 3.9. Figure 3.10 shows 
the results of lymphocyte subset analysis, indicating the fall in total lymphocyte 
count at 1 week post-transplantation, and recovery at six months and one year 
post-transplantation. No immediate post-transplantation blood samples were 
collected from this recipient, due to there being insufficient cells present to allow 
full immunophenotyping. The CD45+ cell count for the Day +7 time point was 
obtained from routine blood count results available on the Leeds Teaching 
Hospitals Trust (LTHT) electronic results system (Telepath).
3.2.6 Participant 11
A procedural timeline is shown for participant 11 in figure 3.11, and figure 3.12 
shows the results of lymphocyte subset analysis. A reduction in total lymphocyte 
count at one week post-transplantation, and recovery at six months and one year 
post-transplantation are evident (figure 3.12 (a)). No immediate post­
transplantation blood samples were collected from this recipient, due to there 
being insufficient cells present to allow full immunophenotyping. The CD45+ cell 
count for the Day +7 time point was obtained from routine blood count results as 
for participant 9, above.
3.2.7 Participant 14
A procedural timeline and results of lymphocyte subset analysis are shown for 
participant 14 in figures 3.13 and 3.14 respectively. The fall in total lymphocyte 
count at one week post-transplantation, and recovery at six months and one year 
post-transplantation are indicated in figure 3.14 (a). No immediate post­
transplantation blood samples were collected from this recipient, due to there 
being insufficient cells present to allow full immunophenotyping. The CD45+ cell 
count for the Day +7 time point was obtained from routine blood count results.
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Figure 3.9 Timeline showing key study, laboratory and clinical interventions for
participant 9
Study/laboratory timeline
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The timeline is not drawn to scale. Study samples are indicated in red 
text/textbox. Study/laboratory interventions are shown on the top of the timeline. 
Clinical interventions are indicated on the bottom of the timeline.
Day -5 sample was originally intended to be day -1, but transplantation was 
postponed for four days, at short notice, for logistical reasons.
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Figure 3.10 Longitudinal results of lymphocyte subset analysis for participant 9
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(a) Absolute cell counts (cells/pl) plotted at the sample collection time points 
indicated on the x-axis. The CD45+ cell count at Day +7 was obtained from routine 
blood count results available on the Leeds Teaching Hospitals Trust (LTHT) 
electronic results system (Telepath), indicated by black-filled data point; (b) 
Lymphocyte subset percentages plotted as a percentage of total lymphocytes 
(CD45+). A dotted line indicates Day 0 (day of transplant). Sample time points are 
described fully in figure 3.9.
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Figure 3.11 Timeline showing key study, laboratory and clinical interventions for
participant 11
Study/laboratory timeline
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The timeline is not drawn to scale. Study samples are indicated in red 
text/textbox. Study/laboratory interventions are shown on the top of the timeline. 
Clinical interventions are indicated on the bottom of the timeline.
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Figure 3.12 Longitudinal results of lymphocyte subset analysis for participant 11
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(a) Absolute cell counts (cells/pl) plotted at the sample collection time points
indicated on the x-axis. The CD45+ cell count at Day +7 was obtained from routine
blood count results available on the LTHT electronic results system (Telepath),
indicated by black-filled data point, (b) Lymphocyte subset percentages plotted
as a percentage of total lymphocytes (CD45+). A dotted line indicates Day 0 (day
of transplant). Sample time points are described fully in figure 3.11.
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Figure 3.13 Timeline showing key study, laboratory and clinical interventions for
participant 14
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The timeline is not drawn to scale. Study samples are indicated in red 
text/textbox. Study/laboratory interventions are shown on the top of the timeline. 
Clinical interventions are indicated on the bottom of the timeline.
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Figure 3.14 Longitudinal results of lymphocyte subset analysis for participant 14
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(a) Absolute cell counts (cells/pl) plotted at the sample collection time points
indicated on the x-axis. The CD45+ cell count at Day +7 was obtained from routine
blood count results available on the LTHT electronic results system (Telepath),
indicated by black-filled data point; (b) Lymphocyte subset percentages plotted
as a percentage of total lymphocytes (CD45+). A dotted line indicates Day 0 (day
of transplant). Sample time points are described fully in figure 3.13.
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Both participants 2 and 3 showed an increase in absolute cell counts between 
samples taken at baseline and the day prior to transplant, particularly in the 
CD45+, CD3+ and CD4+ populations (figures 3.4 (a) and 3.6 (a)). This pattern is 
in contrast to transplanted participants 9 and 14. Sample time points for 
participants 7 and 11 did not allow this comparison. The conditioning protocols 
for participants 2 and 3 were similar in that they both received MMF at the start 
of treatment, followed by plasma exchange and low dose Ivlg. However, this is 
unlikely to provide the explanation for the increase in cell counts observed, as 
participants 9 and 14 received similar conditioning.
All five transplanted patients showed a fall in lymphocyte counts immediately 
post-transplantation. For participants 3 and 7 this was demonstrated in the 
samples collected according to the original schedule (Day +8 for participant 3 and 
Day +5 for participant 7). However, neither of these samples contained sufficient 
cells to allow full immunophenotyping analysis to be undertaken. This was found 
to be caused by a recent alteration to the general immunosuppression protocol, 
which included the addition of the drug alemtuzumab, which had rendered this 
sample time point uninformative due to the total reduction of cells, and therefore 
subsequent participants (9,11 and 14) were not sampled at this point.
In order to check that all participants did indeed have insufficient cells for full 
immunophenotyping analysis at this point, and also to indicate the fall in total 
lymphocytes, immediately post-transplant, on the participant graphs for absolute 
cell counts, a CD45+ cell count was taken from the routine haematology test 
results on the LTHT results server (Telepath). The use of the CD45+ cell count 
figure from Telepath, for participants 9, 11 and 14, allowed the graphs showing 
absolute cell counts to indicate the extent of the depletion of total lymphocytes.
All transplanted participants for whom follow-up was possible (participants 7, 9,
11 and 14) showed some recovery of their total lymphocyte counts over the first
year post-transplantation. However, consistent for all cases, the cell counts did
not recover to pre-treatment levels, and in most cases (9,11 and 14) the one year
post-transplant sample indicated a CD45+ cell count of less than half of that of
the pre-transplant sample, and a value much reduced compared to the mean for
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the normal controls of 2,130 cells/jjl. However, with the exception of participant 
14, the transplanted participants all showed a recovery of CD19+ cells to near 
pre-transplantation cell counts. The delayed B cell recovery, observed in 
participant 14, may be due to treatment with methyl-prednisolone for a rejection 
episode post-transplantation.
For participant 7, the cell recovery for the individual lymphocyte populations was 
not in proportion to the pre-transplant levels, with CD8+ cells in particular making 
a slower recovery. This is indicated in figure 3.8 (b), in that the proportions of cell 
types present were not consistent with the pre-transplantation sampling point. 
With the exception of the CD19+ subset, participants 9, 11 and 14 appeared to 
make only a small recovery of their lymphocyte subsets by one year post­
transplantation (figures 3.10, 3.12 and 3.14), and indeed participants 9 and 11 
showed a decrease in cell counts of both CD3+ and CD8+ cell populations 
between six months and one year post-transplantation (figures 3.10 (a) and 3.12
(a)). For all four transplanted participants, the proportions of cell types did not 
reconstitute consistently in relation to the pre-transplant sample (indicated on the 
lymphocyte subsets percentages graphs shown in figures 3.8 (b), 3.10 (b), 3.12
(b) and 3.14 (b)). This demonstrates that the four participants remained 
immunocompromised at one year post-transplantation, both in terms of absolute 
cell counts and in terms of relative proportions of cellular populations as a 
percentage of overall lymphocytes.
3.2.8 CD4:CD8 T cell ratios for the prospective transplant participants
The Multitest™ kit provides a ratio for CD4:CD8 T lymphocytes, calculated by 
dividing the absolute count of the CD4+ cells by the absolute count of the CD8+ 
cells. This was plotted longitudinally for each prospective participant for their 
sample collection time points (figure 3.15). For participants for whom there was 
an age and gender matched normal control recruited to the study, this CD4:CD8 
ratio is also indicated on the graph.
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Figure 3.15 Prospective participants CD4:CD8 T cell ratios
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The CD4:CD8 T cell ratios are shown longitudinally for each prospective 
participant, x-axis - sample time points as described in individual participant 
timelines, in section 3.2. Where an age and gender matched normal control has 
been recruited to the study, the CD4:CD8 ratio for the control is indicated in red 
(for participants 1, 7,11 and 14).
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As indicated in figure 3.15, the absolute count of CD4+ cells is greater than that 
of CD8+ cells in healthy individuals, denoted by a CD4:CD8 ratio of >1. In the 
participants who were not transplanted, the CD4:CD8 ratio remained steady; 
whereas the transplanted participants all displayed dramatic changes in their 
ratios. Where an immediate post-transplant sample was analysed (participants 3 
and 7) the ratio was close to zero, a reflection of the fall in both cell populations. 
Participant 7 demonstrated the highest increase in their CD4:CD8 ratio, peaking 
at a value of 4.4 at eight months post-transplantation. This reiterates that the 
recovery of the CD8+ T lymphocyte population was particularly slow in this 
participant. For the remainder of the participants (9, 11 and 14), the CD4:CD8 
ratio was lowest in their six month post-transplantation sample (range 0.3 to 1.0), 
and then showed some recovery in their one year post-transplantation sample 
(range 1.0 to 1.5); although in all cases the ratio did not reach the pre­
transplantation value. It is also noteworthy that for participant 14, the CD4:CD8 
ratio (3.6) was relatively high in the pre-treatment sample.
3.3 Retrospective participant results
A total of thirteen retrospective HLAi transplant patients were analysed at a single 
post-transplant time point and full datasets for lymphocyte subset analysis were 
obtained. For the purpose of initial analysis, the results from the single time points 
for the retrospective cohort were plotted alongside the results from the normal 
controls. The prospective cohort results from a pre-transplant sample, and also 
six months and one year post-transplant were also included for comparison 
(figure 3.16).
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Figure 3.16 Lymphocyte subset analysis for the retrospective cohort, alongside
the normal controls, and prospective cohort
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Absolute cell counts (cells/pl); K-W -  Kruskal-Wallis test; significant p values are versus the 
normal control cohort, unless indicated otherwise; ns - not significant; horizontal line indicates 
mean. Normal controls, n= 9; retrospective cohort, n= 13; prospective cohort pre-transplant, n= 
7; prospective cohort six months post-transplant, n= 4; prospective cohort one year post­
transplant, n= 4.
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The absolute count of each population of lymphocytes was studied, for the five 
study groups; normal controls, retrospective participants and prospective 
participants pre-transplantation, six months post-transplantation and one year 
post-transplantation (figure 3.16). The graph for total lymphocytes showed that 
there was much variation observed within the groups of normal controls, 
retrospective participants and the prospective participants pre-transplantation. A 
similar amount of variation between individuals within each of the aforementioned 
three cohorts was evident for the absolute counts of CD3+ and CD4+ cells. 
Conversely, the graphs for CD8+, CD19+ and NK cells display less variation within 
these cohorts.
The prospective pre-transplantation cohort had a mean absolute count of total 
lymphocytes that was reduced compared to the normal controls (not significant). 
With the exception of NK cells, this was the case for the cell counts of each of the 
lymphocyte subsets studied, for the prospective cohort prior to any interventions. 
The six month and one year post-transplantation groups demonstrated a drastic 
reduction in total lymphocytes (p £0.01 compared to the normal controls) due to 
the lymphoablative effect of the transplantation conditioning protocol and the 
continued use of immunosuppression. A significant reduction in absolute cell 
counts, for these groups, was also observed for the CD3+, CD8+ and CD4+ 
subsets.
The mean CD45+ cell count for the retrospective cohort was also reduced 
compared to the normal controls (not significant) indicating that some transplant 
patients never totally recover their lymphocyte cell counts to a ‘normal’ level. 
These findings were mirrored in the analyses for CD3+, CD8+, CD4+, CD19+ and 
NK cells, in terms of the mean values being consistently reduced compared to 
the normal control group (not significant).
Within each graph, certain data points were striking. The graph of the absolute
count of CD8+ cells showed two retrospective participants who had higher counts
than all other participants. These outlying data belong to participants 8 and 18,
with absolute cell counts of 1,573 and 1,194 cells/pl respectively. Retrospective
participant 17 was somewhat of an outlier for CD4+ cells, with an absolute cell
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count of 1,339 cells/|jl. Retrospective participant 8 also had a much higher than 
the mean number of NK cells, with a count of 368 cells/pl.
Participant 7 differed markedly to the rest of the prospective cohort on the graphs 
for NK and CD19+ cells in that over the course of the year post transplantation, 
they made a stronger recovery for these cell types compared to the other three 
transplanted participants. In both cases the data points for participant 7 are above 
the mean. However, as previously mentioned, in relation to figure 3.8, this 
participant made a comparatively slow recovery of their CD8+ cells.
The graph for CD19+ B cells demonstrated the serious depletion of these cells 
not only in most of the prospective group at the 6 month post-transplantation time 
point, but interestingly also in many of the retrospective group (not significant). 
Here participants 4, 8 and 19 had very low counts.
CD4:CD8 ratios were also plotted for the retrospective cohort, alongside the 
normal control cohort and the three time points for the prospective cohort (figure 
3.17). From this, it was clear that there was a greater range of values for the 
transplant recipient cohorts compared with the normal controls. The normal 
controls all showed a CD4:CD8 ratio of greater than 1, and less than 3, with a 
mean of 1.8. The retrospective cohort, in particular, showed a large spread in 
CD4:CD8 ratio results, from a minimum value of 0.2 to a maximum of 3.6. Despite 
this a similar mean value of 1.7 was observed. Several participants, most notably 
4, 6 and 8, had an inverted CD4:CD8 ratio (0.53, 0.55, 0.2 respectively) due to 
their CD4+ cell count being lower than their CD8+ cell count. As previously noted, 
prospective participant 7 was striking in showing a high CD4:CD8 ratio at the 
sample time points equivalent to six months and one year post-transplantation.
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Figure 3.17 CD4:CD8 T cell ratios for the retrospective cohort, alongside the
normal controls, and prospective cohort
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K-W -  Kruskal-Wallis test; ns - not significant; horizontal line indicates mean. Normal 
controls, n= 9; retrospective cohort, n= 13; prospective cohort pre-transplant, n= 7; 
prospective cohort six months post-transplant, n= 4; prospective cohort one year post­
transplant, n= 4
3.4 Normal control participant results
Nine normal controls were recruited to the study and assessed at a single time 
point, described in section 2.4.3. The results for the normal controls are shown in 
appendix 6. Appendix 7 shows a comparison of the median results for the nine 
normal controls with published data for healthy adults (n = 51) (Bonilla and 
Oettgen 1997). The study data for normal controls shows similar values to the 
published data although, except in the case of NK cells, slightly higher absolute
counts were observed across all subset populations.
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3.5 Further stratified analysis of the results of lymphocyte subsets
3.5.1 HLA-DR mismatching analysis of the data from the retrospective participant 
cohort
Due to the fact that the retrospective cohort had a larger number of individual 
participants than the prospective cohort, an analysis of the impact of HLA-DR 
mismatching on the study data, was first attempted using this study group. The 
retrospective cohort was stratified according to HLA-DR mismatches present 
between each individual donor and recipient pair, in the recipient versus donor 
direction. One group consisted of zero or 1 HLA-DR mismatches (n = 8) whilst 
the second group was of recipient and donor pairs with 2 HLA-DR mismatches 
(n = 5). The results from the lymphocyte subset analysis were plotted for the two 
groups, for each cell type (data not shown). No differences between the two 
cohorts were observed from these analyses.
3.5.2 The effect of alemtuzumab on lymphocyte subsets in the retrospective 
participant cohort
The results from lymphocyte subset analysis were re-examined in light of which 
participants had received alemtuzumab as a part of their transplantation 
schedule. Three of the retrospective participants (4, 5, and 20) received 
alemtuzumab, but no correlation was observed between this and persistent low 
cell counts (data not shown).
3.5.3 The effect of time since transplantation on CD45+ cell absolute counts, in 
the retrospective participant cohort
The time since transplantation, in months, was examined to ascertain any effect 
on CD45+ cell counts, but no correlation was observed (data not shown).
3.5.4 The effect of the use of MMF in the prospective participant cohort, pre­
transplantation. on lymphocyte subsets
Three prospective participants (3, 7 and 9) received pre-conditioning with MMF 
prior to the first study sample being taken. Further analysis showed no correlation
n o
between this and the reduced cell counts observed, in comparison to the normal
controls (data not shown).
3.5.5 Reanalvsis of the data from the retrospective cohort, to examine a possible 
association between lymphocyte subset results and a post-transplantation 
rejection episode
As indicated in table 3.5, five retrospective participants (6, 13, 15, 17 and 18) 
experienced a rejection episode post-transplantation. The CD45+ cell counts 
differed significantly (p = 0.0451) between the group of participants who 
experienced a post-transplant rejection episode and those who did not, using the 
Mann-Whitney test (table 3.6). No association between rejection episodes and 
the other lymphocyte subsets data was observed (data not shown).
Table 3.6 The CD45* absolute cell count for retrospective participants who 
experienced a post-transplant rejection episode versus participants with no post­
transplant rejection episode
Participants who 
experienced post­
transplant rejection 
(n = 5)
Participants with no 
post-transplant 
rejection (n = 8)
P value (Mann 
Whitney test)
Median CD45+ 
absolute cell count 
(cells/pl)
1524 1025 0.0451
3.6 Discussion of the results of lymphocyte subset analysis
The lymphocyte subset results presented for participant 1 were predictable 
following treatment with cyclophosphamide, a powerful alkylating agent, which 
thereby inhibits DNA replication and cell division (Parham 2009). Due to its 
cytotoxic action, cell apoptosis occurs in all rapidly dividing cells, leading to bone 
marrow suppression (Parham 2009). As stated previously, participant 1 
presented a particularly difficult desensitisation case as they possessed high 
levels of both HLA Class I and Class II antibodies. Therefore, in this case, the
i n
objective of using cyclophosphamide in conditioning was to eradicate the 
recipient’s immune system, reducing the numbers of activated B cells producing 
donor-directed antibodies, and subsequently reducing the capacity of the patient 
to respond to the incompatible transplant.
The five transplanted prospective participants also demonstrated the 
lymphoablative effect of the immunosuppressive drugs administered, with the 
reduction in cell counts of all lymphocyte subsets immediately post­
transplantation. Despite some degree of recovery, particularly in the B cell subset, 
all four participants, with follow-up, remained immunocompromised at one year 
post-transplantation. The drug alemtuzumab was used to target recipient 
lymphocytes peri-operatively, and the effect of this was evident in all of the 
transplanted prospective participants. Alemtuzumab, a drug originally approved 
for the treatment of cancer, is a monoclonal antibody targeted against the cell 
marker CD52 (Parham 2009), which is present on all mature lymphocytes, but 
absent on bone marrow stem cells. This observed scenario fits in with the 
literature regarding alemtuzumab, which is known to cause lymphopenia, with a 
reported recovery of CD 19 cells within 3-12 months, whilst CD4 and CD8 T cells 
may remain lowered for three years (Morales et al. 2008).
Interestingly, the retrospective cohort also displayed mean absolute cell counts 
that were reduced compared to the mean of the normal controls. This may be an 
indication of the long-term effect of the preconditioning and the continued use of 
immunosuppressive drugs. In an attempt to ascertain whether the use of 
alemtuzumab, in particular, had also affected the lymphocyte recovery of the 
retrospective cohort, the data was reanalysed according to whether or not the 
patient received this drug, but no correlation was observed. In addition, no 
correlation was observed between the time since transplantation and total 
lymphocyte cell counts, indicating that it is not the case that the most recently 
transplanted patients were responsible for the reduced mean value.
The observations described above suggest that some transplanted patients 
never recover their lymphocyte subset counts to ‘normal’ levels. However, the 
results from the prospective (pre-transplant) cohort, compared to the normal
controls, point towards a ‘chronic renal failure’ effect, so it may be the case that 
the recovery of lymphocyte counts could be to pre-transplant levels rather than 
to ‘normal’ levels. Although three prospective participants received pre­
conditioning with MMF prior to the first study sample being taken, this does not 
account for the low cell counts observed pre-transplantation. It seems likely that 
the immune systems of patients awaiting transplantation have already been 
compromised, either from the illness itself or the impact of dialysis. This 
phenomenon has been previously documented, with reports of reduced absolute 
cell counts for T cells (CD3+), ‘helper’ T cells (CD4+) and ‘cytotoxic’ T cells (CD8+) 
in patients undergoing long-term haemodialysis (Raska et al. 1983, Chida, 
Sakurai and Yoshiyama 1986). Furthermore, it was also reported that changes in 
lymphocyte subset cell counts are specifically linked with multiple blood 
transfusions in dialysis patients (Nanishi e ta i  1986), although this could not be 
confirmed in the current study.
A chronic reduction in lymphocyte subsets, demonstrated in some of the 
retrospective participants in this study, can have serious repercussions, in terms 
of the risk of infection and malignancy. For example, alongside other risk factors, 
the long-term reduction of CD4+ T cells and CD19+ B cells, in renal transplant 
recipients, has been shown to correspond with solid cancer and lymphoma 
development (Ducloux et al. 2002).
The observation that several retrospective participants had elevated cell counts 
for CD8+, CD4+ or NK populations may be explained by an infection. In particular, 
participant 8 appeared as an ‘outlier’ with an increased cell count for both CD8+ 
and NK cells, compared to the mean, so may have had a viral infection. However, 
a review of the patient’s laboratory file provided no evidence for this and further 
investigation was not possible due to information governance issues. Conversely, 
participant 8 was one of three retrospective participants (4, 8 and 19) who 
demonstrated particularly low cell counts for the CD19+ subset. These 
participants were all at different time points post-transplantation, at eight months, 
eleven years and four years respectively. However, a factor that they did have in 
common was the continued use of prednisolone, which is the most likely 
explanation of this observation.
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An altered CD4:CD8 ratio was a characteristic observed in many of the transplant 
recipients, and an inverted CD4:CD8 ratio persisted in several of the retrospective 
participants, i.e. CD8+ cells present in greater numbers than CD4+ cells. This is 
often associated with chronic or opportunistic viral infections, such as herpes 
virus and cytomegalovirus (CMV) (Schooley et al. 1983) and this is most likely 
the causative factor in participant 6 who had Hepatitis B. An inverted CD4:CD8 
ratio, of less than 1, has also been linked with ageing and ‘immunosenescence’, 
and carries an increased morbidity and mortality risk irrespective of age (Luz 
Correa etal. 2014). Excluding participant 6, four further retrospective participants 
had an inverted CD4:CD8 ratio. Participants 4, 8 and 18 were the three eldest 
participants in the cohort of retrospective transplant patients, so age may have 
been a factor which affected their T cell reconstitution. Participant 4 was sampled 
at just eight months post-transplantation, which was another factor that most 
likely influenced their value for the CD4:CD8 ratio. The remaining participant who 
exhibited an inverted CD4:CD8 ratio was just over the median age of the cohort. 
These observations suggest that reconstitution of the T cell population, to within 
normal ranges, is less efficient in older patients.
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CHAPTER 4 T AND B CELL IMMUNOPHENOTYPING ANALYSIS OF 
PROSPECTIVE AND RETROSPECTIVE HLAi TRANSPLANT RECIPIENTS
4.1 Results of T cell immunophenotyping
Three T cell immunophenotyping antibody panels were used for the study; a 
‘recent thymic emigrants’ (RTE) panel, an ‘activated’ T cell panel and a ‘regulatory 
T cell’ (Treg) panel. The results are presented for the prospective and 
retrospective study participants in figures 4.1-4.14. The target cell populations for 
each panel, and the gating strategy employed, are described in sections 2.7 and 
2 .8.
Incomplete data sets were collected for 3 prospective participants, due to sample 
and/or time constraints, or because there were insufficient lymphocytes present 
for immunophenotyping.
• Participant 1, Day -9 -  no regulatory T cell data was collected.
• Participant 3, Day -8 and Day -1 samples, and participant 7, Day -8 -  the 
intracellular FoxP3 marker was not performed for the Treg panel. Instead, 
CD127 phenotyping was performed for regulatory T cells (data not shown).
• Participant 3, Day +8, and participant 7, Day +5.
An incomplete data set was collected for one retrospective participant. For 
participant 6, the intracellular FoxP3 staining was not carried out due to this 
participant being Hepatitis B positive. Instead, data forTregs was collected using 
the CD127 marker (data not shown), which, unlike intracellular FoxP3 staining, 
did not require isolation of PBMCs. The CD127 marker was carried out on whole 
blood, thereby necessitating less intervention with the sample.
4.1.1 Recent thymic emigrants (RTE) immunophenotyping
The results for the prospective participants from the RTE panel are shown in 
figure 4.1. The percentage of cells gated, for each population identified by this 
panel, is indicated for each participant longitudinally for their individual sampling 
time points.
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Figure 4.1 Recent thymic emigrants (RTE) immunophenotyping results for the
prospective participant cohort
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Figure 4.2 shows the results from the single time points for the retrospective 
cohort, plotted alongside the results for the normal controls, and the prospective 
cohort for comparison (from pre-transplant, six months and one year post­
transplant time points).
Figure 4.1 shows that four of the seven prospective participants had a larger 
percentage of memory T cells (CD4+CD45RO+) compared to naive T cells 
(CD4+CD45RO-) present at the pre-transplantation time points. Participants 1, 9 
and 14 display the reverse, with larger populations of naive T cells. There was 
little variation in population percentages seen in participants 1,2 and 3, for whom 
there are no post-transplant analysis time points. The only exception to this was 
participant 1, who showed an increase in memory T cells between the sample 
taken on the day prior to the scheduled transplant (Day -1) (41%), and 11 days 
post the scheduled transplant (Day +11) (47%). It is plausible that this increase 
in activated memory T cells indicates an ongoing immune stimulus, which was 
unchecked by the desensitisation treatment. This corresponds with the increase 
in lymphocyte subsets, in this patient, discussed in section 3.2.1.
In contrast to participants 1, 2 and 3, who had no post-transplant follow-up, 
transplanted participants 7, 9, 11 and 14 showed dramatic changes in the T cell 
populations detected, as would be expected from the results of lymphocyte 
subset analysis, discussed in chapter 3. When considering figure 4.1, for the 
transplanted participants 7, 9,11 and 14, it should be borne in mind that the post­
transplantation time points represent a reconstitution of T cell populations from 
an absolute cell count of almost zero (see figures 3.8, 3.10, 3.12 and 3.14). 
However, due to there being insufficient cells to analyse in the immediate days 
following transplantation, this is not represented on the plots. This is the case for 
all similar graphs in this chapter.
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Figure 4.2 Recent thymic emigrants (RTE) immunophenotyping results for the
retrospective, normal control and prospective participant cohorts
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The graphs for participants 7, 9, 11 and 14 are similar in that there was a trend 
for an increase in memory T cells and a decrease in naive T cells post­
transplantation, when compared to the pre-transplantation time point(s). This 
suggests that the reconstitution of CD4+ T cells is predominantly from the memory 
compartment rather than with recent thymic emigrants. This observation is also 
evidenced by the decrease in RTE cells post transplantation in participants 9 (+6 
months) and 14 (+6 months). It is also of note that, in all cases, there remained 
differences in the percentages of these T cell populations at one year post­
transplantation, compared to pre-transplantation, suggesting that the effects of 
the HLAi transplant protocol are long-lived.
Whilst participant 11 fits with the overall trend described above, the increase in 
the memory T cell population, compared to pre-transplantation, was not as 
marked when compared with transplanted participants 7, 9 and 14, increasing 
from 51% (Day -9) to 62% (+6 months). For comparison, participant 9 had pre 
and post-transplantation values of 37% (Day -5) and 84% (+6 months) 
respectively. Also in contrast with the other aforementioned transplanted 
participants, figure 4.1 shows that participant 11 did not display such disparate 
cell percentages at the one year post-transplantation time point (compared to pre­
transplantation). This participant is also the only one of the four to show an 
increase in RTEs at one year post-transplantation (from 13% pre transplantation 
(Day -9) to 20% at one year post-transplantation), suggesting thymic dependent 
re-population. This may be a reflection of the fact that although this participant 
received alemtuzumab, they did not have any pre-conditioning prior to 
transplantation.
The plot for participant 14 (figure 4.1) is of note for indicating an increase in RTEs 
between the pre-treatment sample (Day -14) and the day of transplantation (Day 
0). This is in contrast to the other participants where there were sufficient samples 
to allow for this comparison. It has previously been shown that this participant 
demonstrated a slight increase in the absolute count and percentage of CD4+ 
cells between these time points (figure 3.14), so the patient may have 
experienced an increase in thymic activity due to the pre-conditioning protocol 
followed.
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The trend for the population of memory T cells being increased, in percentage 
terms, in HLAi transplant recipients is repeated in figure 4.2, which shows the 
retrospective participant cohort alongside the normal controls and specific time 
points for the prospective participants. Figure 4.2 (a) displays a mean value of 
46% for the prospective group pre-transplantation, indicating no difference with 
the normal controls (45%). In contrast to these figures, the mean for the 
retrospective cohort is 62%, whilst the prospective cohort has percentages for 
this population of cells of 73% (p^0.05) and 66% at 6 months and 1 year post­
transplantation respectively. As would be predicted, the converse of this picture 
is evident in figure 4.2 (b) which shows the population percentages for naive T 
cells. These observations suggest that the prospective cohort would continue to 
slightly decrease their memory T cell populations, but only to within the range of 
the retrospective figures, which remained increased when compared with normal 
controls, again indicating a long-term effect of HLAi transplant conditioning and 
immunosuppression.
In contrast, figure 4.2 (c) indicates that the populations of RTEs remained 
reduced in percentage terms in the retrospective cohort, with a mean value of 
15% compared to 26% for the normal controls. This provides further evidence 
that the reconstitution of the T cell compartment, post-transplantation, is largely 
thymic independent.
4.1.2 Activated T cell immunophenotyping
The expression of HLA-DR on CD4+ and CD8+ T cells is shown in figures 4.3 and 
4.4, for the prospective and retrospective cohorts respectively. All participants 
possessed a greater percentage of CD3+CD8+HLA-DR+ cells than 
CD3+CD4+HLA-DR+ cells pre-transplantation (figure 4.3), and this relationship 
continued post-transplantation in all cases, except for participant 7 (discussed in 
further detail below). Participants 1 and 2, neither of whom were transplanted due 
to persistent DSAs at too high a level to proceed, were both interesting in terms 
of these cell populations. For participant 1, the percentage of CD3+CD4+HLA-DR+ 
cells did not alter over the HLAi conditioning protocol.
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Figure 4.3 Activated T cell immunophenotyping results for the prospective
participant cohort
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Figure 4.4 Activated T cell immunophenotyping results for the retrospective,
normal control and prospective participant cohorts
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However, the percentage of CD3+CD8+HLA-DR+ cells steadily increased over the 
course of the treatment, for participant 1, from 29% at initial assessment (-4.5 
months), peaking at 68% on the day prior to transplantation (Day -1). The 
percentage of this cell population reduced by 11 days post-transplantation to a 
level similar to -4.5 months, at 32%. As a comparison, the mean figure for this 
population of cells from the normal control cohort was 33% (indicated in figure 
4.4). This observation is in contrast to all other participants for whom multiple pre­
transplantation samples were analysed, in that the percentage of CD3+CD8+HLA- 
DR+ cells decreased over the course of the desensitisation treatment. This is very 
clear in the case of participant 2, also not transplanted, who had a relatively high 
percentage of CD3+CD8+HLA-DR+ cells at pre-treatment (Day -11) of 72%, which 
declined to 43% by the day prior to the scheduled transplant (Day -1).
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Of the transplanted participants with follow-up, the plots for 9, 11 and 14 (figure 
4.3) show similarities, in that the six month post transplantation samples indicate 
an increase in HLA-DR positivity on both CD4+ and CD8+ T cells when compared 
to the pre-transplantation levels. These percentages were then seen to decrease 
at the one year post-transplantation time points. For these participants, the lines 
on the plot for the two populations of cells appear to parallel each other. Figure 
4.4 also demonstrates this trend for the prospective cohort. However, in all three 
cases, HLA-DR expression on both populations of cells had not returned to pre­
transplantation levels by one year post-transplantation.
Participant 7 differed to transplanted patients 9,11 and 14, in that the increase in 
the population percentage of their CD3+CD4+HLA-DR+ cells exceeded the 
percentage of the CD3+CD8+HLA-DR+ population, at eight months post­
transplantation, the only participant to show this pattern. This participant already 
possessed a relatively high proportion of CD4+HLA-DR+ T cells, prior to 
transplantation, as shown in figure 4.4(a), where the data point for participant 7 
lies relatively high above the mean for the group (21%), at the pre-transplantation 
time point, at 36%. The percentage of CD8+HLA-DR+ T cells remained stable, for 
this participant, over this time period with a value of 45% pre-transplantation (Day 
-8) and 44% at 8 months post-transplantation. In common with the 3 other 
participants, both cell population percentages had reduced by 13 months post­
transplantation. Figure 4.4(b) clearly shows participant 7 as an ‘outlier’ for the 
samples equivalent to six months (44%) and one year (37%) data points. For the 
CD3+CD8+HLA-DR+ cells, at 37%, this population was at a level below that 
obtained pre-transplantation. Participant 11 was the only other participant to have 
a lower percentage of CD3+CD8+HLA-DR+ cells present at 1 year post­
transplantation, compared to pre-transplantation. However, as participant 7 was 
sampled at eight months and thirteen months post-transplantation, it is not 
possible to assess fluctuations that occurred at precisely six months and one year 
post-transplantation.
Figure 4.4 (a) compares five different cohorts of participants for their percentage 
of CD4+HLA-DR+ T cells and indicates that the retrospective cohort and the 
prospective cohort pre-transplantation do not differ to the normal controls for this
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population. However, there are two clear exceptions to this within the 
retrospective cohort; participant 4 with 94%, and, to a lesser degree, participant 
8 with 49% CD4+HLA-DR+ T cells. The mean value for this group was 24%. 
Participant 4 was sampled at only eight months post-transplantation, and the 
percentages obtained exceeded the values for the prospective cohort at a similar 
time point of six months. This participant also displayed a high percentage of 
CD3+CD8+HLA-DR+ cells present, indicated in figure 4.4 (b), of 97%, compared 
to a mean value for the group of 54%. It is possible that this could be an effect of 
alemtuzumab administered at the point of transplantation; however, two further 
participants (5 and 20) who were also given this drug, did not show this effect. 
The higher than the mean value for participant 8, in figure 4.4 (a), is also of 
interest, as this patient was sampled at eleven years post-transplantation, and 
was noteworthy for possessing no B cells during the lymphocyte subset analysis, 
most likely due to the continued use of prednisolone as a part of their 
immunosuppression. Figure 4.4 (b) shows the retrospective cohort appears to 
separate into two groups around the mean value of 54%. It is also of interest that, 
in contrast to the results shown in figure 4.4 (a), the prospective cohort, pre­
transplantation, already have increased values for this population of cells 
compared with the normal controls (not significant).
4.1.3 Regulatory T cell (Treg) immunophenotyping
Data is presented for the prospective cohort for the populations of CD4+CD25+ 
(effector T cells) and CD4+CD25hiFoxP3+ (Tregs), in figures 4.5 and 4.6, with the 
latter depicting a calculated ratio of CD4+CD25+ T cells:Tregs.
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Figure 4.5 Regulatory T cell (Treg) immunophenotyping results for the
prospective participant cohort
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Figure 4.6 Ratio of CD4+CD25+ T celkTreg cell populations for the prospective
participant cohort
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The collective Treg immunophenotyping results are shown in figure 4.7, 
displaying the single time points for the retrospective cohort, plotted alongside 
the results from the normal controls and the prospective cohort for comparison 
(from pre-transplant, six months and one year post-transplant time points). The 
analyses performed using the CD127 cell surface marker, in place of intracellular 
FoxP3 staining, did not provide any noteworthy data, and were difficult to 
compare with the Tregs immunophenotyping analyses carried out on the majority 
of the participant samples. Hence, these data are not presented in this report.
Prospective participants 7, 11 and 14 showed a reduction in the Treg cell 
population post-transplantation, between six months and one year time points 
(figure 4.5). In participants 7 and 14 there was a concurrent decrease in the 
CD4+CD25+ T cells; however this population of cells shows an increase in 
participant 11 (figure 4.5). For participant 11, this has resulted in an increase of 
the CD4+CD25+:Treg ratio (figure 4.6), between six months and one year post­
transplantation. Participant 9 is the exception amongst the transplanted 
prospective participants, in that the percentage of Tregs present for this 
participant showed a sample by sample increase from pre-transplantation to one 
year post transplantation (figure 4.5). For this participant, the percentage of Tregs 
present at one year post-transplantation was therefore greater than pre- 
transplantation, at 13.8% compared to 6.7%. However, the CD4+CD25+:Treg 
ratio remained steady over this time, due to a concurrent increase in effector T 
cells. At one year post-transplantation, the two other transplanted participants for 
whom this comparison is possible (11 and 14) both had reduced percentages of 
Tregs present compared to pre-transplantation.
A further observation from these data is that an increase in percentages of Tregs 
was evident over the course of the HLAi conditioning in participants 1 , 2 , 9  and 
14 (figure 4.5). For participant 2, this was reflected by a decrease in the 
CD4+CD25+:Treg ratio (figure 4.6). In participant 1, who was not transplanted 
this had started to reduce by 11 days post the scheduled transplant.
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Figure 4.7 Regulatory T cell (Treq) immunophenotyping results for the
retrospective, normal control and prospective participant cohorts
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Figure 4.7 shows that there is no difference between the different cohorts of 
participants for the population of CD4+CD25+ cells (4.7 (a)). The retrospective 
cohort had reduced percentages of Tregs compared to the normal controls 
(p<0.05), with a mean of 5.4% and 8.6% respectively (figure 4.7 (b)). Within this 
cohort, participants 10, 12, 13 and 18 showed particularly low populations of 
Tregs.
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4.2 Results of B cell immunophenotyping
The results from the three B cell immunophenotyping panels used for the study, 
‘memory’ B cell, ‘transitional’ B cell and ‘plasma’ B cell panels, are shown in 
graphical format for both the prospective and retrospective participants. The 
target cell populations and the gating strategy employed for each panel are 
described in section 2.7.
Incomplete data was obtained on prospective participants 3, Day +8, and 7, Day 
+5, as it was identified by the Multitest™ kit that there were insufficient cells 
present for full immunophenotyping panels to be performed. Also, for 
retrospective participants 4, 8 and 19 an insufficient absolute count of B cells was 
identified by the Multitest™ kit for the B cell immunophenotyping panels to be 
performed, so T cell data only was collected for these samples.
4.2.1 Memory B cell immunophenotyping
The results for the prospective participants from the memory B cell 
immunophenotyping panel are shown in figure 4.8. Figure 4.9 shows the results 
from the single time points for the retrospective cohort, plotted alongside the 
results from the normal controls, and the prospective cohort for comparison (from 
pre-transplant, six months and one year post-transplant time points).
Participants 1 and 2, who did not progress to transplantation, both showed an 
increase in memory B cells over the course of their conditioning treatment. 
Participant 1 had a greater percentage of IgM memory B cells, whilst for 
participant 2 it was the ‘switched’ IgG memory B cells which predominated. In 
addition, participant 1 showed a sharp increase in CD27+ memory B cells at the 
11 day post scheduled transplant time point.
The only other participant who exhibited an increase in memory B cells prior to 
transplantation was participant 14 (although this comparative time point was only 
analysed for participants 3, 9 and 14). Participant 3 had a comparatively high 
percentage of memory B cells present, but the overall percentage of CD27+ cells 
did not alter over the course of the conditioning treatment, although the 
predominant cells appeared to change from IgM memory to ‘switched’ IgG 
memory cells.
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Figure 4.8 Memory B ceil immunophenotyping results for the prospective
participant cohort
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Figure 4.9 Memory B cell immunophenotyping results for the retrospective.
normal control and prospective participant cohorts
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Of the transplanted participants, 7, 9 and 11 showed a similar pattern of a 
dramatic decrease in the percentage of memory B cells observed at six months 
post-transplantation, compared to pre-transplantation. For participant 7, these 
levels had not recovered by thirteen months post-transplantation, increasing from 
4% at eight months post-transplantation to 7% for CD27+ B cells, compared to a 
pre-transplantation level of 46%. A similar picture was evident for participant 9, 
whose population of CD27+ B cells measured 57% pre-transplantation, and 8% 
at one year post-transplantation. Interestingly, this participant showed a further 
decrease in memory B cells between the six months and one year time points, 
indicating that this population of cells had not yet started to return. This was also 
the case for participant 11, whose populations of memory B cells also displayed 
further decreases between the six months and one year time points. Figure 4.9 
also clearly shows the reduction in the mean percentage of memory B cells for 
the prospective cohort between the pre- and the post-transplantation samples 
(p<0.05). This overall picture suggests that the population of returning B cells 
post-transplantation is not derived from memory cells, unlike the observation 
previously described for T cells in section 4.1.1.
Participant 14 had a different pattern of memory B cell populations, in that the 
percentage of CD27+ cells present was comparatively low, at 8% pre HLAi 
transplantation conditioning treatment (Day -14). At six months post­
transplantation, the memory population of B cells remained low, but by one year 
showed an increase to a level which exceeded pre-treatment levels at 12%. This 
was largely due to an increase in isotype class ‘switched’ B cells. This participant 
was the only one of the four transplanted patients whose levels of memory B cells 
at one year exceeded their pre-treatment level. However, the overall low levels 
observed in this participant, could be a reflection of suppressed B cell counts 
(noted in chapter 3), possibly post treatment with methyl-prednisolone.
Figure 4.9 shows the collective data for the different study cohorts for the memory
B cell panel. It is striking that there was more variation in the percentage of
memory B cells present in the transplant patient cohorts compared to the normal
controls, particularly for total CD27+ B cells (figure 4.9 (a)). However, whilst the
mean value of the prospective cohort pre-transplantation did not differ to the
normal controls (38% compared with 34% for CD27+ B cells), the retrospective
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cohort showed a trend towards a lower mean value of memory B cells across all 
populations (not significant), with a mean of 25% for CD27+ B cells (figure 4.9 
(a)). These observations suggest that the elimination of memory B cells by the 
conditioning regime and post-transplantation immunosuppression is a long-term 
phenomenon. No correlation was observed between memory B cell population 
and the time elapsed since transplantation, indicating that the outlying participant 
results with particularly low percentages present, did not represent those 
participants who were most recently transplanted (data not shown).
Within the retrospective cohort, participant 17 was of note for being an exception 
to the pattern described above, having the highest percentage of memory B cells, 
with a population of 63% CD27+ cells. The matched normal control for participant 
17 had a value of 36% for this population of cells, whilst the mean for the normal 
controls was 34%. In particular, this participant had an expanded population of 
IgM memory (lgD+) cells present at 38%. Participant 17 was 8 years post­
transplantation and experiencing chronic graft rejection, which may have been a 
factor influencing this phenomenon.
4.2.2 Transitional B cell immunophenotyping
The results for the prospective participants from the transitional B cell panel are 
shown in figure 4.10, whilst figure 4.11 shows the same data, but without the 
mature B cell population (CD19+CD38+CD24+), so that variations in the 
transitional B cell (CD19+CD38hiCD24hi) and plasmablast (CD19+CD38hiCD27+) 
populations can be seen more clearly. The results from the collective cohorts are 
displayed in figure 4.12.
Little change in transitional B cell populations for participants 1 and 2, who did 
not progress to transplantation, was seen (figure 4.10). Participant 3 exhibited 
approximately half of the percentage of mature B cell population, as participants 
1 and 2. This participant also differed by showing an increase in this cell 
population during the conditioning treatment (figure 4.10). Unfortunately, as the 
participant was lost to follow up, it was not possible to track further changes.
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Figure 4.10 Transitional B cell immunophenotyping results for the prospective
participant cohort
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Figure 4.11 Results of analysis of CD38hi cell populations from the transitional B
cell panel, for the prospective participant cohort
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Figure 4.12 Transitional B cell immunophenotyping results for the retrospective,
normal control and prospective participant cohorts
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The results from the remainder of the transplanted participants suggest that both 
mature and transitional B cell populations reconstituted efficiently post­
transplantation. In contrast to the memory B cell results, all four of the 
transplanted patients with follow-up (participants 7, 9, 11 and 14) showed a 
recovery of mature B cells by six months post-transplantation. For participants 7, 
9 and 11, this population represented a greater percentage than in the pre­
transplantation sample, and continued to increase up to one year post­
transplantation. This observation can also be seen in figure 4.12 (a). Participant 
14 differed in their response in that at six months post-transplantation, the mature 
B cell population had reconstituted to a lower percentage than the pre­
transplantation sample (66% compared to 85%). This increased slightly to 69% 
at one year post-transplantation.
Mirroring the observation described above, and more clearly seen in figures 4.11 
and 4.12 (b), participants 7,11 and 14 also showed an increase in transitional B 
cell populations at six months (p<0.05), compared to pre-transplantation, 
although this had decreased by one year post-transplantation. A similar pattern 
was observed for participant 9; however here the increase in population size at 
six months was also evident for plasmablasts.
No difference was seen between percentages of cell populations studied using 
the transitional B cell panel for the normal controls, the retrospective cohort and 
the prospective cohort pre-transplantation (figure 4.12). Regarding the 
prospective cohort pre-transplantation, this would suggest that chronic renal 
failure and its treatment does not affect these cell populations. The fact that the 
mean values for the retrospective cohort are not dissimilar to the normal controls 
implies that either these cell populations did not increase post-transplantation, as 
observed in the prospective cohort, or that they had declined back to pre­
transplantation ‘normal’ levels.
Retrospective participant 13 is a clear outlier in figure 4.12 (a). This patient was 
transplanted 5 years ago, and was striking for possessing a mature B cell 
population of just 10%, compared to 79% for their matched normal control, and a
mean value of 60% for the retrospective cohort.
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Several participants noteworthy for their plasmablast population percentages can 
be seen in figure 4.12 (c). The overall picture for this population of cells in the 
normal controls, the retrospective cohort and the prospective cohort pre­
transplantation was of little variation around the mean. However, there are 
exceptions to this, particularly retrospective participant 5 who, with a value of 11 % 
differed markedly to the rest of the cohort which has a mean of 3%. Prospective 
participant 11 also had a high value for this population of cells, pre­
transplantation, at 8%. Two normal controls also differed to the trend for the rest 
of this group (mean of 4%); controls 1 (10%) and 9 (7%). It is possible that these 
individuals were undergoing some sort of immune stimulus, although overall the 
percentages are low.
4.2.3 Plasma B cell immunophenotyping
The results for the prospective participants from the plasma B cell panel are 
shown in figure 4.13. The percentages of cell populations recorded for this panel 
were small, but demonstrated some large changes for some participants. Hence, 
in figure 4.13 the scale on the y-axis is not consistent between participants, in 
order that the individual changes in each participant can be more easily 
visualised. The collective cohort results are shown in figure 4.14.
In figure 4.13 it is apparent that the plasmablast cells (CD19+CD20*CD138+) 
underwent an overall decrease during the course of pre-treatment, in both 
participants who did not progress to transplantation (1 and 2). For participant 1, 
this cell population then appeared to rebound, at 11 days post-scheduled 
transplant date, when the treatment was halted and the patient was not 
transplanted.
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Figure 4.13 Plasma B cell immunophenotyping results for the prospective
participant cohort
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Figure 4.14 Results of immunophenotyping analysis from the plasma B cell panel
for the retrospective, normal control and prospective participant cohorts
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Of the transplanted participants, 9, 11 and 14 showed a similar pattern for both 
plasmablast populations. All participants started with relatively low levels of these 
cell populations, and then all experienced a ‘spike’ in the 6 month post­
transplantation sample. By one year, the percentage of these cell populations 
had declined, although only participants 9 and 11 showed values which had 
returned to close to the pre-transplantation values. These observations are also 
evident in figures 4.14 (a) and (b) (not significant). Participant 7 differed, as these 
populations of cells did not appear to repopulate to the same level at eight months 
post-transplantation, compared to pre-transplantation, although the values for 
this participant were small. In addition, the plasmablasts (CD19+CD20 CD138+) 
for this participant showed a slight increase between eight and thirteen months 
(figure 4.13).
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No difference was seen, in the plasma cell populations studied, between the 
normal controls, the retrospective cohort and the prospective cohort pre­
transplantation (figures 4.14 (a) and (b)). This observation suggests that the 
process described above for the prospective participants is short-lived, either 
caused by the conditioning or the transplant itself. However, several retrospective 
participants were of note; in figure 4.14 (a) participant 13 differs by being 
practically CD38*. Several participants (5, 10, 16 and 18) appeared to have 
populations of plasmablasts present (figure 4.14 (b)).
4.3 Further stratified analysis of the results of immunophenotyping, in the 
retrospective participant cohort
4.3.1 HLA-DR mismatching analysis
As described in section 3.5.1, the retrospective participant cohort was stratified 
according to the recipient-donor HLA-DR mismatch grade. The results from this 
analysis for the activated T cell panel (0/1 HLA-DR mismatches n = 8, 2 HLA-DR 
mismatches n = 5) are shown in figure 4.15. The 2 HLA-DR mismatched group 
had a higher percentage of HLA-DR+ T cells recorded; this was particularly 
striking in the CD3+CD4+HLA-DR+ cell population (p = 0.0295). The remainder of 
the immunophenotyping panels analysed in this manner, stratified according to 
HLA-DR mismatch, showed no differences between the groups (data not shown).
4.3.2 The effect of alemtuzumab on immunophenotyping results
The results from the immunophenotyping analysis were re-examined in light of 
which participants had received alemtuzumab, in place of basiliximab, as part of 
their transplantation schedule. Three of the retrospective participants (4, 5, and 
20) received alemtuzumab, but no correlation was observed between this and the 
immunophenotyping data collected (data not shown).
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Figure 4.15 Results from the retrospective cohort, for the activated T cell
immunophenotyping panel, stratified according to HLA-DR mismatches
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4.3.3 Reanalvsis of the data, to examine a possible association between the 
immunophenotyping results and a post-transplantation rejection episode
As indicated in table 3.5, five retrospective participants (6, 13, 15, 17 and 18) 
experienced a rejection episode post-transplantation. No association between 
this and the immunophenotyping data was observed (data not shown).
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4.4 Discussion of T and B cell immunophenotyping results
4.4.1 Lymphocyte recovery post-HLAi transplantation
The immunophenotyping results from the transplanted prospective participants 
highlighted similarities in how the different populations of lymphocytes 
reconstituted post-transplantation. CD4+ T cell reconstitution largely took place 
from within the memory T cell (CD4+CD45RO+) compartment. In contrast, RTEs 
(CD4+CD45RO*CD31+) accounted for little of the post-transplant reconstitution, 
evidenced by this population of cells either remaining at a relatively steady 
percentage, or showing a decrease by one year post-transplantation, compared 
to pre-transplantation levels. A different phenomenon was observed for B cells, 
with memory B cell populations remaining notably reduced at one year post­
transplantation. This was associated with an efficient reconstitution of the 
CD19+CD38hiCD24hi transitional B cell population, which peaked at 6 months 
post-transplantation. These cells reflect repopulation of the B cell compartment 
from immature B cells.
Despite differences in the induction (peri-operative) immunosuppression received 
(alemtuzumab in the prospective cohort and mostly basiliximab in the 
retrospective cohort), a similar pattern of changes in the lymphocyte populations 
was observed in the retrospective cohort of patients. In the retrospective cohort, 
increased memory T cell populations were noted when compared to the normal 
control cohort. This phenomenon is not explained by examining the time since 
transplantation, i.e. the participants who were more recently transplanted do not 
correlate with the higher data points for memory T cells (data not shown). 
Alongside this, there was a trend for the population of RTEs to remain reduced 
compared to the normal controls. Neither of these observations were noted in the 
cohort of prospective participants pre-transplantation, indicating that this effect 
was due to an aspect of the transplantation process, and not caused by renal 
failure and/or its treatment.
In terms of B cell populations, a lower mean value of memory B cells in the 
retrospective cohort was seen compared to the normal controls indicating that the 
elimination of peripheral memory B cells was long-lived. However, the results for
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the transitional B cells do not differ greatly for the retrospective cohort compared 
to the normal controls. This suggests that either the percentage of this B cell 
population has declined back to within ‘normal’ levels in the retrospective group, 
or, more likely, that the use of basiliximab in the majority (ten of thirteen) of this 
participant cohort has resulted in a different pattern of B cell populations observed 
post-transplantation, compared with the alemtuzumab treated prospective 
participants.
The observations around lymphocyte recovery post-transplantation, noted above, 
should be viewed in terms of knowledge of the process of haematopoiesis. 
However, the additional consideration of the mode of suppression (alemtuzumab 
or basiliximab) of the immune response, must also be taken into account. In 
relation to the former, thymic involution, which initiates during infanthood, results 
in a reduction of naive T cells exiting into the periphery via this route over time. 
Hence, the expression of the CD45RO marker is affected by an individual’s age, 
with the CD45RO+ variant being prevalent in adults, whilst the CD45RO_ population 
(CD45RA+) decreases with age (Lazuardi et al. 2005). This is ‘compensated’ for 
by the fact that mature peripheral T cells are more long-lived than mature B cells, 
and are self-renewing (Parham 2009). In adults, then, it is unlikely that recovery 
of T cell populations would be as a result of increased thymic activity. Instead, 
the T cell populations observed post-transplantation correspond with an 
expansion of mature memory T cells in the secondary lymphoid tissues. It has 
been suggested that in adults, naive T cells may also expand in the periphery 
(Kohler and Thiel 2009), but these cells would most likely have been eliminated 
during the pre-transplant induction process.
Conversely, the mature B cell repertoire consists of short-lived cells, which are 
continually renewed by the bone marrow (Parham 2009). Thus, the space created 
in the periphery by the use of the induction drugs could promote replenishment 
of the B cell populations from this route. Simultaneously, the peripheral memory 
B cell population would take longer to recover, although these cells could survive 
in the secondary lymphoid organs.
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It has been suggested that due to its lympho-depleting properties, alemtuzumab 
may promote a state of transplant tolerance (Cherukuri et al. 2012). In a study 
previously carried out at this centre (Cherukuri et al. 2012), patients undergoing 
‘standard’ renal transplantation and enrolled in a randomised control trial (RCT), 
were investigated for various T and B cell phenotypes approximately two years 
post transplantation. Alemtuzumab treated patients exhibited increased 
populations of naive, transitional and regulatory B cells, whilst there was a shift 
towards a memory phenotype in the T cell subsets. The observations detailed in 
the current study agree with those described by Cherukuri et al. (2012), in 
alemtuzumab treated patients. The depletion of the peripheral memory B cell 
compartment, and a shift towards a more naive B cell phenotype can be deemed 
to be a benefit of this mode of immunosuppression, potentially limiting the 
initiation of the secondary immune response.
It is noteworthy that one of the participants identified as having a peripheral 
population of plasmablasts present, participant 16, received the therapeutic 
monoclonal antibody rituximab as part of their transplant conditioning. As 
previously mentioned, rituximab targets the CD20 cell marker present on the 
majority of B cells, but absent on plasma cells. Participant 16 was tested at eight 
years post transplantation, which had unfortunately failed at four months due to 
recurrence of original disease. It was interesting to note that 89% of this 
participant’s B cells were now expressing the CD20 marker. A further 
retrospective participant (19) also received rituximab pre-transplantation, but at 
four years post-transplantation this individual possessed insufficient B cells to 
phenotype, most likely due to the continued use of prednisolone.
Kamburova etal. (2014) reported the long-term depletion of peripheral B cells by 
rituximab remaining evident in low counts noted at 24 months post-treatment, 
suggesting that both of the aforementioned retrospective participants had most 
likely recovered from the rituximab effect by the time of testing. In addition, it has 
been reported (Anolik et al. 2007, Kamburova et al. 2014) that B cell depletion 
observed in rituximab treated patients, corresponds with an increased transitional 
B cell phenotype in the repopulating cells. The results for participant 16 concur 
with this observation, as they exhibited the joint highest value for the transitional
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B cell population within the retrospective cohort, indicating the possibility that 
HLAi transplant conditioning may continue to affect lymphocyte phenotype many 
years post treatment.
4.4.2 Changes in T cell expression of HLA-DR
Participant 1 was notable in terms of the activated T cell panel for demonstrating 
a steady increase in the CD3+CD8+HLA-DR+ cell population over the course of 
the desensitisation treatment. This increase was noted between the samples for 
-4.5 months and Day -1, which represents a time course of in excess of two 
weeks, during which time this participant underwent seven sessions of plasma 
exchange treatment and received Ivlg. HLA-DR is designated as a late activation 
marker on T lymphocytes, and is upregulated in response to activation of the T 
cell receptor (TCR) (Reddy etal. 2004). The kinetics of HLA-DR upregulation has 
been demonstrated to be rapid; a study examining the maturation of monocytes 
to dendritic cells induced by IL-15 reported an increase and a peak in HLA-DR 
expression over the course of eight days (Saikh et al. 2001). Reddy et al. (2004) 
studied the expression of cell surface activation markers and cytokine secretion 
of stimulated PBMCs, and noted that a rise in HLA-DR expression was initiated 
from 24 hours following stimulation. Further studies have reported detecting 
inducible expression of HLA-DR between 48-72 hours (Ferenczi et al. 2000) and 
between 48-60 hours (Rea, McNerlan and Alexander 1999) following T cell 
activation. This reported literature indicates a feasible timeframe for participant 1 
to experience such an increase in HLA-DR expression, and it is possible that this 
was in response to the desensitisation treatment that this participant underwent, 
although this was not observed in any of the other participants.
Plasma exchange has been reported to cause changes in lymphocyte subsets
and antigen expression, including upregulating HLA-DR (Reeves and Winters
2014). However, elsewhere it has been stated that plasmapheresis (PP)
modulates T lymphocyte activation, and is associated with a decrease in HLA-
DR expression (Sadeghi et al. 2013). This seeming discord may represent the
fact that these two modes of plasma removal differ in that plasma exchange
involves a replacement fluid being transferred to the patient, while
plasmapheresis does not. The use of Ivlg introduces yet another complicating
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factor into the analysis, as this too has been shown to have an effect on T cell 
activation, decreasing the proliferation and cytokine secretion of CD8+ T cells 
(Trepanier, Chabot and Bazin 2013). It is therefore possible that the repeated 
plasma exchange treatments received by participant 1 contributed to the increase 
observed in activated CD8+ T cells, and this upregulation of an activation marker 
could be deemed as being undesirable in a patient undergoing desensitisation 
treatment in preparation for transplantation.
The rise in percentages of both CD4+HLA-DR+ and CD8+HLA-DR+ T cells in the 
transplanted prospective participants 9, 11 and 14, at the six months post­
transplantation time point, is also worthy of discussion. In addition to being a late 
marker of T cell activation, HLA-DR expression on CD8+ T cells is also known to 
be associated with T cell proliferation (Speiser et al. 2001), and in this instance 
could be representative of returning T cell populations post-alemtuzumab 
induction. However, it is interesting to note that participant 7 did not exhibit the 
same marked response.
A large degree of variation between individuals is also evident in the retrospective 
cohort for the CD3+CD8+HLA-DR+ population of cells. Possible explanations for 
this again include T cell activation or proliferation. In addition, it is interesting to 
note that when the retrospective cohort was segregated according to HLA-DR 
mismatches present between the donor and recipient, the population of 
CD4+HLA-DR+ T cells was significantly increased in the group with 2 DR 
mismatches (p = 0.0295). This group also had a higher mean value for the 
CD8+HLA-DR+ T cell population (not significant). This evidence points towards 
recipients possessing a larger percentage of activated T cells (both CD4+ and 
CD8+) when their grafts have been poorly HLA matched. However, no link with 
rejection episodes was seen.
4.4.3 Changes in the frequency of Tregs over the course of HLAi transplantation
All of the prospective participants for whom the data points were available (1, 2, 
9 and 14) showed an increase to some degree in the percentage of Tregs present 
over the conditioning period for HLAi transplantation. This trend has been
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reported in the literature to be associated with repeated plasma exchange 
treatments in patients with severe systemic lupus erythematosus (SLE) (Barath 
et al. 2007). Barath et al. (2007) suggested that this observation in their patient 
cohort could be linked with the removal of interferon-alpha (IFN-a) and 
autoreactive lymphocytotoxic antibodies by the plasma exchange.
It has been reported (Morales et al. 2008) that alemtuzumab induction correlates 
with an increase in the population size of Tregs (defined as CD4+CD25+FoxP3+) 
for up to six months post-transplantation, compared to normal controls and a non- 
alemtuzumab treated cohort. This agrees with the combined results shown for 
the prospective cohort (figure 4.7 (b)). An earlier study (Ciancio et al. 2005) also 
suggested an increase in Tregs post-transplantation in alemtuzumab treated 
patients, whilst noting that this population was not increased in a daclizumab 
treated cohort. In the current study, the majority (ten) of the retrospective 
participants received the immunosuppressive drug basiliximab (Simulect) at the 
point of transplant. Basiliximab is a monoclonal antibody directed against the a- 
chain of the interleukin (IL) -2 receptor, or CD25. The mode of action of this drug 
is by binding the IL-2 receptor present on activated T cells, thereby blocking IL-2 
binding and subsequent T cell proliferation (Vondran et al. 2010). Similarly to 
basiliximab, daclizumab also targets the CD25 molecule. As previously noted, 
this study suggests that the effect of basiliximab on the CD25 molecule is short­
lived as there was no difference in the percentage of CD25+ cells between the 
retrospective cohort and the normal controls. Previous studies have 
demonstrated a decrease in CD4+CD25+ cells following basiliximab induction; 
however post-transplantation follow up was limited to two weeks (Zhao et al. 
2012) and six weeks (Vondran etal. 2010). Vondran etal. (2010) concluded that 
the reduction in CD25 expressing T cells was due to down regulation, but that the 
suppressive properties of Tregs was maintained, measured by using in vitro 
assays.
The results obtained from the retrospective cohort in this study clearly show a 
reduction in the percentage of CD4+CD25+FoxP3+ cells present compared to the 
normal controls. This was not observed by Ciancio et al. (2005) as an effect of 
daclizumab; however their study reported on a post-transplantation follow up of
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only one year. Another study with a longer follow-up time (van de Berg etal. 2012) 
reported that Tregs were decreased at both six months and two years post­
transplantation, in patients with stable graft function, but had returned to levels 
which were similar to normal controls within five years. The retrospective cohort 
in this study consists of participants who are between eight months and eleven 
years post-transplantation, at a single sampling time point. The results for these 
participants differ somewhat from those reported elsewhere for patients following 
anti-CD25 induction therapy, so this may indicate other factors at play alongside 
the immunosuppressive drugs used. As Tregs have been determined as being 
key in inducing and maintaining tolerance in the transplantation setting (Villard 
2006), a reduction in this population of cells is a non-desirable trend.
4.4.4 Plasmablast populations in the prospective and retrospective participant 
cohorts post-HLAi transplantation
There were changes noted in the plasmablast populations of the transplanted 
prospective participants and, in addition, several of the retrospective cohort were 
noted as demonstrating populations of these cells. These observations are 
investigated and discussed further in chapter 5.
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CHAPTER 5 HLA ANTIBODY DETECTION AND SPECIFICITY 
ANALYSIS IN PROSPECTIVE AND RETROSPECTIVE HLAi TRANSPLANT 
RECIPIENTS
5.1 HLA-specific antibodies in the transplanted prospective participants
The objective of the antibody screening analyses was to assess HLA-specific 
antibodies, including donor specific antibodies (DSA), present in the recipients’ 
serum, pre and post-transplantation, and to examine this data in the light of the 
results from the lymphocyte subset and immunophenotyping data, described in 
chapters 3 and 4. The results presented from the prospective participants are 
focussed around the four recipients who were transplanted and for whom follow- 
up samples were available (participants 7, 9, 11 and 14). The complete serum 
screening results, from the LABScreen® Single Antigen (One Lambda) assay, for 
each participant, are shown in appendices 8-11. The results were further 
examined, in order to determine any association between participant’s antibody 
profiles and changes in lymphocyte populations. Where necessary, antibody 
serum screening results performed as part of the routine laboratory work-up for 
transplantation were obtained from the antibody raw data files, and combined 
with the antibody screening results obtained during this study, in order that an 
antibody profile was available for each sample time point.
5.1.1 HLA-specific antibody profile of prospective participant 7
One pre-transplant sample and three post-transplant samples were analysed, for 
this participant. Figure 5.1 shows the changes in the levels of DSA present (5.1 
(a) and (b)). Due to the potential for cross-reactivity the levels for all HLA-DQ3 
specific antibodies are shown. Similarly, all DQA1*03 directed antibodies were 
plotted in figure 5.1 (b). Also presented are the results of other selected HLA 
Class II specific antibodies, which represented those detected with the highest 
MFI levels (5.1(c)).
150
Figure 5.1 HLA antibody profiles for selected HLA specificities in prospective
participant 7
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Participant 7 showed a general trend of a decrease in antibody levels at five days 
post-transplantation, as would be predicted with a patient going through an 
antibody removal protocol. With the exception of DQA1 *03:03, the eight month 
sample showed a small resurgence of antibody, which had started to decline 
again by thirteen months post-transplantation. In contrast, the ‘spike’ in antibody 
directed against the epitopes encoded by HLA-DQA1 *03:03, in the +8 months 
sample, was particularly striking (figure 5.1 (b)), exceeding pre-transplantation 
level, and remaining high at one year post-transplantation. This was in contrast 
to the other DSA levels, which remained below pre-transplant levels at one year 
post-transplantation. The observation regarding DQA1 *03:03 is also mirrored in 
figure 5.1 (c), as the data for DQA1 *03:03 is identical to that for DQB1 *04:01 
(bead 70), due to the epitopes encoded by these two genes being immobilised 
together, as the complete Class II molecule, on the same bead (bead 70). The 
profile for DQB1 *04:01 identified on a separate bead (bead 32, possessing a 
different DQa chain), confirms that the reactivity observed with bead 70 was 
chiefly due to the DQA encoded molecule present. Extended HLA typing of the 
patient and donor, for the DQA1 locus, during the course of this study, revealed 
that the DQA1 *03:03 antibody was potentially donor relevant, as the donor was 
mismatched with the recipient for DQA1*03 (see appendix 14).
5.1.2 HLA-specific antibody profile of prospective participant 9 
For participant 9, two post-transplant samples were analysed (+6 months and +1 
year), (see appendix 9). The results from Day -12 and Day -5 samples were 
available as part of routine laboratory transplant work-up (data not shown). The 
results from all four samples were then used to extract the data presented in 
figure 5.2, which shows the selected antibody profiles for this participant, in terms 
of DSA, and the changes in the level of the Class II directed antibody with the 
highest MFI post-transplantation (HLA-DPB1 *09:01). Finally, due to the 
complexity of this recipient’s full antibody profile, the HLA Class II specific 
antibodies were examined in order to assess if they were broadening out over 
time, particularly between the pre and post-transplant time points, but also 
between six months and one year post-transplant. An ‘expansion’ of the HLA 
Class II directed antibodies was evident in both post-transplantation samples (+6 
months and +1 year), with antibodies against HLA-DR in particular, which were 
previously undetected in this patient.
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Figure 5.2 HLA antibody profiles for selected HLA specificities in prospective
participant 9
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A total of sixteen ‘de-novo’ antibodies were detected in the post-transplantation 
samples; of these, antibody directed against HI_A-DPB1*15:01 and DPB1*23:01 
were present in the +6 months sample only, whilst HLA-DRB1 *10:01 antibody 
was in +1 year only. The ‘expanded’ HLA directed antibodies detected with the 
highest MFI levels are included in figure 5.2(d).
Participant 9 showed a ‘spike’ in both DSA and other selected HLA-specific 
antibodies at six months post-transplantation (figure 5.2), which was much more 
prominent than in participant 7. The one year post-transplantation time point 
sample indicated that antibody levels had started to decrease, in most cases, 
although this was to a level which still exceeded pre-transplantation levels. There 
were some exceptions to this pattern within the ‘expanded’ specificities, with 
several of the ‘cfe novo’ antibodies continuing to increase in MFI level between 6 
months and 1 year post-transplantation (data not shown). One such newly 
emergent antibody was directed against DRB1*10:01,which had an MFI level of 
925 recorded at 6 months, increasing to 2615 at 1 year post-transplantation. As 
previously indicated in table 3.2, this participant unfortunately suffered a failed 
transplant, and underwent a graft nephrectomy one month after the 
transplantation. In addition, they also received six units of blood around this time. 
Both of these events will have had an impact on their subsequent HLA-directed 
antibody repertoire.
5.1.3 HLA-specific antibody profile of prospective participant 11
Two post-transplant samples were analysed for participant 11 (appendix 10). The 
results from the Day -9 sample were available as part of routine laboratory 
transplant work-up (data not shown). The data from all three samples was then 
presented in figure 5.3. The MFI levels of the DSA present were plotted, 
alongside plots showing the changes in the levels of the Class I and Class II 
specificities with the highest MFI.
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Figure 5.3 HLA antibody profiles for selected HLA specificities in prospective
participant 11
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Following the decline in HLA Class II directed antibodies between the pre­
transplantation and 6 month post-transplantation samples, a slight increase in 
HLA Class II antibodies, both DSA and the specificities with the highest MFI, 
between the six month and one year post-transplantation sampling time points 
was observed. However, as figures 5.3 (a) and (c) indicate, this increase was still 
considerably lower than the pre-transplantation levels recorded at Day -9. In 
contrast to this, figure 5.3 (b) shows a steep increase in levels of selected HLA 
Class I antibodies between the point of transplantation and 6 months post­
transplantation, which had declined little by one year post-transplantation. The 
MFI reading for these antibodies remained higher than the pre-transplantation 
level.
5.1.4 HLA-specific antibody profile of prospective participant 14
For participant 14, two post-transplant samples were analysed (+6 months and 
+1 year, appendix 11). The results from Day -14 and Day 0 were available as part 
of routine laboratory transplant work-up (data not shown). Figure 5.4 shows data 
gathered from all four samples, indicating the changes in the levels of DSA 
(5.4(a)), but also the HLA-specific antibodies with the highest MFI, (5.4(b) and 
(c)) and the ‘expanded’ HLA specificities (5.4(d)). To assess the ‘expanded’ HLA 
directed antibodies, the profiles for the six month post-transplant and the one year 
post-transplant samples were examined, and any HLA directed antibodies which 
were not present in the pre-transplantation study samples were noted.
As would be expected, a fall in HLA-specific antibodies between the pre­
treatment sample (Day -14) and the day of transplant was seen (figure 5.4). 
Consistent across the four graphs, a ‘spike’ in antibody levels was then observed 
at the six month post-transplantation time point. In figures 5.4 (b), (c) and (d), this 
rise was in excess of the pre-transplantation levels. The increase in DSA levels 
observed in figure 5.4 (a) (+6 months) was also in excess of pre-transplantation 
levels for HLA-B*08:01; however for A*24 antibody, the MFI level observed at +6 
months was less than pre-transplantation levels (an MFI of 175 compared to 650 
for A*24:02, and 335 compared to 797 for A*24:03).
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Figure 5.4 HLA antibody profiles for selected HLA specificities in prospective
participant 14
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In all cases, with the exception of the highest Class II specificities (figure 5.4 (c)), 
the antibody levels were declining by the one year time point. In contrast, 
antibodies directed towards the beads for HLA-DRB1 *14:01 and DRB1 *13:03 
had increased slightly further by 1 year. Figure 5.4 (d) indicates a general 
upregulation of the antibody response in this participant, particularly around the 
six month post-transplantation time point. However, in contrast to participant 9, 
the ‘broadening’ of the antibody response in the six month post-transplantation 
sample did not represent any ‘de novo’ reactivity; rather the antibodies noted had 
all been detected at some point over the previous eight years of records held for 
this patient.
5.2 Re-examination of the B cell immunophenotyping analyses, alongside 
the HLA-specific antibody profiles, in the prospective participant cohort
The HLA-specific antibody profiles presented in section 5.1 were aligned with the 
results from the B cell immunophenotyping panels (chapter 4), with particular 
regard to the cells involved in antibody generation, in order to shed light on any 
link between these two sets of data. Again, the data presented is for the four 
transplanted participants (7, 9,11 and 14). For each participant, the HLA-specific 
antibody screening data, shown in figures 5.1-5.4, was combined on a single 
graph, and is presented with the graphs showing the percentage of cell 
populations recorded, at each sample time point, for three B cell populations; 
plasmablasts bearing the phenotype CD19+CD38hiCD27+ and CD19+CD20' 
CD138+, and the memory B cell population (CD19+CD27+).
5.2.1 Participant 7 - combined longitudinal antibody profiles, with selected B cell 
populations
Figure 5.5 presents the combined HLA-specific antibody screening profiles for 
participant 7, together with selected B cell immunophenotyping data. With the 
exception of the DSA directed against HLA-DQA1 *03:03, the levels of the HLA- 
specific antibodies represented in figure 5.5 (a) remained relatively stable post­
transplantation, with a small resurgence at six months, which did not reach pre­
transplantation levels. These mainly small changes are reflected in the B cell 
populations in (b) and (c), which show little fluctuation between +8 months and 
+13 months samples.
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Figure 5.5 Combined graphs of longitudinal HLA-specific antibody levels, with
plasmablast and memory B cell populations, for participant 7
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MFI -  mean fluorescence intensity. Sample time points are described fully in the 
individual participant timeline in section 3.2. The antibody data sets are intended 
to provide an overview of antibody responses; for full specificities refer to figure
5.1.
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5.2.2 Participant 9 - combined longitudinal antibody profiles, with selected B cell 
populations
The combined HLA-specific antibody screening profiles for participant 9, together 
with selected B cell immunophenotyping data, is shown in figure 5.6. Here it can 
be seen that the obvious increase in overall HLA antibody levels at +6 months 
(5.6 (a)) is reflected in a similar peak in plasmablast cell populations (5.6 (b)). 
Simultaneously, the memory B cell population remains reduced post­
transplantation.
5.2.3 Participant 11- combined longitudinal antibody profiles, with selected B cell 
populations
Figure 5.7 shows the combined HLA-specific antibody screening profiles for 
participant 11, together with the selected B cell immunophenotyping data. Small 
changes in plasmablast populations appear to correspond with mainly low levels 
of HLA Class II directed antibodies post-transplantation. The MFI levels of the 
highest Class I antibody specificities (detailed in figure 5.3 (b)) appear to be in 
contrast to this overall picture; however there is a peak in the CD19+CD20' 
CD138+ plasmablast population at six months post-transplantation which 
coincides with this.
5.2.4 Participant 14 - combined longitudinal antibody profiles, with selected B cell 
populations
The combined HLA-specific antibody screening profiles for participant 14, 
together with the selected B cell immunophenotyping data, are shown in figure 
5.8. The resurgence of HLA directed antibodies displayed at the six months post­
transplantation time point (5.8 (a)), appears at the same time point as a peak in 
the plasmablast population (CD19+CD20'CD138+).
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Figure 5.6 Combined graphs of longitudinal HLA-specific antibody levels, with
plasmablast and memory B cell populations, for participant 9
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Figure 5.7 Combined graphs of longitudinal HLA-specific antibody levels, with
plasmablast and memory B cell populations, for participant 11
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Figure 5.8 Combined graphs of longitudinal HLA-specific antibody levels, with
plasmablast and memory B cell populations, for participant 14
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5.3 Post-transplantation HLA-specific antibodies in the retrospective
participants
Serum antibody screening of the retrospective participants indicated an 
extremely diverse group of patients, with several of the individual participants’ 
results (appendices 12 and 13) worthy of comment. The following were of 
particular interest.
Participant 4 was a female patient, who possessed DSA against HLA-B8, B17 
and DR3, pre-transplantation. Her post-transplantation study sample showed 
only DSA against HLA-B8 to be present, although further DSA had been identified 
in routine screening samples post-transplantation. This participant has since 
tested negative for DSA, demonstrating antibody fluctuations.
Participant 5 provided an example of an individual possessing clear and strong 
antibodies directed towards various HLA Class I specificities, although none of 
these were DSA. Interpretation of the screening results were aided by the fact 
that the antibodies were of a high MFI level and showed clear ‘clustering’ around 
related HLA, for instance those belonging to the same ‘broad’ group or cross­
reactive group (CREG). Conversely, the same participant displayed complex 
results for HLA Class II antibody screening, including DSA (directed towards 
HLA-DR1, DQ8 and DR53). Interestingly, the HLA-DP type expressed by the 
donor for this participant, was not represented on the screening test panel 
(DPB1 *16:01), so it was not possible to assess if this DSA was present.
Participant 6 also demonstrated a complex reactivity pattern for their Class II 
results, illustrating the difficulty of separating alloreactivity against the HLA-DQa 
chain from that against the DQp chain. In this participant it appeared that positive 
beads originally attributable to DQ3 were in fact most likely due to reactivity 
against the product of HLA-DQA1 *03:02. This is relevant, in this case, as the 
donor was subsequently typed within this study as DQA1*03.
Participant 10 was an example of an individual whose results were not clear-cut 
for antibodies to HLA Class I, with lots of weak and background reactivity present. 
This confused the results, making it difficult to decipher genuine HLA-directed 
antibodies. It is interesting to note that amongst the antibodies detected in the 
study sample for this participant were those against non-inherited maternal
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antigens (NIMA), HLA-A29 and Cw16. The Class II results for this participant 
were also complex with weak background reactivity present. However, clear DSA 
were observed against HLA-DR4 (also a NIMA) and DP3.
Participant 13 was an example of a patient who had clear sensitisation resulting 
from a previous transplant. HLA-A1, A11, B57, Cw6, DR13 and DR52 directed 
antibodies were detected, amongst the profile of Class I and Class II specificities, 
representing the HLA mismatches present with a previous deceased donor. This 
case illustrates the benefit of having full details of previous donor types and 
sensitising events as an aid to the interpretation of antibody screening results.
Participant 16 was an extremely complex case, with an extensive sensitisation 
history and antibody profile. Clear high MFI levels of DSAs (HLA-A3, A11, B35, 
DR4, DR11, DR52, DR53 and DQ7) were present in the antibody profile. This 
individual was so highly sensitised to HLA that negative tests were mostly 
attributable to the patient’s own HLA type. However, it was noteworthy that 
despite having a history of previous transplantation, this patient did not possess 
HLA-DP specific antibodies.
Participant 17 supplied a later routine screening sample which confirmed the 
presence of DSA against HLA-B5 and cross reactive antibodies against B35.
Participant 19 possessed HLA-B46 specific antibody. Although this does not 
represent a DSA, it was of interest due to the low frequency that this antigen is 
observed in the general population. Class II DSA had been previously detected 
in routine post-transplantation screening samples, despite the current study 
sample being negative for these antibodies, again indicating how antibody levels 
can fluctuate.
5.4 Stratified analysis of the retrospective participant cohort according to 
the HLA-specific antibody screening results
5.4.1 Analysis of the retrospective participant cohort according to the presence 
or absence of DSA
The retrospective study cohort was stratified according to whether DSA (Class I 
or Class II) was present or absent. DSAs were present in eight of the 
retrospective participants and five participants had no DSA. The results from the
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lymphocyte subset analysis were plotted for the two groups, for each cell type. 
The normal controls were used for comparison (data not shown). No differences 
between the segregated cohorts were observed from these analyses.
In a similar manner, the results from the B cell immunophenotyping panels were 
then reanalysed according to DSA presence (n = 7) or absence (n = 3) (data not 
shown). The results showed no striking differences between the 3 groups (DSA 
positive, DSA negative, normal controls) for any of the immunophenotyping 
panels. The cohort numbers were deemed to be too small for any further 
stratification to be undertaken, e.g. dividing into HLA Class I or Class II DSA, or 
overall HLA antibody positive or negative.
5.4.2 Analysis of the retrospective participant cohort according to ‘high8 or ‘low’ 
MFI value
A further stratification was carried out on the retrospective participants, according 
to whether they had ‘high’ levels of circulating HLA-specific antibody (with an MFI 
value of >5000) or ‘low’ levels of HLA-specific antibody present (MFI <5000). The 
data from the B cell immunophenotyping panels were plotted accordingly 
(retrospectives with high MFI, n = 6, retrospectives with low MFI, n = 4). Again, 
the results showed no clear differences between the 3 groups (high MFI, low MFI, 
normal controls) for each of the immunophenotyping panels.
5.5 Re-examination of the B cell immunophenotyping analyses, alongside 
the HLA-specific antibody screening results, for four of the retrospective 
participants
In section 4.2.3., it was noted that four of the retrospective participants had a 
population of plasmablast cells (CD19+CD20'CD138+) present. The percentage 
of plasmablasts, for these four participants all appeared above the mean for the 
cohort. This data has been reproduced, alongside similar plasmablast data 
(CD19+CD38hiCD27+) from the transitional B cell panel, and the memory B cell 
data (CD19+CD27+), in figure 5.9. Each of the four participants noted have been 
assigned a colour, in order to compare their individual results for these cell 
populations. The HLA-specific antibody screening results for the four participants 
are shown in table 5.1, in order to examine any associations between these sets 
of data.
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As would be expected, figure 5.9 (a) indicates that the four participants also 
showed a relatively high percentage of CD19+CD38hiCD27+ cells, which are likely 
to represent the same plasmablast population, as the cells detected possessing 
the phenotype CD19+CD20*CD138+. Figure 5.9 (b) indicates that for three of the 
four participants highlighted (5, 10 and 16), the plasmablast populations 
corresponded with a depleted memory B cell pool. Participant 18, however, 
possessed a percentage of memory B cells which was above the mean for the 
cohort. The plasmablast populations identified in participants 5, 10 and 16 
correspond with the extensive sensitisation (including DSA) and high MFI levels, 
shown in table 5.1. In contrast, participant 18 did not possess any DSA and had 
a narrow sensitisation of 2% PRA (albeit with a corresponding cRF of 26%), 
representing two antibody specificities (HLA-B8 and HLA-B82), at a fairly high 
MFI level of 12,996.
Table 5.1 HLA-specific antibody screening results for the four retrospective 
participants highlighted in figure 5.9
Retrospective
participant
% PRA Highest MFI %
cRF
DSA
Class
I
Class
II
Class
1
Class
II
5 36 23 19,819 3979 96 Class II present
10 4 41 1474 4836 95 Class II present
16 81 51 18,387 20,271 100 Class I and 
Class II present
18 2 0 12,996 N/A 26 None
% PRA -  percentage panel reactive antibody; MFI -  mean fluorescence intensity; 
% cRF -  percentage calculated reaction frequency; DSA -  donor specific 
antibody.
This data is a summary of that shown more fully in appendices 12 and 13.
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Figure 5.9 Plasmablast and memory B cell populations for the retrospective
cohort, highlighting the four participants noted for populations of plasmablasts
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(b) Memory B cell population
Y axis -  percentage of each cell population identified. Horizontal line indicates 
mean. Retrospective cohort, n= 10.
The coloured data points indicate the four participants noted for plasmablast 
populations; blue -  participant 5, red -  participant 10, yellow -  participant 16, 
green -  participant 18. The remainder of the cohort are indicated by black data 
points.
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5.6 Results from HLA typing performed to assist in the interpretation of 
HLA-specific antibody screening results
As described in section 2.11, supplementary HLA typing was carried out on five 
recipient and donor pairs, for HLA loci which were not typed as a part of the 
standard routine laboratory work-up for transplantation. This genetic typing 
information was required in order to allow full interpretation of the antibody data 
generated by this study. The HLA typing data obtained on the five recipients and 
their respective donors is presented in appendix 14.
5.7 Discussion of HLA-specific antibody detection in the prospective and 
retrospective HLAi transplant recipients
5.7.1 General observations of the problems encountered in interpreting results 
from HLA-specific antibody screening, as demonstrated in the retrospective 
participant cohort
The HLA-specific antibody screening results from the retrospective participant 
cohort can be used to highlight some of the difficulties often encountered with 
interpreting this type of data. The importance of viewing this information in the 
context of HLA typing results and with a knowledge of the frequencies of HLA 
types in different populations is also emphasised. Due to the nature of the cohort, 
being HLAi transplant patients, the screening results were complex, with many 
HLA specificities to decipher, often with much weak background reactivity, cross­
reactivity or allelic reactivity present.
The choice of test methodology and commercial kit used for the detection of HLA- 
specific antibodies has an obvious influence on the results obtained. Solid-phase 
single antigen systems now provide the ‘gold standard’ within H&l laboratories 
(Roberts et a/. 2014) and microbead analysis is recommended for monitoring 
patients undergoing HLAi transplantation (BTS 2015). Single-antigen tests can 
excel in providing clear, definitive interpretation of HLA-directed antibodies, 
without the confusing factor of picking apart reactivity against the numerous 
antigens expressed on a single cell, yet they too are not without their intrinsic 
drawbacks (Middleton, Jones and Lowe 2014, Roberts et al. 2014). The
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phenomenon of HLA linkage disequilibrium, where certain genes are 
characteristically inherited together as a haplotype, has historically made cellular 
based antibody screening assays difficult to interpret. However, the 
representation of antigens in a commercial kit still affects the results obtained. 
For instance, in the case of participant 5, it was not possible to identify reactivity 
towards the HLA-DP antigen encoded by DPB1 *16:01, despite this being donor 
relevant. In this kind of scenario HLA epitope analysis can be informative, by 
identifying shared epitopes between the HLA targets of antibodies detected by 
the assay, and donor mismatches which are not represented. Participant 5 
showed extensive HLA-DP sensitisation (appendix 13), with antibodies directed 
against a range of HLA sharing the 84DEAV epitope (University of Piaui 2013). 
DPB1 *16:01 also shares this epitope, so it may be postulated that DSA was likely 
to be present against this donor relevant mismatch.
Single antigen kits can help facilitate the definition of antibodies directed against 
the a-chain of the HLA Class II molecule, but this can often be unclear and, in 
some cases, the antibody may be misassigned as a p-chain directed antibody. 
Due to the HLA Class I molecule consisting of a single heavy chain (associated 
with p-2 microglobulin), corresponding to a single Class I gene, interpretation is 
usually more straightforward. Although Class II HLA-DQA and DPA are not as 
polymorphic as their HLA-DQB and DPB counterparts (Robinson et at. 2015), 
antibodies directed against them are now routinely identified. This is relevant to 
participant 6, where it was difficult to separate reactivity against the p-chain 
encoded by HLA-DQB1*03 and the a-chain product of HLA-DQA1 *03:02, due to 
these two chains often being paired in the same HLA molecule. It is important to 
define HLA-specific antibodies as clearly as possible in order to identify ‘windows’ 
of opportunity for transplantation, particularly in highly sensitised individuals, and 
in order to ensure that donor kidneys are not unnecessarily denied to patients 
waiting for a transplant.
Since memory B cells are able to generate antibodies upon re-exposure to
antigen for the lifetime of an individual, it is important to ascertain the sensitisation
history of potential transplant patients wherever possible. It is also good practice
to ensure that a patient’s sensitisation profile is viewed in the context of their own
HLA type, in order to exclude reactivity against ‘self antigens. An understanding
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of HLA expression and linkage disequilibrium is required in order to avoid 
unintentionally re-exposing patients to previously encountered HLA. As 
demonstrated with participant 13, it is often possible to identify the complete HLA 
mismatches of a previous donor within the antibody profile of a sensitised patient. 
Due to linkage disequilibrium, HLA-B57 and Cw6, and DR13 and DR52, are 
usually found together on the same haplotype, and this was most likely the case 
in the previous donor for participant 13.
HLA types are represented at different frequencies within certain ethnic groups; 
a phenomenon associated with the diverse microbiological pressures 
experienced by different populations. This can have serious repercussions for the 
chances of finding someone a matched donor or for excluding donors in 
sensitised patients. The case of participant 18 demonstrates this, in that HLA-B8 
is a common antigen, present in 25% of the UK organ donor pool (NHSBT 
2016b), so possession of this antibody significantly reduces this patient’s 
chances of being offered a deceased donor kidney. Conversely, participant 19 
was shown to have formed antibody against HLA-B46, which has a reported 
frequency of <1% in the UK organ donor pool (NHSBT 2016b). This antigen is 
expressed almost exclusively in individuals from south-east Asia, with reported 
frequencies of up to 14% in these populations (Akesaka et al. 2000). Initial 
preconceptions may indicate that it is unlikely that this participant would have 
been exposed to this antigen via the standard routes of sensitisation. However, 
the patient’s nationality is documented as being Filipino, so it is possible that they 
received a blood transfusion in their country of origin. However, the formation of 
a single HLA Class I antibody, directed towards a low frequency antigen, often 
suggests an alternative route of sensitisation, such as molecular mimicry. This 
describes a potential cross reactivity between the immune response towards 
pathogens and HLA, due to amino acid sequence similarities. Although it is 
considered safe practice in our centre to list these antibodies, if they are 
consistently present, this does highlight the importance of ascertaining that 
detected antibodies are indeed clinically relevant (Middleton, Jones and Lowe 
2014).
In the course of attempting to identify the most suitable live donor for participant 
10, both parents had been HLA typed, and it was of interest to note that this
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participant had formed antibodies directed against the non-inherited maternal 
HLAs. It is thought that a tolerogenic effect is generated to these HLA, due to the 
exposure by an individual to NIMA in utero. Claas et al. (1988) reported some 
time ago that, in a cohort of multi blood transfused, highly sensitised patients, 
50% did not form antibodies against NIMA, creating a possible ‘window’ for 
transplantation. Although not borne out in this case, such strategies can 
sometimes aid in identifying the most compatible donors for patients awaiting 
transplantation.
5.7.2 Post-transplantation detection of HLA-specific antibodies in four 
prospective participants
Participants 7, 9 and 14 all demonstrated an increase in HLA-specific antibodies 
in general terms, by the six month post transplantation time point, which was 
mainly declining by one year post-transplantation. Obtaining a genuine ‘picture’ 
of DSA levels post-transplantation presents difficulties, as only levels in serum 
are detected, and it is not possible to ascertain if DSA is being produced but 
bound to target antigens present on the donated graft. However, this process of 
sequestration of the antibodies may only provide a partial explanation for their 
absence or reduction post-transplantation (Stastny etal. 2009). For participant 7, 
the pattern observed for the DSA targeting DQA1 *03:03 encoded epitopes was 
striking as being different to the other antibodies present, by peaking to a high 
MFI level post-transplantation. Unlike the DSA directed towards the HLA- 
DQB1*03 encoded antigens in this participant, it may be that the plasma cells 
producing the HLA-DQA1 *03:03 antibody could have ‘escaped’ destruction in 
survival niches within the secondary lymphoid organs.
Participants 9 and 14, in particular, showed similar antibody dynamics, with 
increased levels at six months post-transplantation. These participants both 
underwent transplantation which was incompatible for the ABO blood group 
antigens, as well as being HLAi. Therefore, they received similar transplant 
conditioning, which may explain the pattern of antibody resurgence post­
transplantation. In addition, ABO antibody rebound is common, but often 
associated with a clinical picture of graft accommodation when in excess of three 
weeks post-transplantation. The features of this phenomenon include the
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presence of both increased ABO antibody titres, alongside C4d deposition, with 
no antibody mediated rejection (Koo and Yang 2015). It is possible that a rebound 
in ABO antibody titres could have been associated with an upregulation of other 
antibodies, including those directed towards HLA, around this time period. Both 
patients suffered delayed graft function post transplantation, with participant 14 
also having biopsy proven early rejection, which required treatment with methyl- 
prednisolone.
Participant 9 showed a broadening out of their HLA directed antibody specificities 
by six months post-transplantation, including the production of new specificities, 
which was most likely a direct response to losing their graft (Nair and Heeger 
2012) and receiving multiple blood transfusions. The immunological challenge of 
receiving and then losing their transplanted kidney most likely stimulated this 
antibody production, which may have developed and ‘expanded’ to include new 
specificities, a process known as ‘epitope spreading’ (BSHI/BTS 2014), facilitated 
by shared epitopes within HLA molecules. In addition, the blood transfusions 
would have been from different donors, and despite leukodepletion of red cell 
transfusions it has been evidenced that HLA sensitisation still occurs by this 
route, either due to remaining leucocytes or cell debris present, or because of low 
level HLA expression on erythrocytes (Rees and Kim 2015). Finally, although the 
transplanted donor kidney was removed, it is likely that transplanted donor tissue 
would have remained in situ causing ongoing immunological stimulation (Nair and 
Heeger 2012). Participant 14, who showed a similar pattern of antibody ‘spiking’ 
at six months post-transplantation, also demonstrated an associated broadening 
out of their antibody response at this time point. However, in this case the 
antibodies detected had all been previously documented for this participant.
Participant 11 showed different patterns of detection for antibodies directed 
against HLA Class I and Class II. Class II directed antibodies, including DSA, 
remained at a fairly low level post-transplantation. Simultaneously, Class I 
directed antibodies with the highest MFI, showed a sharp increase post­
transplantation. Antibodies targeting two different alleles encoding the HLA Class 
I antigen B57 showed a peak in MFI at six months post-transplantation, which 
had started to decline by the one year post-transplantation time point.
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5.7.3 Possible links between plasmablast populations and HLA-specific
antibodies present, in the prospective and retrospective participant cohorts, post- 
HLAi transplantation
Figures 5.5-5.8 suggest a link between the plasmablast populations detected by 
the CD19+CD20'CD138+ and CD19+CD38hiCD27+ cell markers, and the patterns 
of post-transplantation antibody production in the four transplanted prospective 
participants. This is key in illuminating the question of where the site of antibody 
production lies for each individual, which could have implications for clinical 
intervention. The ‘spike’ in antibody production shown by participants 9 and 14, 
at six months post-transplantation, seems to correlate with an increase in the 
plasmablast population and a drop in the percentage of memory B cells. 
Participant 11 also demonstrated an increase in plasmablasts of the phenotype 
CD19+CD20'CD138+ associated with an increase in HLA Class I directed 
antibodies at six months post-transplantation.
This possible connection between peripheral plasmablast populations and 
antibody production is interesting, as it suggests a potential new approach to 
monitoring HLAi transplant patients post-transplantation. In the main, a 
resurgence of HLA-specific antibodies in the four transplanted prospective 
participants was accompanied by an increase in peripheral plasmablast 
populations, and both cells and antibodies then showed a decline. It could be 
hypothesised that a situation where both parameters continued to increase would 
indicate a poor prognosis for transplant outcome. In this scenario, plasmablasts 
present in the periphery represent a target for clinical intervention, perhaps with 
increased immunosuppression, accompanied with plasma exchange to clear the 
antibody burden. A worse clinical picture may be represented by a sustained 
increase in HLA directed antibodies, which is not accompanied by the detection 
of peripheral plasmablast populations. This may indicate that the antibody 
producing cells are ‘hidden’ in the survival niches of the secondary lymphoid 
organs, where it is impossible to target them with standard therapies. The 
combined results for participant 7 hints at this situation, with the DQA1 *03:03 
antibody, which appears to be inconsistent with the pattern obtained for their 
other antibodies. However, this antibody started to decline by the one year post­
transplantation time point. It is also interesting to note that the two prospective
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participants (1 and 2) who underwent desensitisation, but did not get 
transplanted, demonstrated an increase in HLA-specific antibodies (HLA-A2 
directed, and HLA-A2 and DQ8 directed respectively) combined with a decrease 
in plasmablasts, over the course of their treatment (figure 4.13).
The observations concerning the plasmablast populations are thought provoking, 
yet it should be borne in mind that these cell populations are present in low 
percentages, so that seemingly substantial fluctuations represent a very small 
number of cells in absolute terms. Plasma cells (CD138+) are reported to be 
present in bone marrow as 0.2-2% of leucocytes (Stemcell Technologies 2015), 
yet a reference for peripheral blood is not provided. It is possible that the severe 
leucodepletion caused by alemtuzumab promotes the migration of plasmablasts 
from the secondary lymphoid tissues to the periphery, but investigation of this 
would require further work.
If the association between antibody levels and plasmablast populations, indicated 
by the four prospective participants, is a consistent finding (or can be reproduced 
in further transplant patients), then observations concerning this trend should also 
be apparent within the retrospective cohort. The results collated in figure 5.9 
indicate that increased peripheral plasmablast populations associated with a 
relatively high % PRA (with a corresponding high % cRF) and MFI level (table 
5.1), in participants 5, 10 and 16, are also linked with a reduced percentage 
population of memory B cells. Participant 18 appears to differ, possessing a 
relatively high percentage of both plasmablasts and memory B cells, yet restricted 
sensitisation to just two antigens, with a high level of antibody. It may be 
postulated that a pattern of increased numbers of plasmablasts, producing large 
quantities of antibodies targeting different epitopes, could lead to a concurrent 
reduction in the memory B cell pool. Conversely, participant 18 may represent a 
different ‘picture’ of a single clone of plasma cells producing antibody targeting a 
shared epitope of HLA-B8 and B82, which is not reflected in a reduction of the 
memory B cell population.
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CHAPTER 6 DISCUSSION
6.1 Summary of the study findings
This study gathered data from blood samples provided by seven prospective and 
thirteen retrospective HLAi kidney transplant recipients, and nine normal control 
individuals. Three sets of data were collected on each of the transplant 
participants; lymphocyte subsets, T and B cell immunophenotyping and HLA- 
specific antibody screening. The results obtained from this study are firstly 
summarised, and presented as a set of characteristics making up a profile for 
each group of participants, where possible. Although there were some 
generalisations that could be drawn from the study participants, there were also 
many exceptions. The evidence for any recommendations for changes in 
practice, which can be supported by this work, will then be described, and 
suggestions for further work to progress this study area will be made.
Several difficulties and limitations were encountered whilst performing this study, 
and these will be described as a part of this discussion. Two limitations were of 
particular importance when considering the results obtained; firstly the 
heterogeneous nature and complexity of the study group, and secondly the small 
number of prospective participants recruited. Further strengths and weaknesses 
of the study, and possible ways that the latter could have been addressed, are 
also considered. Finally, the future direction for HLAi transplantation will be 
reflected upon.
The key study findings are summarised in table 6.1 for the transplanted 
prospective and retrospective participants. The prospective participants who 
were not transplanted have not been included in this profile, as it was not possible 
to draw generalisations from just two individuals.
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6.2 Recommendations for change in practice and further work in relation to 
cellular immunophenotyping HLAi transplant patients
This research project represents a pilot study into the merit of 
immunophenotyping HLAi transplant patients. Although it was not possible, in all 
cases, to extract a common thread from each panel, the results presented by 
these participants demonstrated some intriguing trends and patterns that are 
worthy of further investigation. It is therefore recommended that elements of this 
pilot study are extended into a larger prospective study, and that this should be 
continually monitored by rolling audit. In a sense, a version of the prospective arm 
of the current study should continue, and run alongside the schedule for routine 
laboratory work-up for HLAi transplantation. Figure 6.1 presents a potential 
schedule for best utilisation of these tests. The lymphocyte subset analysis 
provides an informative ‘snapshot’ of a potential transplant participant’s immune 
system, for a relatively simple test, and forms a basis for any subsequent 
immunophenotyping undertaken. The panels which analysed populations of 
RTEs, and memory and transitional B cells, were most informative regarding the 
reconstitution of participants’ lymphocyte populations post-transplantation. If the 
lympho-ablative drug alemtuzumab is continued in use then these panels would 
inform upon repopulation of the immune system, and could potentially alert the 
renal care team of any patients not reconstituting in the expected pattern, or with 
persistently low cell population percentages.
While the activated T cell panel was also informative post-transplantation, the 
results from participant 1, who was not transplanted, demonstrate a potential for 
utilising these immunophenotyping markers during the pre-transplant treatment 
protocol. Along with other test results, changes in these cell populations may 
correspond with an immune profile which is non-responsive to the desensitisation 
treatment. The possible association between rising MFI levels of HLA-specific 
antibodies and changes in the percentage of the population of peripheral 
plasmablasts warrants further investigation, which would need to be carried out 
alongside HLA-specific antibody screening, according to the current schedule.
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Figure 6.1 Possible schedule for T and B cell immunophenotyping for future
prospective patients undergoing HLAi transplantation
HLAi 'baseline' crossmatch 
Lymphocyte subsets; activated T cell, RTE, memory B cell and transitional B cell panels
I *Plasmablast panel, alongside 
♦I each HLA-specific antibody 
| screen
i Activated T cell panel, alongside j 
| each desensitisation clinical j 
event j
Transplantation
--------- ----- -.... .
| *Plasmab!ast panel, alongside 
J each HLA-specific antibod'/
j screen
? . . . . .  . . . .  
| 6 months post-transplantation : 
[ Lymphocyte subsets; activated T cell, RTE, memory B ceil and transitional B cell panels
1 year post-transplantation
Lymphocyte subsets; activated T cell, RTE, memory B cell and transitional B cell panels
2 years post-transplantation
Lymphocyte subsets; activated T cell, RTE, memory B cell and transitional B cell panels
More regular identification of this cell population, may provide an answer to the 
question of whether it is possible to detect an increase in plasmablasts, prior to 
an increase in antibody levels. This would then potentially provide an opportunity 
for clinical intervention. Once the optimum testing schedule for this 
immunophenotyping panel was determined, this could then be employed 
alongside the panels already mentioned. HLAi transplantation often presents 
complex immunological cases and these additional tests would contribute 
additional laboratory data, which may potentially aid the clinical management of 
these patients. However, it is acknowledged that it would take time for this test 
repertoire to become embedded into the laboratory work-up, and to ascertain 
precisely how this new knowledge contributes to informing clinicians of the overall 
clinical ‘picture’ of the patient.
* Following identification of the 
optimum testing schedule for this 
panel
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These tests may also provide additional valuable data, on an ‘ad-hoc’ basis, for 
patients undergoing investigations post-transplantation. For instance, the 
plasmablast panel could potentially be employed alongside post-transplantation 
testing for DSA, in patients who are experiencing a decline in graft function, and 
are possibly starting to reject their transplant. If the association between 
peripheral plasmablast populations and HLA-specific antibodies is proven, this 
could provide key information in the problematic scenario of diagnosing AMR in 
the presence of C4d staining but absence of circulating DSA.
In terms of the data already generated from the immunophenotyping panels 
employed during this study, it may be interesting to return to the raw data and 
review it for different cell populations. Kohler and Thiel (2009) suggest that, 
following the decrease in thymic activity correlated with ageing, the naTve T cell 
pool may be repopulated by peripheral expansion of CD31-CD45RA+ T cells. It 
may be of interest to track this population of cells (CD31-CD45RO') to ascertain 
any recovery made in the central naive CD4+ T cell pool. It would also be worth 
reviewing the activated T cells panel in order to identify if there is evidence of a 
HLA-DRhi cell population present in any of the participants. Due to the role of 
HLA-DR as a late marker of T cell activation, it has been suggested that these 
cells may be chronically activated, and could be indicative of immunosenescence 
(Barathan et al. 2015).
6.3 Limitations of the study
As already described, transplant patients who are being progressed down the 
HLAi route are assessed in an individualised manner, on a case by case basis. 
This inevitably meant that the cohort of patients upon which the study was based 
was extremely diverse, not only in terms of sensitisation history, crossmatch 
status, DSA present, degree of HLA mismatching between recipient and donor, 
relationship of donor, and cause of renal failure, but also in the precise 
desensitisation protocol followed and immunosuppressive drugs administered. 
One of the main limitations of the study has been the difficulties this has 
subsequently presented in comparing participants and drawing generalisations 
between participants. In many ways each of the study participants was unique,
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and although commonalities have been identified between patient 
immunophenotyping results, there have been many exceptions and ‘outliers’ 
noted to the overall trend.
During the planning phase of the study, it was anticipated that the prospective 
cohort would form the main focus, as, at the time, it was envisaged that the HLAi 
route to transplantation would be a growth area in our centre. However, during 
the prolonged time spent preparing for, and acquiring, research ethics approval, 
there was a shift in our approach to the transplantation of patients with an 
incompatible live donor. The introduction of the paired/pooled scheme by 
NHSBT-ODT, meant that this was becoming the first choice method towards 
transplantation for these patients, and consideration for a desensitisation 
programme was usually only after several unsuccessful rounds in the scheme. 
This was combined with a move away from managing extremely complex cases, 
for example multiple antibodies present at high MFI levels, directed against both 
HLA Class I and Class II antigens, with desensitisation. The outcome of these 
changes was that, despite an initial prediction of approximately twelve patients 
progressing down this route, just seven were recruited over the specified time 
frame, and unfortunately only five of these were transplanted. This local 
experience is reflected in a similar national trend of a plateau in the number of 
HLAi transplantations being performed over the timeframe of this study, depicted 
in figure 6.2 (BTS 2015). Similarly, the reasons suggested for this concur with 
those described above, indicating that the circumstances in Leeds are part of a 
larger national development.
The project plan had allowed for this eventuality by describing a dual approach, 
with a retrospective participant group to also be recruited. Indeed, much 
interesting data was gathered from the retrospective cohort, but again the group 
was extremely heterogeneous. As these participants had been previously 
transplanted, a single sample collection time point was deemed appropriate. This, 
combined with the fact that the recipients were inevitably at varying time points 
post-transplantation, also affected the utility of the data, and the conclusions 
which could be drawn.
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Figure 6.2 Number of HLAi and ABOi kidney only transplantations performed
each year in the UK. from April 1st 2005 -  March 31st 2015
f l  HLAi
□  ABCi
□  HLAi & ABOi
►005-2009 2006-2007 2007-2008 2008-2000 2009-2010 2010-2011 2C11-2012 2012-2013 2013-2C14 2014-2015
NHSBT (2015, p44)
However, the inclusion of this cohort allowed some of the long-term effects of 
HLAi transplantation to be perceived. It is anticipated that if this pilot study was 
extended into future use, with prospective participants, this would allow the 
collection of more longitudinal data over an extended time frame, with prolonged 
follow-up. Regular audit would continue to assess the potential impact of these 
supplementary tests.
Sample collection was further hindered at times by a lack of communication, 
something which is often the case with laboratory-based studies where the chief 
investigator is ‘one-removed’ from the participants. More recently, and since 
sample collection for this study ceased, a multi-disciplinary team (MDT) meeting 
to discuss complex cases, which are largely focussed around HLAi and ABOi
potential recipient-donor pairs, has been initiated in Leeds, which would be ideal
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to facilitate putting this work into routine use, or a similar study in the future. This 
type of setting is recommended for facilitating excellent clinical and laboratory 
communication around possible AiT cases (BTS 2015). This is crucial in building 
up local experience and knowledge, based upon the continuous assessment of 
previous cases, in order to provide evidence for the risk assessment required to 
proceed with future cases.
The specialised nature of this approach to transplantation, coupled with the 
situation described above, meant that the numbers recruited to the study cohorts 
were small. This made the application of statistical methods somewhat 
challenging, and hence, some of the discussion and conclusions drawn from the 
study data have been anecdotal in nature. In addition, the small numbers involved 
made it difficult to tie any observations in with clinical outcomes, or to stratify the 
group for analysis.
In an observational study of a small, yet diverse patient group, it is perhaps 
predictable that it has been difficult to draw conclusions that can be attributed to 
the process of transplantation, and specifically HLAi transplantation. The effects 
of the conditioning drugs on the immunophenotyping results are evident, but it is 
not possible to extricate this from the study to allow the effects of transplantation 
itself to be clear. The collection of further data, with prolonged follow-up, would 
help with this and allow the group to be stratified for analysis. A future possibility 
could also involve a multi-centre approach to recruit more participants.
Another problem encountered due to unforeseen changes during the time of 
planning and seeking approvals for the study protocol, was due to an alteration 
in the general immunosuppressive drug regimen for renal transplant patients in 
Leeds. The introduction of alemtuzumab, a drug resulting in severe lymphopenia, 
for all HLAi transplant patients caused problems for the proposed schedule of 
collection of study samples. It was originally planned to collect a study sample 
approximately one week post-transplantation for the prospective participants, but 
when the first two were sampled, it was confirmed that insufficient lymphocytes 
were present for full analysis. This will remain a problem for immunophenotyping
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these types of patients post-transplantation, for instance if attempting to monitor 
plasmablast populations as described above. As previously alluded to in the 
discussion of chapter five, the monitoring of small percentages of a small absolute 
number of cells must be acknowledged as a limitation of this study, and 
examining cell populations post-alemtuzumab treatment exacerbates this 
problem.
Finally, an unavoidable limitation of the study involved the technology employed. 
Each peripheral blood sample analysed merely provided a ‘snapshot’ of the 
populations of lymphocytes present at a particular time point. Furthermore, no 
information may be gleaned of what was occurring in the lymphoid organs. 
Memory B cells and plasma cells are known to remain in survival niches, such as 
the spleen, where desensitisation treatments cannot target them (Ramos et al. 
2007). In order to gain a more thorough ‘picture’ it would, therefore, be necessary 
to examine lymphoid tissue samples and bone marrow extracts, which would 
clearly require additional research ethics approval. Although this limitation is 
acknowledged, peripheral blood represents a ‘window’ into the immune system 
and was an appropriate sample choice for this pilot study.
An inherent limitation of the technology of flow cytometry employed in this study 
is that it provides information about cell phenotype but not necessarily function. 
In order to fully understand the role of the cells present, cytokine expression 
studies would be required. Finally, some of the advantages and disadvantages 
of bead-based HLA-specific antibody screening methods have already been 
mentioned.
A research project of this nature, which is carried out in the ‘working world’ will 
inevitably have shortcomings related to the technology utilised, the study design 
and the interpretation of the data. Therefore, an attempt has been made to 
acknowledge these weaknesses, and to take them into account when drawing 
conclusions.
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6.4 Comments on the future direction of HLAi transplantation
The success of kidney transplantation as a treatment means that it is essential 
that access to donor organs is an equitable and transparent process. However, 
this must be balanced against the best utility of this valuable resource. Various 
strategies to improve the access to transplantation for sensitised patients have 
been investigated (Fuggle and Martin 2004; Doxiadis, Duquesnoy and Claas 
2005). However, despite prioritisation in the deceased donor national kidney 
allocation scheme (NHSBT 2016c) for highly sensitised patients, defined as 
£85% cRF, these potential recipients continue to experience increased waiting 
times. Notably, most recent analyses (Bradbury 2016) have indicated that 
prioritisation of long waiting patients, for a deceased donor kidney offer, has failed 
to address the problem for the most highly sensitised individuals.
Within the UK, there are currently two main strategies for approaching 
transplantation for recipients who have a potential live donor who is HLA 
incompatible. Alongside HLAi transplantation, the national living donor kidney 
sharing schemes, organised by NHSBT-ODT, represent the second part to this 
dual tactic. The paired/pooled scheme facilitates national sharing of live donor 
kidneys within an algorithm that allows paired exchanges of kidneys, or more 
complicated chains of exchanges. These chains can now be initiated by a non­
directed altruistic donation (NDAD), from a live donor who wishes to donate to 
the pool.
As standard compatible live donor transplants have superior outcomes to HLAi 
transplants, it is recommended that potential HLAi recipient-donor pairs enter the 
exchange scheme before proceeding down the HLAi transplantation route (BTS 
2015). However, it is acknowledged that clinical urgency may prompt a more 
direct progression to HLAi transplantation. In addition, individual choice may lead 
some potential recipients towards this route sooner, with their preferred live donor 
of choice.
In any case, due to the nature of sensitisation to HLA, not all patients will be 
matched with a live donor in the paired-pooled scheme. For this reason, a place 
for HLAi transplantation as an option should remain. Indeed, in certain cases
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these two options may be combined, with the removal of unacceptable antigens 
when entering the paired-pooled scheme, if it is deemed that these antibodies 
can be dealt with clinically peri- and post-transplantation by some degree of 
antibody removal therapy (BTS 2015). Using the same principle, some centres 
are using this approach of removing low level HLA-specific antibodies listed with 
NHSBT, for sensitised patients waiting for deceased donor transplantation.
Pre-conditioning for HLAi transplantation in the deceased donor setting also 
provides another area where this type of transplant may be utilised for a 
sensitised patient. However, this is difficult to manage logistically due to the 
inability to predict an offer of a deceased kidney, and is usually reserved for 
clinically urgent cases. In addition, current graft and patient survival rates for HLAi 
deceased donor transplantation are considerably below those for all other types 
of transplantation. Yet, it must be reiterated that these types of decisions are 
based around a risk assessment; the long-term mortality rates of a deceased 
donor HLAi transplantation still compare well with the mortality associated with 
continued dialysis (BTS 2015).
Increasingly acceptable outcomes and continued clinical need ensures that HLAi 
transplantation, in its various guises, will remain firmly embedded in a ‘multi­
faceted’ strategy of transplanting sensitised patients. However, these transplants 
will most likely remain as individualised cases, progressed on a risk assessed 
basis. As this study highlights, there is still much knowledge to be gained and 
potential H&l laboratory support that could be given, that may improve the 
delivery of these programmes and thereby access to the superior treatment of 
transplantation.
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Appendix 1 A copy of the letter for participants’ GPs. submitted with the NHS 
REC application and granted final approval in July 2011
Version 1.0 22/03/11 Immunological Profiling in AiT Recipients Version 1
The Leeds Teaching Hospitals
NHS Trust
Pathology Directorate 
Department of Transplant Immunology 
CPA Accredited Laboratory 
EFI Accredited Laboratory
St James’s University Hospital 
Level 09 Gledhow Wing 
Beckett Street 
LEEDS 
LS97TF UK
Direct Line: (0113) 206 4579 
Fax No: (0113) 206 4579 
e-mail: katherine.mounsey@leedsth.nhs.uk
http://www.leedsth.nhs.uk/
i
Address
Date
Dear D r .................
Re: Patient:
Date of birth:
The above named patient has consented for recruitment into the ‘Immunological Profiling in Renal 
Transplant Recipients Receiving an Antibody Incompatible Kidney’ study. As part of the study 
protocol, blood samples will be collected, for laboratory analysis, pre- and/or post-kidney 
transplantation at set time points, dependent on whether the patient has been recruited as part of the 
study group or as a control. No changes will be made to their routine clinical care or medication.
This letter is purely for information purposes. There will be no requirement for any additional clinical 
input from the patient's normal primary care practitioners.
Please do not hesitate to contact me if you have any further queries.
Yours sincerely,
Katherine Mounsey DipRCPath 
Principal Clinical Scientist
Chairman Mike Collier Chief Executive Maggie Boyle
The Leeds Teaching Hospitals incorporating: Chapel Allerton Hospital Leeds Chest Clinic Leeds Dental Institute 
Seacroft Hospital St James's University Hospital The General Infirmary at Leeds Wharfedale Hospital
|
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Appendix 2 Copy of the participant information sheet and consent form, submitted
with the NHS REC application and granted final approval in July 2011
Version 2.0 15/06/11
The Leeds Teaching Hospitals
NHS Trust
PARTICIPANT INFORMATION SHEET 
Immunological Profiling in Renal Transplant Recipients 
Receiving an Antibody Incompatible Kidney
Introduction
You are being invited to take part in a research study. Before you decide whether to take 
part, it is important for you to understand why the research is being done, and what it will 
involve. Please take time to read the following information carefully, and discuss it with 
others if you wish.
Please ask us if there is anything that is not clear, or if you would like more information. 
Take time to decide whether or not you wish to take part.
Thank you for reading this information sheet and for considering taking part in this study. 
Background to the study
As you know, transplantation provides the best treatment for patients with advanced 
kidney failure. However, sometimes it can be very difficult identifying a compatible donor 
for patients who have anti-donor antibodies. Antibody incompatible transplantation (AiT) is 
a specialised procedure that helps patients with anti-donor antibodies to be transplanted, 
usually with a living donor. However, there is much that it is not understood about the 
biological process of this procedure.
What is the purpose of the study?
The purpose of the study is to examine the different populations of immune cells, present 
in the blood, at different stages of AiT. This information will be combined with other 
laboratory and clinical results, with the aim of building up an ‘immunological profile’ of AiT 
patients. In the future, this may allow us to carry out additional monitoring of patients 
undergoing AiT, with the overall long-term aim of improving transplant outcome.
Why have I been chosen?
You have been chosen because you are either preparing to be transplanted with a living 
donor, or you have been transplanted in the past with a living donor kidney, at St James’s 
Hospital, and you are attending follow-up sessions in the transplant clinic. If you have 
previously had, or are preparing for, an antibody incompatible kidney transplant, then you 
are being invited to be part of the study group. If you have had, or are preparing for, a 
standard live donor kidney transplant, then you are being invited to be part of the 
comparison group for the study.
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What will I have to do?
If you are preparing for transplantation with an antibody incompatible living donor,
you will be asked to donate approximately 15 mis of blood (about 3 teaspoons) 3 times 
during the fortnight before your transplant, and 3 times during the fortnight following your 
transplant, then again at approximately 6 months and 1 year following your transplant. You 
may also be asked to donate an additional 10mls of blood (about 2 teaspoons) at the 6 
months and 1 year time points. These blood samples would be taken when we see you in 
the clinic (either at St James's or at your referral centre).
If you have been transplanted with an antibody incompatible living donor in the 
past, you will be asked to donate between 15-25 mis of blood (about 3-5 teaspoons) once, 
when we see you in the clinic for follow up. In addition, we may wish to test samples that 
you have previously given as part of your routine care, and which are stored in the 
laboratory.
If you are preparing for transplantation with a standard living donor, you will be 
asked to donate 15 mis of blood (about 3 teaspoons) once before your transplant, and 15- 
25 mis of blood once during the week following your transplant, and between 6 months to 
a year after your transplant. These blood samples would be taken when we see you in the 
clinic (either at St James’s or at your referral centre).
If you have been transplanted with a standard living donor in the past, you will be 
asked to donate between 15-25 mis of blood (about 3-5 teaspoons) once, when we see 
you in the clinic for follow up.
We will study your blood samples in the laboratory (at St James's) to analyse the different 
populations of immune cells present before and after transplantation. Any leftover cells will 
be disposed of. We may also test for the presence of anti-donor antibodies, and examine 
these antibodies in greater detail. This may include testing samples that you have 
previously given as part of your routine care, and which are stored in the laboratory. Any 
new samples given for this purpose will be stored in the laboratory, according to laboratory 
protocol.
• You will not be asked to give blood if you are anaemic
Your interest in participation will be established by a member of your clinical care team, 
who will then discuss the study further with you. If you agree, they will obtain your written 
consent, and plan the day on which the blood sample may be taken. You will receive a 
copy of this information sheet to keep.
What are the benefits?
There are no immediate benefits to you, and participation in the study will have no 
influence on your treatment. However, the long term aim of this study is to increase our 
understanding of antibody incompatible kidney transplantation. In the future we hope that 
this will help doctors to be able to modify treatment, with the aim of improving transplant 
outcome.
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W hat are the risks?
The risks are very small. The amount of blood taken (up to 25mls, about 5 teaspoons) is 
small, and is not harmful (for example the volume is very much less that the loss of a 
clotted haemodiaiysis circuit).
W hat if I do not want to take part?
Involvement in this study is entirely voluntary. It is up to you to decide whether or not you 
wish to take part. If you decide to take part, you will be given this information sheet to keep 
and be asked to sign a consent form. If you give your consent to take part, you are still free 
to withdraw at any time without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the care that you receive.
Will mv taking part in this study be kept confidential?
All information collected from the study will be kept entirely confidential.
W hat will happen to the results of the research study?
The results of the study will be published in medical or scientific journals, and presented at 
scientific meetings. In addition, the results will be written up (in fully anonymised form), by 
Ms Mounsey, as a thesis, and submitted as part-fulfilment of a Doctorate in Professional 
Studies (Biomedical Science) to Sheffield Hallam University. A summary sheet of research 
findings will be available from Ms Mounsey.
W hat if there is a problem?
Any complaint about the way you have been dealt with during the study, or any possible 
harm you might suffer, will be addressed. If you have a concern about any aspect of this 
study, you should ask to speak to the member of the clinical care team who took your 
consent, or Ms Mounsey who will do their best to answer your questions. If you remain 
unhappy and wish to complain formally, you can do this by contacting the Patient Advice 
and Liaison Service (PALS), contact telephone number: 0113 206 7168.
Who is organising and funding the research?
The Chief Investigator of this study is Ms Katherine Mounsey, Principal Clinical Scientist, 
based within the Transplant Immunology Laboratory at St James’s Hospital. Ms Mounsey 
is carrying out this study as part-fulfilment of a Doctorate in Professional Studies 
(Biomedical Science) at Sheffield Hallam University. Ms Mounsey is supervised by Dr 
Brendan Clark (Consultant in Histocompatibility and Immunogenetics - H&l, at St James’s) 
in collaboration with Dr Chas Newstead (Consultant Renal Physician).
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Further contact information
If you would like further information about the study, you can contact any of the following:
For Leeds clinic:
Rosalyn Wheatley (Research Nurse) or Kay Tobin (Senior Research Nurse), Renal 
Research, St James’s University Hospital, Leeds
Transplant Co-ordinators Joanne Barwick, Georgina Speak or Kathryn Brady,
Renal and Transplant Medicine, St James’s University Hospital, Leeds
For Bradford clinic:
Transplant Co-ordinators Claire Burton, Michael Speight or Helen Phelan,
Renal Medicine, St Luke's Hospital, Bradford
For York clinic:
Consultant Renal Physicians Dr David Border, or Dr Colin Jones, Renal Medicine, York 
Hospital
For Hull clinic:
Consultant Renal Physician Dr David Eadington or Transplant Co-ordinator Julie Hill, 
Renal Medicine, Hull Royal Infirmary
If you would rather initially discuss your participation with a knowledgeable individual not 
directly involved in the study:
Patient Advice and Liaison Service Tufail Anwar (Research Nurse)
Patient Relations Department Renal Medicine,
Trust Headquarters St Luke’s Hospital,
St James’s Hospital Bradford
Leeds BD5 ONA
LS9 7TF Tel: 01274 365536
Tel: 0113 206 7168
Email: patient.relations@leedsth.nhs.uk
Immunological Profiling in AiT Recipients Version 2 4
Ms Katherine Mounsey
Transplant Immunology
Gledhow Wing, Level 9
St James’s University Hospital
Beckett Street
Leeds
LS9 7TF
Tel: 0113 206 4579
Email: katherine.mounsey@leedsth.nhs.uk
Dr Clive Carter
Cellular Immunology
Gledhow Wing, Level 9
St James’s University Hospital
Beckett Street
Leeds
LS9 7TF
Tel: 0113 206 4579
Email: clive.carter@leedsth.nhs.uk
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PARTICIPANT CONSENT FORM 
Immunological Profiling in Renal Transplant Recipients 
Receiving an Antibody Incompatible Kidney
(Please initial box)
1. I confirm that I have read and understand the information sheet for the above study, 
and have had the opportunity to ask questions.
2. 1 understand that my participation is voluntary' and that I am free to withdraw at any time, 
without my medical care or legal rights being affected.
3. I understand that even if  I withdraw from the above study, the data and samples collected 
from me will be used in analysing the results, unless I specifically withdraw consent for this. 
I understand that my identity will remain anonymous.
4. I consent to my GP being notified of my participation in this study.
5. I consent to storage, including electronic, of personal information for the purposes of this 
study. I understand that any information that could identify me will be kept strictly 
confidential, and no personal information will be included in the study report or other 
publication.
6. I agree to allow the use of any information or results arising from this study for presentation 
or publication. I understand that my identity will remain anonymous.
7. I understand that relevant sections of my medical notes and data, collected during the study, 
may be looked at by individuals from the Renal Care Team, from regulatory authorities or 
from the NHS Trust, where it is relevant to me taking part in this research. I give permission 
for these individuals to have access to my records.
8. I agree to take part in the study. I understand this includes giving fresh blood samples and, if  
necessary, the testing of samples that I have previously given as part of my routine care, and 
which are stored in the laboratory'.
Signatures:
NAME OF THE PATIENT DATE SIGNATURE
NAME OF THE PERSON DATE SIGNATURE
TAKING THE CONSENT
The Leeds Teaching Hospitals [a2
Immunological Profiling in AiT Recipients Version 2 5
□ 
□ 
□ 
□
□
 
□ 
□
□
Appendix 3 Copy of the participant information sheet and consent form for the
normal controls, submitted with the NHS REC application and granted final
approval in July 2011
Version 1.0 15/06/11
The Leeds Teaching Hospitals
NHS Trust
PARTICIPANT INFORMATION SHEET /NORMAL CONTROLS)
Immunological Profiling in Renal Transplant Recipients 
Receiving an Antibody Incompatible Kidnev
Introduction
You are being invited to take part in a research study. Before you decide whether to take 
part, it is important for you to understand why the research is being done, and what it will 
involve. Please take time to read the following information carefully, and discuss it with 
others if you wish.
Please ask us if there is anything that is not clear, or if you would like more information.
Take time to decide whether or not you wish to take part.
Thank you for reading this information sheet and for considering taking part in this study. 
Background to the study
Transplantation provides the best treatment for patients with advanced kidney failure.
However, sometimes it can be very difficult identifying a compatible donor for patients who 
have anti-donor antibodies. Antibody incompatible transplantation (AIT) is a specialised 
procedure that helps patients with anti-donor antibodies to be transplanted, usually with a 
living donor. However, there is much that it is not understood about the biological process 
of this procedure.
What is the purpose of the study?
The purpose of the study is to examine the different populations of immune cells, present 
in the blood, at different stages of AiT. This information will be combined with other 
laboratory and clinical results, with the aim of building up an ‘immunological profile’ of AiT 
patients. In the future, this may allow us to carry out additional monitoring of patients 
undergoing AiT, with the overall long-term aim of improving transplant outcome. In order 
for the research study to have scientific rigour, it is necessary to obtain laboratory data 
from ‘normal’ individuals, against which to compare the patient results. j
\
Why have I been chosen?
j
As an NHS staff colleague, you are being invited to be part of the ‘normal’ comparison 
group for the study. In order to draw scientifically valid conclusions from the study data, it 
is necessary to compare the results from kidney transplant patients with ‘normal’ controls.
You will be able to participate in the study as a ‘healthy volunteer' if you are able to confirm 
that you have no history of renal failure or transplantation.
Immunological Profiling in AiT Recipients Version 1
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W hat will 1 have to do?
As a healthy volunteer, you will be asked to donate approximately 15 mis of blood (about 
3 teaspoons) once.
We will study your blood sample in the laboratory (at St James’s) to analyse the different 
populations of immune cells present. Any leftover cells will be disposed of.
Your interest in participation will be established by the Chief Investigator, who will then 
discuss the study further with you. If you agree, they will obtain your written consent, and 
plan the day on which the blood sample may be taken, by a member of the renal clinical 
care team. You will receive a copy of this information sheet to keep. Your blood sample 
results will be anonymised for the purpose of analysis, with only data on your gender and 
age being stored. You will receive no feedback on your individual sample results.
What are the benefits?
There are no benefits to you. However, the long term aim of this study is to increase our 
understanding of antibody incompatible kidney transplantation. In the future we hope that 
this will help doctors to be able to modify treatment, with the aim of improving transplant 
outcome.
What are the risks?
The risks are very small. The amount of blood taken (up to 15mls, about 3 teaspoons) is 
small, and is not harmful.
What If I do not want to take part?
Involvement in this study is entirely voluntary. It is up to you to decide whether or not you 
wish to take part. If you decide to take part, you will be given this information sheet to keep 
and be asked to sign a consent form. If you give your consent to take part, you are still free 
to withdraw at any time without giving a reason.
Will mv taking part in this study be kept confidential?
All information collected from the study will be kept entirely confidential.
What will happen to the results of the research study?
The results of the study will be published in medical or scientific journals, and presented at 
scientific meetings. In addition, the results will be written up (in fully anonymised form), by 
Ms Mounsey, as a thesis, and submitted as part-fulfilment of a Doctorate in Professional 
Studies (Biomedical Science) to Sheffield Hallam University. A summary sheet of research 
findings will be available from Ms Mounsey.
Immunological Profiling in AiT Recipients Version 1 2
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What if there is a problem?
Any complaint about the way you have been dealt with during the study, or any possible 
harm you might suffer, will be addressed. If you have a concern about any aspect of this 
study, you should ask to speak to Ms Mounsey, who will do her best to answer your 
questions.
Who is organising and funding the research?
The Chief Investigator of this study is Ms Katherine Mounsey, Principal Clinical Scientist, 
based within the Transplant Immunology Laboratory at St James’s Hospital, Ms Mounsey 
is carrying out this study as part-fulfilment of a Doctorate in Professional Studies 
{Biomedical Science) at Sheffield Hallam University. Ms Mounsey is supervised by Dr 
Brendan Clark (Consultant in Histocompatibility and Immunogenetics - H&l, at St James's) 
in collaboration with Dr Chas Newstead (Consultant Renal Physician).
Further contact information
If you would like further information about the study, you can contact either of the 
following:
Ms Katherine Mounsey Dr Clive Carter
Transplant Immunology Cellular Immunology
Gledhow Wing, Level 9 Gledhow Wing, Level 9
St James’s University Hospital St James’s University Hospital
Beckett Street Beckett Street
Leeds Leeds
LS9 7TF LS9 7TF
Tel: 0113 206 4579 Tel: 0113 206 4579
Email: katherine.mounsev@leedsth.nhs.uk Email: ctive.carter@leedsth.nhs.uk
If you would rather initially discuss your participation with a knowledgeable individual not 
directly involved in the study:
Patient Advice and Liaison Service Tufail Anwar (Research Nurse)
Patient Relations Department Renal Medicine,
Trust Headquarters St Luke’s Hospital,
St James’s Hospital Bradford
Leeds BD5 ONA
LS9 7TF Tel: 01274 365536
Tel: 0113 206 7168
Email: patient.relations@leedsth.nhs.uk
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PARTICIPANT CONSENT FORM (NORMAL CONTROLS! 
Immunological Profiling in Renal Transplant Recipients 
Receiving an Antibody Incompatible Kidnev
(Please initial box)
1. I confirm that I have read and understand the information sheet for the above study, 
and have had the opportunity to ask questions. □
2. I understand that my participation is voluntary and that I am free to withdraw at any time.
I understand that my status and position in the workplace will not be affected by the decision_|__ |
that I make.
3. I understand that even i f  I withdraw from the above study, the data and samples collected
from me will be used in analysing the results, unless I specifically withdraw consent for this. I I
I understand that my identity will remain anonymous.
4. I consent to storage, including electronic, of personal information for the purposes of this
study. I understand that any information that could identify me will be kept strictly--I----1
confidential, and no personal information will be included in the study report or other 
publication.
5. I agree to allow the use of any information or results arising from this study for presentation I
or publication. T understand that my identity will remain anonymous. I I
6. I confirm that:
I am fit and healthy
I have never suffered from renal failure 
I have never had a transplant.
7. I confirm that I do not have, or suspect I have, an infection, and have not been exposed to an
infection, which may endanger my colleague in taking my blood sample. I___I
8. I agree to take part in the study. I understand this includes giving a fresh blood sample.
Signatures:
NAME OF THE PATIENT DATE SIGNATURE
NAME OF THE PERSON 
TAKING THE CONSENT
DATE SIGNATURE
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Appendix 4 A summary of manufacturers and suppliers of reagents used in the
study
General laboratory chemicals were manufactured by BDH and supplied by 
VWR.
Becton, Dickinson and Company, BD Biosciences
The Danby Building
Edmund Hailey Road
Oxford Science Park, Oxford 0X4 4DQ
England
http ://www. bd. com/u k/
Products supplied by BD Biosciences.
Cedarlane
1210 Turrentine Street 
Burlington, NC, 27215 
https://www.cedarlanelabs.com/
Products supplied by VH Bio Limited, Unit 11B Station Approach, Team Valley
Trading Estate, Gateshead, NE11 OZF
http://www.vhbio.com/
invitrogen (Thermo Fisher Scientific Incorporated)
3 Fountain Drive 
Inchinnan Business Park 
Paisley 
UK
Supplied by Life Technologies Limited (Thermo Fisher Scientific Incorporated), 
http ://www. lifetech nolog ies. com/u k/en/home. htm I
One Lambda incorporated (Thermo Fisher Scientific Incorporated)
21001 Kittridge,
Canoga Park,
California,
USA.
2 1 0
http://www.onelambda.com/en/home.html
Supplied by VHBio Limited, Unit 11B Station Approach, Team Valley Trading
Estate, Gateshead, NE11 OZF
http://www.vhbio.com/
Promega Corporation
2800 Woods Hollow Road,
Madison, Wl 53711 
USA
http://www.promega.co.uk/
Supplied by Promega UK, Southampton, UK
Sigma-Aldrich Limited
The Old Brickyard,
New Road,
Gillingham,
Dorset 
SP84XT
https://www.sigmaaldrich.com/united-kingdom.html 
Supplied by Sigma-Aldrich Company Limited.
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Appendix 5 Serum creatinine levels for the retrospective participant cohort
Participant
ID
Creatinine (pmol/L)
Approximately 
6 months post­
transplantation
Approximately 
1 year post­
transplantation
Latest 
(time post­
transplant date)
4 166 163
167
(2 years and 7 
months)
5 117 131 491 (3 years)
6 119 130 159 (3 years)
8 123 132
115
(12 years and 9 
months)
10 118 118 105 (4 years)
12 105 104
111
(9 years and 7 
months)
13 129 131 145 (7 years)
15 118 115
81
(5 years and 3 
months)
16 695 1058
913 
(9 years and 5 
months)
17 206 198
607 
(9 years and 4 
months)
18 283 257
282 
(5 years and 5 
months)
19 148 243
201
(5 years and 3 
months)
20 140 117 144(7 years)
ID -  identification
pmol/L -  micromoles per litre
Adult reference range for serum creatinine (Leeds & Bradford Pathology 
Service 2011):
Male 64-104 pmol/L; Female 49-90 pmol/L
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Appendix 6 Results of lymphocyte subset analysis for the normal controls
Results of lymphocyte subset analysis (absolute cell counts) for the normal 
controls
Norm al contro ls
2000-
,1000-
-9
Absolute cell counts (cells/pl). Horizontal line indicates mean.
Normal controls, n= 9.
The lymphocyte subset percentages of total lymphocytes for the normal controls.
Norm al contro ls
100-,
80- >•••
£* 60-
40-
• ••
20-
-9
Lymphocyte subsets plotted as a percentage of total lymphocytes (CD45+) cells. 
Horizontal line indicates mean. Normal controls, n= 9.
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Appendix 7 A comparison of the median results of lymphocyte subsets for the 
study normal controls data with published data for healthy adults
Lymphocyte
subset
CD45+ CD3+ CD8+ CD4+ CD19+ NK
Study data 2.1 1.5 0.5 0.9 0.3 0.2
Published
data
1.8 1.2 0.4 0.7 0.2 0.3
Absolute counts (x109/l)
Published data is for healthy adults (n = 51) (Bonilla and Oettgen 1997) 
Study normal controls (n = 9)
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Appendix 8 Results from the LABScreen® Single Antigen assay for prospective
participant 7
Sample
ID
%
PRA
HLA specificities 
(MFI >1000)
Highest
MFI
DSA present in sample 
(MFI)
HLA Class I resu ts:
Day -8 0 None detected N/A N/A
Day +5 0 None detected N/A N/A
+8
months
0 None detected N/A N/A
+13
months
0 None detected N/A N/A
HLA Class II results:
Day -8 18 DQ4, DQ7, DQ8, 
DQ9
7049 DQ7
(2143)
Day +5 3 DQA1*03? 2642 DQA1*03 
(DQA1*03:01=537, 
DQA1 *03:02=1135, 
DQA1 *03:03=2642)
+8
months
10 DQ4, DQ9, 
DQA1 *03:01?
7537 DQ3?
(DQB1*03:03 = 2167[bead 
069]+418[bead 045]+1174[bead 
044])
DQA1*03? 
(DQA1*03:01=1193,
DQA1 *03:02=2137,
DQA1 *03:03=7537)
+13
months
10 DQ4, DQ9, 
DQA1 *03:01?
6541 DQ3?
(DQB1*03:03 = 1678[bead 
069]+337[bead 045]+1077[bead 
044])
DQA1*03?
(DQA1 *03:01=1050,
DQA1 *03:02=1629,
DQA1 *03:03=6541)
ID - identification; % PRA -  percentage panel reactive antibody, calculated for each test 
by dividing the number of positive beads by the total number of beads for each panel, 
and multiplying by 100; HLA - human leucocyte antigen; MFI -  mean fluorescence 
intensity; DSA -  donor specific antibody; N/A -  not applicable.
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Appendix 9 Results from the LABScreen® Single Antigen assay for prospective
participant 9
Sample
ID
%
PRA
HLA specificities 
(MFI >1000)
Highest
MFI
DSA present in sample 
(MFI)
HLA Class I results:
+6
months
0 None detected N/A N/A
+1 year 0 None detected N/A N/A
HLA Class II results:
+6
months
74 DR1, DR4, DR9, DR11, 
DR12, DR13, DR14, DR15, 
DR16, DR17 (self), DR18, 
DR51, DQ4, DQ6, DQ7, 
DQ8, DQ9, DP1, DP3, DP5, 
DP6, DP9, DP10, DP11, 
DP13, DP14, DP15, DP17, 
DP19, DP23
19,742 DR4 (DRB1*04:05 = 12,679, 
04:04= 16,687, 04:01 = 
15,099, 04:02 = 8864, 04:03 = 
9851) DQ8 (03:02 = 
10,341 [bead 068], 8431[bead 
042], 7863[bead 043], 
7891 [bead 082],
DP1 (15,778[bead 083], 
17,408[bead 046], DP3 
(17,750[bead 091], 
16,707[bead 084], 
17,117[bead 048]
+1 year 64 DR1, DR4, DR9, DR10, 
DR11, DR12, DR13, DR14, 
DR15, DR16, DR18, DR51, 
DQ4, DQ6, DQ7, DQ8, DQ9, 
DP1, DP3, DP5, DP6, DP9, 
DP10, DP11, DP13, DP14, 
DP17, DP19
9719 DR4 (DRB1*04:01 =9045, 
04:04 = 9719, 04:05 = 9529, 
04:02 = 5026, 04:03 = 6904) 
DQ8 (03:02 = 6867[bead 068], 
5120[bead 042], 4606[bead 
043], 4661 [bead 082], DP1 
(5478[bead 046], 4428[bead 
083], DP3 (5997[bead 048], 
5871 [bead 091], 5485[bead 
084]
ID - identification; % PRA -  percentage panel reactive anti x>dy, calculated for each test
by dividing the number of positive beads by the total number of beads for each panel, 
and multiplying by 100; HLA - human leucocyte antigen; MFI -  mean fluorescence 
intensity; DSA -  donor specific antibody; N/A -  not applicable.
Samples Day -12 and Day -5, data not shown, but available as part of routine laboratory 
transplant work-up.
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Appendix 10 Results from the LABScreen® Single Antigen assay for prospective
participant 11
Sample
ID
%
PRA
HLA specificities 
(MFI >1000)
Highest
MFI
DSA present in sample 
(MFI)
HLA Class I results:
+6
months
4 B57, B58, B63 5658 None
+1 year 4 B57, B58, B63 5164 None
HLA Class II results:
+6
months
0 None detected N/A N/A
(weak DRB1*13:03 = 542)
+1 year 0 None detected N/A N/A
(weak DRB1*13:03 = 967)
ID - identification; % PRA -  percentage panel reactive antibody, calculated for each test 
by dividing the number of positive beads by the total number of beads for each panel, 
and multiplying by 100; HLA - human leucocyte antigen; MFI -  mean fluorescence 
intensity; DSA -  donor specific antibody; N/A -  not applicable.
Day -9, data not shown, but available as part of routine laboratory transplant work-up.
2 1 7
Appendix 11 Results from the LABScreen® Single Antigen assay for prospective
participant 14
Sample
ID
%
PRA
HLA specificities 
(MFI >1000)
Highest
MFI
DSA present in sample 
(MFI)
HLA Class I resu ts:
+6
months
44 A2, A28, B5, B12, B13, 
B15, B16, B17, B18, B21, 
B35, B37, B40, B41, B46, 
B53, B55, B56, B59, B67, 
B70, B78
13,032 None
+1 year 39 A2, A68, A69, B13, B35, 
B41, B44, B45, B46, B47, 
B49, B50, B51, B52, B53, 
B55, B56, B57, B58, B60, 
B61, B71, B72, B62, B63, 
B75, B76, B77, B78
9889 None
HLA Class II results:
+6
months
25 DR3, DR5, DR6, DR7, 
DR8, DR9, DR52, DQ2
17,886 None
+1 year 25 DR7, DR8, DR9, DR11, 
DR12, DR13, DR14, 
DR17, DR18, DR52, DQ2
19,806 None
ID - identification; % PRA -  percentage panel reactive antibody, calculated for each test 
by dividing the number of positive beads by the total number of beads for each panel, 
and multiplying by 100; HLA - human leucocyte antigen; MFI -  mean fluorescence 
intensity; DSA -  donor specific antibody; N/A -  not applicable.
Day -14 and Day 0, data not shown, but available as part of routine laboratory transplant 
work-up.
+6 months was analysed as a part of the routine antibody screening laboratory work.
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